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Bioinformatics is an interdisciplinary field that provides methods and tools for the interpretation of
biological data. Being a bridge between biology and informatics (hence the term bio-informatics), this
field combines knowledge from computer science, mathematics, statistics, and engineering and applies it
on biological data. Unlike biology, bioinformatics itself as a field does not produce data, it performs data
analysis and delivers information about given data using given or developed algorithms. Bioinformatics
is applied to better understand fundamental cellular and molecular processes, to identify drug targets,
to improve disease diagnostics and to support clinical decision making.
Bioinformatics is a rather new field and there is a continuous need for the development of tools to
perform various types of analyses (an example of such a tool is provided in Chapter 2, and Chapter 3
contains its further, more extensive biological application). However, the possibilities and opportunities
of currently existing methods and tools are rarely explored to their full extent, and important biolog-
ical and medical questions can already be answered using existing tools (examples of this are given in
Chapter 4 and Chapter 5). In this thesis, I focus on the development and application of bioinfor-
matics tools for the analysis of genetic data. The basics of our current understandings of genetics and
bioinformatics is summarized below.
1.1 Background information
1.1.1 DNA and RNA
The human genetic code is contained in DNA, or deoxyribonucleic acid, a double-stranded helical
molecule located mainly in the nucleus and additionally in the mitochondria. The helix is formed
from a repeated pattern of a monosaccharide sugar deoxyribose and a phosphate group. The bases
attached to the backbone create a full DNA molecule. These bases can be four nucleotides: adenine A,
cytosine C, guanine G, and thymine T. The double helix consists of two complementary antiparallel
strands formed in such a way that the nucleotides A:T and C:G situated on the opposite strands are
paired [1].
Genetic information used as a template for proteins is encoded in the regions of DNA called genes1.
The complete DNA sequence including all of its genes is called genome, and the genetic makeup of
a particular cell or organism under specific conditions is called genotype. During transcription (Fig-
ure 1.1, A) genes and sometimes other regions of DNA are copied into RNA2 by the RNA polymerase
enzyme.
1Note that, however, not all genes code for proteins.
2Ribonucleic acid.
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Figure 1.1: A. Eukaryotic transcription and mRNA processing. A eukaryotic cell; the light-blue region of the DNA and pre-mRNA molecules
indicate introns; dark-blue regions of the DNA and RNA molecules indicate exons. The main steps of mRNA formation and processing –
transcription, splicing, further processing (capping and polyadenylation) – are shown as well as mRNA transport to the cytoplasm, where
mRNAs are translated into proteins. Note that the processing steps depicted here do not always take place in the indicated order. B. Main
classes of alternative splicing events.
RNA is a single-stranded molecule similar to DNA in its content. However, instead of thymine T, as
it is in DNA, RNA contains uracil U, and the backbone is formed from ribose instead of deoxyribose.
Different types of RNA have different roles in the cell (Table 1.1). One of the classes of RNA –
messenger RNA or mRNA – is focused on in this thesis and will be discussed in more detail.
1.1.2 RNA maturation
In humans, RNA undergoes a series of steps before it can be used as a template for proteins. During
its life, which begins with transcription, an RNA molecule is processed to mature mRNA, transported
from the nucleus to the cytoplasm and then translated.
Table 1.1: Different types of human RNAs and their functions.
Name Type Function
mRNA Messenger RNA Templates for proteins
rRNA Ribosomal RNA Translation
tRNA Transfer RNA Translation, amino acid transport
snRNA Small nuclear RNA Splicing
snoRNA Small nuclear RNA Chemical modifications of RNA
Y RNA Y RNA RNA processing, DNA replication
TERC Telomerase RNA Component Telomere synthesis
pncRNA promoter associated non-coding RNA Transcription regulation
encRNA enhancer associated non-coding RNA Transcription regulation
lncRNA Long non-coding RNA Gene regulation
miRNA Micro RNA Gene regulation
piRNA Piwi-interacting RNA Gene regulation
siRNA Small interfering RNA Gene regulation
The transcription of mRNA is performed by RNA polymerases. Transcription is a multi-step pro-
cess, which consists of pre-initiation, initiation, promoter clearance, elongation and termination. During
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pre- initiation, special proteins called transcription factors bind to promoters – regions of DNA situated
upstream of the start of a gene. This facilitates the binding of RNA polymerases to the DNA, which
triggers the next step of transcription – initiation. After the bond between the first two nucleotides
has been created, the polymerase releases from the promoter (promoter clearance), and keeps synthe-
sizing RNA using one DNA strand as a template (elongation) to produce the transcript. While RNA
polymerase moves from the 3’ to the 5’ end on the template strand, the transcript is produced in a 5’
towards 3’ direction. The last step of transcription – termination, when the newly synthesized RNA, or
precursor messenger RNA (pre-mRNA) is released from the RNA polymerase – is poorly understood.
After (or concurrently with) transcription pre-mRNA undergoes several processing steps: capping,
splicing, polyadenylation and editing. During capping, which is initiated before the completion of tran-
scription [2], the 5’ terminal phosphate group of the nascent RNA molecule is enzymatically removed,
GTP is added to the remaining bisphosphate with an unusual 5’ to 5’ triphosphate bond and is methy-
lated. During polyadenylation, which often takes place after transcription, a big protein complex cleaves
the 3’-most part of a newly produced RNA and polyadenylates (adds a sequence that consists of dozens
or even hundreds of A’s) the end produced by this cleavage. During editing, which happens during or
after transcription, certain nucleotides in the pre-mRNA or mRNA can be chemically modified [3] or
deleted [4, 5].
Another processing step happening after or concurrently with transcription is pre-mRNA splicing.
Unlike transcription, splicing is unique to higher eukaryotes, including humans. Splicing is performed by
a big riboprotein complex, the spliceosome, which removes introns and joins the adjacent exons [6, 7].
Spliceosome finds and recognizes two splice sites – a donor (5’ end of the intron) and an acceptor site
(3’ end of the intron). More intronic sequences – a polypyrimidine tract and a branchpoint – are also
essential for efficient splicing, as they bind to the spliseosomal proteins. A polypyrimidine tract is a
pyrimidine (C and T) rich area of approximately 20-50 nucleotides upstream the acceptor splice site. A
branchpoint is an A nucleotide situated upstream from the polypyrimidine tract. After conformational
changes within the spliceosome the adjacent exons that were separated by the introns are joined together
by a transesterification reaction, and the intron leaves the complex as a lariat, which is usually quickly
degraded [8, 9].
Genes can give rise to multiple mRNA transcripts, because pre-mRNA splicing can occur via multiple
alternative routes [10, 11, 12, 13]. Depending on the nature of the cell or tissue or as a consequence
of signals from the environment, the spliceosome may remove different regions from the same pre-
mRNA molecule. This can happen within the same cell. Such variation in splicing is called alternative
splicing, (Figure 1.1, B), creating a range of different transcripts from one gene. Five major classes
of alternative splicing are known – exon skipping (which is the most prominent in humans), mutually
exclusive exons (a combination of exon skipping events, where one of two exons is included in one mRNA
molecule), intron retention (which is the least prominent in humans) and the usage of alternative donor
or acceptor splice sites making exons longer or shorter [14, 15].
Alternative splicing is not the only way to create multiple transcripts from one gene [11]. Alternative
polyadenylation or initiation of transcription at alternative start sites [14] also contribute to the variety
of transcripts. Alternative transcription initiation, splicing and polyadenylation result in generating
over 80,000 transcripts from just over 20,000 genes [16]. The set of all RNA molecules, including mRNA
and non-coding RNA like rRNA and tRNA transcribed, is much larger. This set is referred to as the
transcriptome [12]. However, in this thesis, we define a transcriptome to be only mRNA molecules
present in one cell or a population of cells. The amount of identical (not alternative) transcripts
generated from identical pre-mRNAs is called transcript expression level, and the overall expression of
all transcripts from one gene is called gene expression level [17].
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1.1.3 Principles of Illumina NGS
One way to analyze genomes and transcriptomes is massively parallel sequencing, usually referred to as
next generation sequencing, or NGS [18, 19, 20]. Unlike previously used sequencing of one amplicon at
a time (i.e., Sanger sequencing [21, 22]), NGS involves sequencing large amounts of DNA or RNA at
once usually3 on a whole genome or transcriptome scale. NGS technologies require a pool of DNA or
RNA molecules [18] that can be isolated following various protocols depending on the research question.
Since the majority of current NGS technologies cannot read beyond 100-250 nucleotides, full-length
molecules are usually fragmented and (part of) the sequence of each short fragment is read. Short
sequences determined during NGS are called reads.
One of the most popular and widely used sequencing technologies at the moment is Illumina [23].
All the analyses in this thesis has been performed on Illumina sequencing data. Sample preparations,
protocol details and technical issues and biases described below therefore regard Illumina sequencing.
Note that some of them can apply to the data from other sequencers as well.
A basic Illumina protocol for sequencing consists of the following steps (Figure 1.2, A). Double-
stranded DNA molecules are fragmented. After fragmentation, artificially synthesized sequences called
adapters are ligated to the short, size selected fragments, to facilitate PCR amplification. Denaturated
amplified fragments are hybridized to the oligos that are attached to a water tight flowcell. Using bridge
amplification, clusters of identical molecules are formed from each fragment. Four types of fluorescently
labelled nucleotides4 and a polymerase are added. The fluorescent label, which is also a block that
prevents adding more than one nucleotide, is added per sequence cycle. Incorporation of a nucleotide
into a fragment is detected using a CCD camera. The nucleotide is identified based on the signal
detected from the fluorescent label. After imaging the fluorescent label is cleaved off, nucleotides are
added again and the next nucleotide is incorporated. This process is repeated numerous times, and the
number of repetitions defines the length of the fragments that will be sequenced. As every nucleotide
has its own color coding, an automated image processing pipeline decodes the signal and produces text
files – fastq files – containing the sequence and the quality of the individual nucleotide calls, or Phred
quality score [24].
Phred quality score Q is a value logarithmically related to the base-calling error probability P.
Q = -10 log10 P (1.1)
E.g., if Phred score of a base is 30, the chance that this base is called incorrectly is 1 in 1000. In case
of RNA sequencing, or RNA-Seq, cDNA is synthesized from RNA. This step introduces a lot of biases in
the data, one of which is the uneven coverage of the molecules due to non-random priming. After RNA
has been extracted, the enzyme reverse transcriptase is used to create cDNA from the RNA template.
Reverse transcriptase is used together with random hexamers, synthetic polynucleotide fragments that
should in theory anneal to any part of the RNA molecule. However, partly due to the non-uniform
sequence of the transcripts expressed in the human genome [25], the use of random hexamer priming for
transcriptomics has been shown to result in a non-uniform coverage along the expressed transcripts [26].
After the synthesis and fragmentation [27] of cDNA the protocol for RNA sequencing resembles
DNA sequencing.
The quality of Illumina reads is known to be very high (>99.9% probability of calling the correct
nucleotide). Quality usually drops towards the end of the read, mainly due to a problem called phasing.
As mentioned previously, sequencing works with blocked nucleotides. However, when blocking does not
work perfectly, individual molecules in a cluster can get out of phase and have one nucleotide extra (or
3Note that NGS can also be targeted and explore variable loci at very high depth.
4Note that for Illumina HiSeq, two lasers are used to identify two colours, less and more intense green and red, however,
four labels are added.
14
fewer, when no nucleotide is incorporated). This effect accumulates towards the 3’ end of the read and
the sequencer cannot correct the phasing anymore.
Figure 1.2: A. Main steps of Next Generation Sequencing performed by Illumina sequencers. For a detailed description of the process, see
Section 1.1.3. B. Schematic representation of paired-end reads. Stretches of nucleotides flanked by dots represent two regions of a DNA or
RNA molecule. Short stretches of nucleotides separated by a dashed black line (representing the insert size) represent two ends of a read pair.
C. Example base quality report for an Illumina fastq file. Left panel shows the base quality plot of the raw reads received directly from the
Illumina sequencer. Right panel shows the base quality report of the reads after clipping and trimming low quality bases. The drop of the base
calling quality towards the 3’ end of the read can be appreciated from the left panel.
The output of Illumina HiSeq sequencing runs (commonly used for transcriptome analyses) amounts
to billions of reads [28, 29]. Maximum available length of one Illumina HiSeq read is currently limited
to ˜250 bases. Such small length is a disadvantage in the downstream analysis, as short fragments can
be very hard to locate on the genome or transcriptome, especially when mismatches with the reference
sequence are allowed (see Section 1.2 for more detail). One way to increase read length is to use paired-
end sequencing (Figure 1.2, B), when a fragment longer than the maximum Illumina read length is
sequenced from both ends [30]. Since the approximate length of the fragment generated is known, the
length of the region between two reads (or ends) can be inferred (only after the alignment has been
generated, see Section 1.2 for more detail). This region is called the insert size. Sometimes the terms
“inner” or “outer mapping coordinates” are used to describe the insert size. To learn more about how
the information about insert sizes can be used during the bioinformatic analysis, see Section 1.2.
1.1.4 RNA-Seq protocols
The first important step in sequencing RNA is to isolate the RNA molecules of interest, i.e., mRNA,
miRNA or pre-mRNA, from the rest of the cell. Since this thesis focuses mainly on mRNA, only this
type of RNA will be discussed.
Enrichment for mRNA can be achieved using oligo-dT capture or rRNA depletion. The oligo-dT
method uses oligo-dT primers immobilized on beads to capture polyA tails of mRNAs (and some long
non-coding RNAs with polyA tails, see Section 1.1.1). The method enriches for mRNA quite effectively,
and the amount of other types of RNA is minimal. The second widely used way of enriching for mRNA is
to deplete rRNA which comprises around 90% of total RNA, by selectively eliminating rRNA. However,
since this technique does not specifically target polyA tails of full mRNA molecules, the amount of RNA
types other than mRNA is usually higher when using this protocol compared to the oligo-dT protocol.
Since RNA can not be sequenced directly on the Illumina platform (as mentioned in Section 1.1.3), it
is necessary to create a DNA copy. One of the most common ways to generate cDNA is to use a reverse
transcriptase enzyme and a mixture of random hexamer primers – 6 bases long oligonucleotide synthetic
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sequences with random nucleotide compositions [31]. These hexamers anneal to random regions on the
RNA and work like primers for the reverse transcriptase enzyme, which starts elongating the DNA
sequence. The step of synthesizing cDNA is prone to errors occuring in the cDNA product due to
various reasons. E.g., the ability of reverse transcriptase to switch templates is known to affect cDNA
synthesis [32, 33, 34]. During the reverse transcription, the nascent cDNA fragment can periodically
dissociate from the RNA template and reanneal to a different stretch of RNA with the sequence similar
to the original RNA template. Such template switching might lead to generating artificial cDNA and
sequence reads.
Due to the factors mentioned above (and many more), a possibility of sequencing RNA directly,
without cDNA synthesis, becomes very appealing and will be highlighted in the Discussion section of
this thesis.
1.2 Bioinformatic analysis
Pre- and post-alignment data cleaning
Since the quality of reads tends to drop towards the 3’ end of the read [35], it is common practice to check
the sequencing quality of each base, trim low-quality bases from the end of the read and proceed with
trimmed reads (Figure 1.2, C). Another step in the pre-alignment phase is to check for the presence of
the adapter sequences, which should be removed from the fastq files (introduced in 1.1.3) before running
the downstream analysis (such as alignment).
Alignment
Aligning, or mapping reads to the reference sequence means finding the most probable location (origin)
of the reads in the genome. Alignments can be exact (when all nucleotides from the read match the
reference sequence) or contain insertions, deletions and substitutions. RNA-Seq reads can be aligned to
the reference transcriptome, as well as to the reference genome. If transcriptome samples are aligned to
the genome, some reads need to be split in order to allow mapping across exon-exon junctions and span
the introns that are present in the reference genome. Mapping RNA-Seq reads to the transcriptome does
not require special aligners, as the reads do not have to be split. A disadvantage of such approach is that
the “reference transcriptome” is incomplete. Transcriptomes may differ between different cell types,
experimental conditions or treatments. To have a proper alignment to the transcriptome, RNA-Seq
reads would ideally be mapped to the transcriptome of the cells they were isolated from. Unfortunately,
this information is not always available, therefore it is common practice to align RNA-Seq reads to
the genome. Another problem is that a transcriptome contains multiple transcripts coming from the
same gene, which makes alignment more challenging. However, when the whole genome sequence is not
available and only the transcriptome is known, this alignment strategy may be used.
Alignment strategies
Numerous tools for paired-end RNA-Seq data alignment have been developed. They can be divided into
two main categories. Alignment tools from the first category (Figure 1.3, A) use one end as an “anchor”
and map it without splitting it [36]. After mapping non-split reads a list of “coverage islands” – regions
where the majority of reads mapped to – is generated. Second ends and remaining unmapped reads
are initially mapped to the coverage islands. When mapping the second end, the insert size (or inner
and outer mapping coordinates) is taken into account for a more precise mapping. It works as a factor
limiting the search for the second read location near the first read and not genome-wide. Additionally,
consistent deviations of insert sizes are used to detect deletions, insertions and splicing events.
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Another type of alignment tools (Figure 1.3, B) treats reads of one pair as individual reads, splits
them and stores the pieces in a table (a hash table). A similar table for the reference sequence is created,
and the aligner overlaps the two, records the best matches for separate pieces and tries to merge them
to give a full alignment of one paired-end read as an output. Tools from both categories can often work
with a list of known exon-exon junctions provided by the user. In this case, aligners will try to split
reads only or preferably at positions of known junctions. Such an approach usually helps to decrease
the number of false-positive alignments, but it introduces a bias towards known splice sites that can
incapacitate the discovery of novel exon-exon junctions.
Figure 1.3: A. Aligning short reads using “anchor” strategy. Thick black lines represent reads mapped without splitting them. Thick red lines
represent reads mapped after being split. Grey blocks represent coverage islands. For a detailed description of the procedure, see Section 1.2. B.
Aligning short reads using a “hash table” strategy. For a detailed description of the procedure, see Section 1.2. C. Post-alignment bioinformatic
analysis. In the top panel, differential expression analysis is schematically shown (in this example, differential gene expression analysis), where
the gene in black (thick black blocks) is differentially expressed between samples 1 and 2 unlike the gene in blue. Thick lines depict reads and
thin lines connecting the thick ones depict the area where the reads were split. In the bottom left panel, differential exon usage analysis is
depicted. In the bottom right panel, variant calling on RNA is shown (in this case, identifying RNA editing events), where letters “G” in red
depict nucleotides different from the reference sequence (in this case, “A”).
The choice of the aligner should always be guided by the research question. However, the second
strategy is becoming more popular, and depending on the application it is used in different modes. For
instance, if only known splice sites and quantifying their abundance is the aim of the study, aligners use
pre-selected annotation and do not explore the reads mapped elsewhere. On the other hand, if finding
novel splice sites, estimating intronic coverage and finding splice sites with low abundance is a priority,
the second approach is used in the “annotation-free” mode.
Unique and non-unique alignments
An important parameter of aligners is the allowed number of alignments per read. Since the read length
is limited and the reference contains regions that are not unique, there is a possibility of finding the
same sequence in the reference genome or transcriptome multiple times [37], especially when allowing
for
mismatches. Unique mapping mode means that only reads for which one location in the reference with
a certain quality (number of mismatches, insertions and deletions) has been found, will be reported.
Non-unique or multiple mapping mode means that all (or, optionally, a limited number of) alignments
per read will be reported. The choice of the best mapping strategy always depends on the research
question and will not be discussed here.
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1.2.1 Post-alignment processing
Since most Illumina protocols include PCR amplification, there is a possibility of PCR duplicates
being sequenced multiple times (to see which stages of sample preparation and sequencing include
PCR amplification steps, see Sections 1.1.3 and 1.1.4). To avoid counting PCR duplicates as separate
molecules, reads that are considered duplicates can be removed. Whether a paired-end read is a duplicate
or not is usually decided based on its mapping coordinates coming from the alignment. When two paired-
end reads have the same mapping coordinates at both ends, the read is considered a duplicate, as the
probability of the same paired-end read being sequenced twice is rather low. One of the reads can
be removed (sometimes regardless the sequence content). Removing such reads from RNA-Seq data
is problematic for single end sequencing data [38], as they may also originate from different transcript
molecules in case when a transcript is highly expressed. However, such reads occur less in paired-end
sequencing because the length of the fragments is not constant.
Regardless of whether reads are mapped to the genome or to the transcriptome, alignment results
are reported in a standard sam file format (Sequence Alignment M ap) [39]. This file contains the
identifier, the sequence of the read and the information about its mapping, i.e., mapping coordinates,
number of matching and mismatching bases, etc. Another way of showing the alignment results using
the information from the sam file is using the coverage information in wiggle files. Each nucleotide of
the reference sequence has a certain coverage, which is the number of reads mapped to this position.
Web-based (such as the UCSC genome browser [40]) and standalone (such as IGV [41, 42]) tools have
been designed to visualize the alignment results for better visibility and easier interpretation.
Biases in NGS data
RNA-Seq is a great source of biological data that can be used for a wide range of applications. However, it
is not error-free and suffers from some major biases. One of them is a 5’-3’ bias [43, 44] (see Section 1.1.4
for more details), which means that the 3’ end of transcripts are overrepresented because those are the
fragments containing the polyA tails [45, 46, 47].
Reference bias in NGS data [48, 49] means that the “perfect” alignment without mismatches is by
default prioritized by aligners over an alignment with a mismatch. When a sample and therefore the
reads contain a genetic variant, they have a lower probability to map to their original location than
a read that does not contain a variant. This bias is also seen with respect to the reference sequence.
When a read can be mapped to two locations, one of which is perfect, the aligner usually chooses the
perfect alignment, which will filter out the cases when the read is coming from a different region and
has a variant. One possibility to tackle this bias is to “mask” the reference sequence [46] – replace
certain positions (i.e., know SNPs) of the reference sequence with N. However, such approaches tend to
increases the number of ambiguous alignments.
Another common bias in NGS data is the sequencing bias [26]. One of the sources for that is the
specifics of PCR amplification. The PCR amplification step necessary before sequencing is performed at
the same temperature for all reads. Some reads might have a higher or lower GC content (the amount
of G and C nucleotides), which can happen due to a number of reasons. PCR conditions favor the
amplification of fragments with normal GC percentage and are not optimal for extreme, high GC/high
AT fragments [50]. Thus difference in the GC content influences the optimal melting and annealing
temperatures for the reads. Since only one condition can be used, this results in a better amplification
of reads with an average GC content [51]. Another source of GC bias comes from generating clusters
during sequencing, as AT rich molecules tend to make larger clusters that overlap with other clusters,
therefore giving a weaker signal.
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1.2.2 Post-alignment transcriptome analysis
Researchers analyzing RNA-Seq data may be interested in various features of the transcriptome, each
requiring separate analysis strategies (Figure 1.3, C). Transcriptome analyses can be divided into two
major categories: annotation-guided analysis – comparison to a reference transcriptome assembly, or
an annotation – and de novo assembly and analyses of the transcripts, without any prior information
about the composition of the transcriptome [52, 53, 54].
Annotation-based and annotation-free analyses
When RNA-Seq data comes from an organism that has a known reference sequence, gene, transcript
and/or exon annotation – a list of all genes, transcripts or exons identified within a particular organism,
tissue or cell culture – is often available as well. It is usually stored in a text file as a list of coordinates
of all exons and introns identified in the transcriptome [53]. The analysis of an RNA-Seq sample can be
restricted by the annotation, which implies that only known exons, transcripts or genes will be searched
for. In other words, the number of reads supporting each exon, transcript or gene will be reported. A
less rigorous way of using the annotation – “annotation-guided” – means that the known transcripts
will be searched for as well as the novel or unknown ones.
If no annotation is available, transcripts can be assembled either fully in case of longer reads or partly,
i.e., at the level of individual exons in case of shorter reads. When the transcripts are assembled, the
downstream analysis is not different for an annotation-based or an annotation-guided mode. However,
an annotation-free approach is less reliable and requires deeper sequencing and longer reads to provide
trustworthy results [55]. Another way to get the transcript information is de novo transcript assembly
(not to be confused with de novo genome assembly [56]). When no reference sequence is available, reads
are assembled and the information about transcriptome composition can be obtained [57, 58, 59, 60].
Detecting alternative splicing
Two major approaches to identify alternative splicing events are coverage- and split reads-based ap-
proaches. Tools like DEXSeq [61], using the coverage-based approach, require the annotation; the
coordinates of a certain exon are selected and the coverage of a region between these coordinates is cal-
culated across all samples. If the region is covered significantly higher or lower in one group of samples
compared to the other group(s), such exon points to a potential alternative splicing event and will be
reported as differentially used. DEXSeq tries to account for possible technical artifacts and considers
the variation between samples within a sample group (a group of technical or biological replicates).
The purely coverage-based approach models the influence of technical and biological replicates very
accurately. However, as it deals with exons and not transcripts, it is often not clear to which transcript
a particular differentially used exon belongs.
Another way to detect alternative splicing events is to combine the information from split reads with
the coverage information. A popular tool in this category is Cufflinks [55, 62]. Split reads come from
two regions that are adjacent in mRNA but not adjacent in DNA (i.e., derived from two exons), thus
positions of splits indicate putative splicing events.
As both approaches have their advantages and disadvantages, choosing the best tool to detect
alternative splicing depends on the research question [54]. Methods considering both coverage- and split
read-based approaches have the highest precision. Information from the coverage, when more reads are
considered (this increases the power of statistics), complements the information from split reads, which
are only ˜20% of all reads, but nevertheless help to improve the mapping of exon boundaries.
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Alternative polyadenylation
A transcript can have multiple polyA sites that can be used under different conditions or in different
tissues [63, 64]. This phenomenon, also known as alternative polyadenylation, is another mechanism to
expand the range of transcripts from one gene (Figure 1.4, A).
Polyadenylation takes place in the 3’ UTR, and many RNA-Seq methods dedicated to determine
polyA sites are available at the moment [65]. Bioinformatic tools [66, 67] usually look at the coverage
in the 3’ UTR, identify where the drops in coverage are (i.e., using a sliding window approach) and
use this to predict the positions of polyA sites [68, 69] (Figure 1.4, B). Sometimes only known polyA
sites [70, 71] are considered, and the coverage of these polyA sites or the areas upstream of the polyA
sites is compared [72]. Since these are purely coverage-based methods, coverage biases are a significant
issue in this type of analysis and should always be taken into account prior to the analysis [73]. It
happens partly due to the length of the 3’ UTRs, which is often comparable to the gene length.
1.2.3 Gene and transcript quantification
Gene expression is often measured in RPKM – Reads mapped Per K ilobase of the targeted region per
M illion mapped reads. The number of reads C mapped to a certain gene is divided by the total number
of nucleotides in this gene L divided by one thousand; the result will be divided by the total number of
mapped reads N and multiplied by one million.
Figure 1.4: A. A schematic representation of alternative polyadenylation: gene structure (the bottom panel) with dashed white lines indicating
the alternative polyadenylation sites; transcripts (middle panel) and their relative expression (the shortest transcript is expressed three times
higher than each of the other two); gene coverage obtained from the sequencing data (the top panel). B. The reflection of alternative polyadeny-
lation in RNA-Seq data: the upper panel shows the coverage pattern under condition 1, and the coverage drops at the first polyadenylation
site (first dashed line); the lower panel shows the coverage pattern under condition 2, and the coverage drops at the second polyadenylation








This measure has been introduced to account for gene length and the number of mapped reads and
to make the expression levels comparable across genes and across samples.
RPKM has been revisited for paired-end reads, since paired-end reads are considered as two in-
dividual reads in the RPKM formula. Therefore, RPKM would be artificially increased by a factor
of two. Another measure has been introduced – FPKM, or F ragments assigned Per K ilobase of the
targeted region per M illion mapped reads. FPKM counts fragments – in case of single-end data this is
single reads, and in case of paired-end data this is paired-end reads. Thus, FPKM is used more often
nowadays, as it makes the single-end and paired-end RNA-Seq experiments comparable.
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Differential expression analysis
Differential gene, transcript or exon expression analysis involves comparing expression levels across
(groups of) samples and selecting genes that have significantly different expression between the groups [74,
75]. At first, gene expression per sample is usually normalized to such factors as sequencing depth and
transcript length. For that, genes known to have stable expression at the majority of conditions and
tissues are used. Next, the intragroup variation (variation within one group of samples, biological or
technical replicates) is compared to the intergroup variation (variation between different groups) [52, 76].
When measuring gene expression, or counting reads mapped to a gene, a distribution to describe
mapped reads has to be chosen5 in order to perform statistical analyses. The Poisson distribution is
often used to describe RNA-Seq data, as only a limited number of events – molecules that are isolated
and sequenced – are selected out of a much bigger pool of events – all RNA molecules present in the cell.
The Poisson distribution is generally used on count data and describes the variation that occurs due to
the sampling procedure, but does not account for the biological or the technical variation due to the
sample preparation. In order to describe the technical and the biological variation, the overdispersion
parameter (which the Poisson distribution does not contain) is introduced. Overdispersion accounts for
the presence of greater variability in a data set than is expected based on a given statistical model. A
Poisson mixture model, or the negative binomial distribution, contains this parameter and is therefore
used to describe gene expression data.
The estimation of the parameters for the appropriate statistical model is followed by a statistical
test to find significant changes in gene expression between conditions. Such tools as edgeR [77] and
DESeq [78] use a variant of the log likelihood ratio test adapted to work with the data following the
negative binomial distribution. Other packages [79] use variations of a T-test to calculate p-values
or estimate likelihood. All methods also use standard approaches for multiple testing correction (for
example, Benjamini-Hochberg) [80].
1.2.4 Post-alignment analysis of variants
A genomic variant is a nucleotide present in DNA of the analyzed sample which differs from the nu-
cleotide at the same position in the reference sequence. Searching for (or calling) variants is usually
performed on DNA data. However, RNA-Seq data can also be used to detect genetic variation. RNA-
Seq contains the information about expression and therefore allows for the study of the expression of
the two different alleles in case of heterozygous variants. Differential allelic expression refers to the im-
balanced (different from 0.5) expression of the two alleles. However, RNA-based variant calling comes
with a series of complications.
Genomic variants and RNA modifications
Since DNA is transcribed directly to RNA, there should be no difference in variants called from DNA or
RNA (unless the variant is not expressed). However, post-transcriptional RNA modifications – called
RNA editing – make variant analysis a challenging task [81, 82]. RNA editing is a chemical change of
a nucleotide in an RNA molecule that results in a different nucleotide. Therefore, while finding such a
change in a number of reads, this can be mistaken for a genomic variant. Statistical filters for the DNA
variant frequency performed to reduce the amount of false positives cannot be applied directly on the
RNA-Seq data. Variants identified on DNA are normally present either on both alleles (a homozygous
variant, and its frequency is 100%), or on one allele (a heterozygous variant, and its frequency is 50%).
Such filters on the frequency cannot be applied directly on RNA due to the possibility of allele-
specific expression (ASE). Variant frequencies in RNA can vary from almost 0% (or higher than the
5http://arxiv.org/abs/1104.3889
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sequencing error rate) to 100%. ASE can happen due to a number of reasons, i.e., pure monoallelic
expression (which is an extreme case of allelic imbalance) can be a consequence of genetic imprinting or
nonsense-mediated degradation (in case of a variant introducing a premature translation termination
signal, or stop codon).
Variant calling on RNA
Calling variants on RNA is required for the analysis of ASE. One of the best ways to distinguish between
RNA editing events and genomic variants in RNA-Seq data is to have DNA genotypes from the same
sample. In this case the variants identified on DNA can be intersected with the variants identified on
RNA. The variants identified on RNA which are not present on DNA can be considered as potential
RNA editing events (REEs). Specific characteristics of RNA editing might also be used to identify these
events more precisely. The most represented type of RNA editing is the hydrolytic deamination of A
which results in a different nucleotide, inosine I. It will be interpreted as a G both by the enzymatic
machinery of the cell and by the Illumina sequencer. Therefore, a way to exclude potential REEs when
calling variants on RNA is to select A to G conversions that are not known genomic variants. Another
possibility to identify REEs is to use the locations of known REEs [83]. However, this is not an optimal
way, since such sources are always incomplete, and RNA editing can be tissue-, cell type- or condition
specific. Therefore, identifying variants on DNA coming from the same sample as the RNA-Seq data is
so far the best way to reliably call variants on RNA.
RNA editing is an interesting and not well-described biological process. It does not always occur on
all RNA molecules and in general can target from almost 0% to 100% of the transcripts (although RNA
editing usually affects a minority of transcripts and is often position-inspecific [3]). The role of RNA
editing has not been elaborately described yet, thus the interpretation of the results of the bioinformatic
analysis remains a challenge. This will be extensively discussed in the Discussion section of this thesis.
1.3 Outline of the thesis
In this thesis, I focus on the bioinformatic analysis of various types of RNA-Seq data both for medical
applications and tried to answer fundamental biological questions. Existing tools, sometimes requiring
modification, were used along with newly developed pipelines. Chapter 2 covers the developing of a
pipeline to analyze nuclear pre-mRNA and seek for biological phenomena as non-sequential and multi-
step intron splicing. Chapter 3 continues the research started in Chapter 2 and applies the pipeline
(with extensions and more biological interpretation) on the largest and one of the most complicated
genes in the human body – the DMD gene coding for the dystrophin protein. Chapter 4 continues
exploring splicing in order to better understand a fundamental biological process of human aging and
its relation to RNA processing. Chapter 5 highlights another type of bioinformatic RNA analysis
– genomic variants and their differential allelic expression – using RNA from tumors of breast cancer
patients (and control samples from the same patients). These chapters aim to cover main directions of
the modern RNA-Seq analysis field and show that existing tools often, but not always, provide extensive
information about the transcriptome, and that to answer certain biological questions, we had to develop
our own tools. Finally, I close this thesis by providing an outlook on ways the field of transcriptomics
and RNA-Seq analysis can evolve.
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Chapter 2
SplicePie: a novel analytical approach for
the detection of alternative, non-sequential
and recursive splicing
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2.1 Abstract
Alternative splicing is a powerful mechanism present in eukaryotic cells to obtain a wide range of
transcripts and protein isoforms from a relatively small number of genes. The mechanisms regulating
(alternative) splicing and the paradigm of consecutive splicing has recently been challenged, especially
for genes with a large number of introns. RNA-Seq, a powerful technology using deep sequencing in
order to determine transcript structure and expression levels, is usually performed on mature mRNA,
therefore not allowing detailed analysis of splicing progression. Sequencing pre-mRNA at different
stages of splicing potentially provides insight into mRNA maturation. Although the number of tools
that analyze total and cytoplasmic RNA in order to elucidate the transcriptome composition is rapidly
growing, there are no tools specifically designed for the analysis of nuclear RNA (which contains mixtures
of pre- and mature mRNA). We developed dedicated algorithms to investigate the splicing process. In
this paper we present a new classification of RNA-Seq reads based on three major stages of splicing:
pre-, intermediate- and post-splicing. Applying this novel classification we demonstrate the possibility
to analyze the order of splicing. Furthermore, we uncover the potential to investigate the multi step
nature of splicing, assessing various types of recursive splicing events. We provide biological insight into
the order of splicing, show that non-sequential splicing of certain introns is reproducible and coinciding
in multiple cell lines. We validated our observations with independent experimental technologies and
showed the reliability of our method. The pipeline, named SplicePie, is freely available online1. The
example data can also be found online2.
2.2 Introduction
During messenger RNA (mRNA) splicing, introns are removed and exons are joined to generate a
mature mRNA or a transcript. One transcript, usually chosen arbitrarily, to which all other transcripts
are compared is called the “reference transcript”. The deviations from this standard reference transcript
are called alternative transcripts.
Data obtained with recent technologies, such as next generation sequencing (NGS) of a whole tran-
scriptome, revealed that around 90% of human genes undergo alternative splicing [12, 84]. Alternative
splicing of a gene comes in different flavours, such as skipping (a part of) an exon [85] or intron reten-
tion [86].
Splicing generally occurs cotranscriptionally [87, 88], and alternative splicing can be influenced by
the speed of transcription [89]. It has been reported that splicing does not always progress sequentially
from the 5’ to the 3’ end of a gene and with the same speed [90, 91]. Instead, different regions can
be spliced rapidly or slowly [92]. A study of pig liver cells showed that for the pCLEC4G gene the
first intron is spliced simultaneously with several more distal introns, while the second intron is spliced
last [93].
Non-sequential intron removal can have unexpected consequences when mutations disrupt splice
sites [94]. The splicing of the COL1A1 gene region between exons 5 and 10 can follow two different
routes. Removing introns 5, 6 and 9 is always rapid, while the excision of intron 8 can be before or after
intron 7 [95]. Additionally, point mutations in splice signals were shown to cause skipping of exon 8,
inclusion of intron 8 or inclusion of both introns 7 and 8. It is not clear yet which factors control the
order of splicing. Theoretically, it might be influenced by the presence of intronic and exonic splice





Recursive splicing is another recently acknowledged feature of the splicing process. The principle
of recursive splicing is that an intron might not be spliced in one piece. Instead, the spliceosome can
recognize an intra-intronic sequence opposed to the canonical exon-intron border as a splice site, hereby
removing the adjacent exon. The rest of such a partly spliced intron will be removed later, at once
or again in multiple pieces following the strategy described above. Another type of multi-step intron
removal [98] involves the usage of non-canonical donor and non-canonical acceptor splice sites. In this
case an inner piece of intron is spliced first and a semi-stable lariat loop structure is formed and will be
degraded later [99].
Alternative splicing cannot be fully understood when only mature mRNA is analyzed. When pre-
mRNA molecules from different stages of splicing (pre-, intermediate- and post-splicing forms) are
captured, the process of splicing can be studied in more detail and previously unknown splicing events
can be identified. This type of analysis has been very challenging until recently. However, the develop-
ment of high-throughput NGS, which involves highly parallelized sequencing of DNA or RNA, enabled
the whole transcriptome analysis at high resolution [100, 101, 102]. In contrast to microarray analysis,
RNA-Seq is a non-targeted approach, allowing the discovery of novel splicing events. Nevertheless,
the analysis of RNA-Seq data is still a challenge, since NGS experiments generally produce millions of
relatively short fragments (reads), even after paired-end sequencing came into play [103]. The distance
between the two sequenced ends of a read pair (“PE distance”) can be calculated and further taken into
account during alignment. Standard mRNA analysis of (paired-end) RNA-Seq data includes mapping
reads to the reference sequence, assembling the transcriptome and identifying the transcripts (transcript
deconvolution), which is often followed by counting transcript levels (transcript quantification).
While mRNA analysis programs and pipelines are suitable for finding novel exons and exon-exon
junctions, they do not consider the presence of pre-mRNA. Instead they analyze the end-result of the
splicing process, using mainly reads mapped to exons. For this reason these tools are not able to properly
deal with mixtures of pre- and mature mRNA, such as found in nuclear RNA extracts.
In this paper we are showing that splicing mechanisms can be analyzed using RNA-Seq data in more
detail than previously achieved. We present SplicePie – a pipeline which contains new, dedicated method
to analyze the order of splicing and pinpoint putative introns undergoing recursive splicing. Applying
this method we show that non-sequentially spliced introns can be identified even in a relatively fast
spliced gene. We also identify non-sequentially spliced introns in a gene that have never been reported
to undergo such splicing scenarios.
2.3 Materials and methods
2.3.1 Captured dataset
Fused myotubes from a healthy human muscle cell line were harvested and the nuclei were separated
from the cytoplasm using a sucrose containing lysis buffer, Dounce homogenizer and ultracentrifugation,
respectively. Nuclear and total RNA were isolated from the nucleus using the Nucleospin RNAII column
from BioKe Kit. DNAse treatment (RNAse-Free DNAse set by Qiagen) was performed to avoid DNA
contamination. Three micrograms of each sample were reverse transcribed into cDNA (SuperScript
II reverse transcriptase by Invitrogen), fragmented to the range of 100-600 bp by sonicating these
samples with two cycles of one minute (Covaris S220, Massachusetts, USA) and purified (QIAquick
PCR purification kit by Qiagen).
To capture target sequences we followed the SureSelect XT Target Enrichment System for the
Illumina Paired-End Sequencing Library (Agilent Technologies). Illumina adapters were ligated to
the fragmented sequences after end repair and A-base tailing (blunting). Further purification steps
(performed with the Agencourt AMPure XP beads in 1:1 ratio) eliminated unbound adapters and short
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fragments (<100 bp).
The library of probes to capture exons, introns and flanking regions of the target genes (FXR1, CKLF
and ACTB) was designed with the Agilent Technologies eArray software3, avoiding areas masked by
repeat masker and using partially overlapping probes. The 120 bp length probes were biotinylated four
replicates of each probe were designed to reach the required number of baits per library.
The designed library [104] was hybridized with the fragmented cDNA from nuclear RNA and total
RNA for 24 hours, followed by a washing step and pull down of the biotinylated cDNA probes using
streptavidin- coated magnetic beads. Eluted samples were amplified to allow for a multiplexed Illumina
run. The samples were quantified with the Agilent 2100 Bioanalyzer and Agilent HS DNA Chip Kit
(Agilent Technologies, USA). The samples were diluted to a concentration of 7 pM and loaded onto an
eight-channel flowcell and sequenced with the Illumina HiSeq 2000(Illumina, USA). After sequencing,
fastq files containing paired-end reads (read length of 100 bp) and the base quality information were
generated with CASAVA version 1.1 and used for further analysis.
2.3.2 ENCODE dataset
An RNA-Seq dataset representing a subset of the long RNA-Seq sequencing from ENCODE/Cold
Spring Harbor Lab was obtained from the CSHL Long RNA-Seq downloadable files archive (Long RNA-
Seq archive from ENCODE/Cold Spring Harbor Lab repository4. This dataset (“ENCODE dataset”)
contains RNA-Seq data from human immortalised myelogenous leukemia cell line, two samples of the
chromatin-associated RNA and one sample of total nucleus RNA. These samples were sequenced by the
Illumina Genome Analyzer II paired-end sequencing technique with read lengths of 75 and 100 bp.
2.3.3 General information
Alignment was performed with GSNAP version 2012-07-12 using a probabilistic mapping approach (one
alignment per read was randomly chosen in case of multiple mappings). Format conversions were done
with Samtools version 0.1.18 [39] and in-house scripts. Statistical manipulations and calculations were
performed using R version 2.15.1. The Ensembl [105] gene annotation was used for all post-alignment
analyses. Only publicly available software was used for the analysis.
2.3.4 Classification
After alignment, reads were classified according to their splicing stage. The first classification step
determines the type of region that the reads are mapped to: exon, intron, exon-exon junction or exon-
intron boundary (Table 2.1).
Each end of a read pair is given a label (Figure 2.1) and a “mapping distance”. Mapping distance
can be calculated for mapped read pairs by measuring the inner distance between the two aligned ends
of a read pair.
Apart from classifying reads into three main categories, we divide them into more specific subgroups.
Read pairs classified as intermediate-splicing reads are used for the analysis of sequentiality if one
end is mapped to the exon-exon junction and the second end is mapped to the adjacent upstream or
downstream intron. Read pairs having ends that are split across anything but an annotated exon-exon
junction are used to identify recursive splicing (ends of a pair are treated separately and the connection
3http://earray.chem.agilent.com





Table 2.1: Labels for reads based on the mapping location according to transcript annotation (j ¿ i).
Read start Read end Label
intron intron “int” (intronic)
exoni exoni “ex” (exonic)
exoni exonj “ex-ex” (exon-exon junction)
exon intron “ex-int” (exon-intron junction)
Figure 2.1: Classification of the paired end reads. A. “Mapping distance” reflects the inner distance between two read ends according to the
genomic coordinates after alignment. B. Classification scheme is built on read labels (“ex” stands for exon, “int” for for intron, “ex-int” for
intron-exon boundary, “ex-ex” for exon-exon junction) and mapping distance (within/outside expected mapping distance). Reads belonging
to pre-, intermediate-, post-splicing and unknown categories are marked with gray, black, striped boxes and a question mark. Example: if one
end of the read pair maps to the exon-intron boundary and the other one maps to the exon-exon junction, this read pair will be classified as
“intermediate”.
between the ends is not considered). Ends of read pairs from the pre-splicing category mapped to
the exon-intron boundary and read pairs from the post-splicing category (mapped to the exon-exon
junctions) are used to calculate the Splice Site Index.
2.3.5 Detection of non-sequential splicing
Non-sequential splicing is approached from two angles: coverage-based and read-based approaches.
For the coverage-based approach the difference between the median coverage of introni+1 and introni
is reported (Figure 2.3). We select negative differences and define the cutoff of significance as the first
quartile Q1 (25% percentile). If the difference is bellow Q1, this is an indication that introni+1 is non-
sequentially spliced before introni. This is calculated for every input sample. If a certain difference is
consistent across a number of samples, the corresponding pair of introns is reported.
The read-based approach addresses read pairs that indicate whether two introns are spliced sequen-
tially or non-sequentially (Figure S1).







Here non-seq is the number of reads supporting non-sequential splicing and seq is the number of
reads supporting sequential splicing of two adjacent introns. When introns are spliced sequentially, the
splice-ratio will be close to 1. However, when a downstream intron is spliced before an upstream intron,
the splice-ratio will be close to 0.
We improve the accuracy of the predictions by assessing how often independent read pairs support
the same pair of introns being spliced sequentially. Single events might indicate false positives due to
mapping artifacts (Figure 2.3).
2.3.6 Detecting recursive splicing
We hypothesize that if an intron undergoes recursive splicing, split reads will map across intermediate
splicing products. Recurring observations of these specific products confirm the existence of partially
spliced introns. To extract such reads, we first identify potential hotspots for recursive splicing (Fig-
ure S2). For each position we calculate how many times a read has been split over it (in other words, we
calculated the “inverted coverage” – coverage of gaps) and then calculate the derivative of this inverted
coverage. The derivative indicates where the inverted coverage changes relatively to the previous posi-
tions, implying how many reads share a breakpoint at that specific location. Positive values represent a
split’s start, while negative values indicate a split’s end. All other positions will have a derivative value
of zero. Each peak is reported in a wiggle file. Positions which are start- and endpoints for splits at
the same time are excluded from this analysis. Reads spanning exon-exon junctions are also removed,
as they indicate annotated exon-exon junctions and do not contribute to the investigation of recursive
splicing.
In order to reduce the amount of noise and false positives, we create wiggle files for all input samples
and evaluate the overlap in the requested number of samples. If the position has positive coverage in a
number of samples, the sum of the coverage from all files will be reported. This results in a single file
with the most robust positions. Reads covering the positions from the final list are extracted from the
initial bam file(s) and analyzed to validate the prediction of recursive splicing hot spots from the wiggle
file and get the connections between the peaks (which are lost in the wiggle file).
Additionally, a text file containing a matrix with all discovered junctions and the number of reads
supporting each junction is created per gene (Figure 2.4).
2.3.7 Calculating Splice Site Index and processing the coverage






Here SSI is the splicing index value, ex-ex is the number of reads spanning exon-exon junctions and
ex-int is the number of reads spanning exon-intron junctions.
A similar function, called completed Splicing Index (coSI), has been recently developed [6]. In
contrast to coSI, SSI is calculated separately for 5’ and 3’ splice sites of each intron, allowing for the
assessment of a) the relative abundance of each intron and b) whether both ends are spliced simulta-
neously. SSI, in combination with the median coverage of introns and exons, gives a more complete
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picture of the alternative splicing events. SSI is calculated as a ratio of different types of reads and does
not consider the difference between the absolute values of coverage.
2.3.8 Experimental validation of non-sequential and recursive splicing
Complementary DNA (cDNA) from three different healthy muscle cell lines (also used in the in sil-
ico analysis) was generated using the reverse transcriptase, 1 µg of pre-mRNA and random primers
(following the standard protocol suggested by SuperScript III RT by Invitrogen).
For the validation of non-sequential splicing, forward primers were designed against exon 10 or
intron 11. Reverse primers were designed against exon 11 or the junction of exon 11 and exon 12. All
combinations of primers were used to detect all splicing intermediates that can be formed in this area of
the gene. Each sample was analyzed with three technical replicates and normalized against the HPRT
gene. QPCR was performed on the LightCycler 480 (Roche Diagnostics Ltd.) using SYBR Green
mix. QPCR results were analyzed using LightCycler 480 and LinRegPCR software [106]. Independent
amplification, with primers in intron 10 and exon 12, was performed for further Sanger sequencing
analysis.
For the validation of recursive splicing events, we amplified the same synthesized cDNA template
using a pair of primers located upstream of the predicted donor and downstream of the predicted
acceptor splice sites. For the event with one non-annotated splice site the forward primer was located
in exon 16 and the reverse primer was located in intron 16. For the event with both non-annotated
splice sites both primers were located in intron 16. PCRs were performed with 35 cycles using Phusion
High-Fidelity PCR 2X Master Mix with HF Buffer (New England BioLabs Inc).
The amplification products were then separated on a 1.5% agarose gel after an RT-PCR reaction.




SplicePie starts with a standard quality check procedure, removes low quality reads and performs split
read alignment to the reference genome. The gene of interest is then extracted from the alignment file
and is used to calculate the Splice Site Index (SSI) and classify reads based on their stage of splicing
(pre-, intermediate- and post-splicing, see Section 2.3.4 and Table 2.1 for details). Reads from specific
categories are used to predict and pinpoint putative non-sequentially or recursively splice introns. An
overview of SplicePie is shown in Figure 2.2.
Alignment to the reference genome (hg19, GRCh37) is performed using GSNAP [107], an aligner
that works with paired-end RNA-Seq data and can split each read end into multiple fragments, thereby
coping effectively with a gene’s intron/exon structure. We have chosen GSNAP over Tophat [62, 108],
PASSion [36], HMMSplicer [109] and MapSplice [96] because, unlike these tools, GSNAP does not give
priority to split alignments. This is crucial for pre-mRNA data, as such data contains reads across exon-
intron boundaries. Unlike other tools, GSNAP uses the information about canonical and non-canonical
splice sites when splitting the reads, which is important for the identification of novel exons. It is also
able to split each read of the pair into as many fragments as necessary (in case of multiple adjacent
small exons). GSNAP provides the results in the commonly used sam format. SplicePie generates bam
and wiggle files from these sam files. Our analysis approach is mostly suitable for very detailed analysis,
therefore it is recommended to analyze one gene of interest at a time.
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Figure 2.2: Lay-out of SplicePie. Light-grey boxes indicate the files required/produced during the mainstream analysis. Labels in bold next
to the arrows indicate the steps of analysis. Labels in italic next to the arrows indicate the additional input files. Label int ex-ex indicates
that the file contains read pairs with one end mapped to the intron and the other end mapped to the exon-exon junction (and vice versa for
ex-ex int).
However, running SplicePie for multiple genes is also supported and all gene annotations provided
by the user in a standard GTF format will be used to build a list of the genes of interest. SplicePie
performs the classification of reads as pre-, intermediate- or post-splicing according to their mapping
position (see Section 2.3.4 for details). After classification all reads spanning a specific exon-exon
junction or an exon-intron boundary are used for the SSI calculation. SSIs will then be calculated for
each splice site (see Section 2.3.7 for details). The output is provided as a text file containing SSIs for
both 5’ (SSI5) and 3’ (SSI3) ends per intron. SSI value is calculated using the reads spanning exon-exon
junctions and exon-intron boundaries. This value is similar to the completed splicing index, coSI [6],
which reflects the amount of RNA molecules containing the exon with spliced adjacent introns. However,
SSI is calculated separately per splice site and therefore reflects the difference between 5’ and 3’, thereby
highlighting alternative splicing and/or incomplete splicing (while coSI reflects the completion of the
splicing of a particular intron).
A parallel branch of SplicePie is analyzing the order of splicing and predicts which introns are spliced
sequentially and which introns are spliced non-sequentially. Median coverage of each intron is calculated
and when the difference between the downstream introni+1 and the upstream introni is low, such pair
of introns is potentially non-sequentialy spliced. At the moment we define this value as “low” when it
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is below Q1, where Q1, or lower quartile, is defined as the middle number between the smallest number
and the median of the dataset (Figure 2.3, A).
Another branch of SplicePie processes the wiggle files and pinpoints introns potentially undergoing
recursive splicing. The wiggle files contain only the coverage of splice sites. We take all combinations
of donors and acceptors and calculate the number of reads supporting them. This creates a summary
matrix containing all potential recursive splicing events and their frequency in each sample (Figure 2.4).
Figure 2.3: Principles of the two approaches to investigate non-sequential splicing. A. Coverage-based approach with the underlying assumption
that the longer the intron is present in the sample, the higher the coverage will be. In case of non-sequential splicing the coverage of the
downstream introni+1 is likely to be lower than the coverage of the upstream introni. Median of the coverage of each intron is used in this
approach. B. The underlying assumptions for the read-based approach to detect non-sequential splicing: evidence for non-sequential splicing
is obtained from read pairs with one end mapped to the upstream introni and the other end mapped to the junction over the downstream
introni+1 (exoni+1-exoni+2 junction). C. Method to select the introns with non-sequential splicing. The read pairs supporting the splicing
intermediate where introni is spliced before introni+1 should be less abundant than the read pairs for the intermediate product where introni+1
is spliced before introni.
2.4.2 Alternative splicing events in captured dataset
Four nuclear RNA, four total RNA and one DNA sample (Table S1) were sequenced (see Section 2.3.1 for
details). The analysis of the target gene – FXR1 – will be discussed in this section. From the targeted
genes, we have studied the pre-mRNA splicing of (70,306 nt long) in detail because it is known to be
alternatively spliced, has an intermediate number of exons (18), introns with variable length between
86 and 18,338 nt and a decent intronic coverage (on average above 1,500 for nuclear RNA samples) in
the cell lines analyzed (Table S1). Note that the numbers of reads for the categories do not always
add up to the total number of reads mapped to the target, since we do not show the number of reads
defined as ’unclassified’ (see Section 2.3). The classification of reads into three categories supporting
pre-, intermediate- and post-splicing events is used to estimate the pre-mRNA content of samples (see
Section 2.3.1 for details). Compared to the total RNA samples, all nuclear RNA samples contain a larger
31
fraction of reads coming from the pre-splicing stage (Figure 2.5). This is expected, as total RNA is
isolated from the whole cell and consists mostly of mature messenger RNA, while nuclear RNA contains
(partly) spliced RNA. The post-splicing category contains a large fraction of reads even in nuclear RNA
samples, which might be a consequence of the fast splicing of FXR1, which makes it hard to capture the
nuclear pre-mRNA of this gene. Reads from the DNA sample were mainly classified as “pre-splicing”,
which is expected, since DNA is not supposed to contain any exon-exon junctions.
Figure 2.4: Graphical representation of the analysis of recursive splicing. Black boxes represent exons and grey boxes represent introns, dashed
lines across the introns and exon-intron borders represent positions of splits in reads. Numbers “1”, “2”, etc. on top of the gene schema
represent the positions of the gene in genomic coordinates. Thick lines connected with dashed lines represent split reads (where the dashed
part of the line represents the area across which the read is split). Step-by-step analysis of all split reads is shown and splicing intermediates
corresponding to each group of split reads are shown on the schema in left part of the figure. The matrix in the right bottom corner contains
donor splice sites (top row) and acceptor splice sites (left column). Each cell in the matrix represents the number of reads supporting such
junction. Numbers in the gray cells of the matrix represent reads with one new non-canonical splice site. Numbers in white cells of the matrix
represent reads with two new non-canonical splice sites (reads split within an intron).
In order to investigate alternative splicing events we use a combination of SSI values and medians
of intronic and exonic coverage.
As the coverage may be influenced by the probe hybridization efficiency, we evaluated the uniformity
of the coverage in the DNA sample D1 (Figure S3). The only dips in coverage take place in the Repeat
Masker regions, which were excluded from probe design (Figure S4). To confirm the limited influence
of probe hybridization on coverage, we calculated the standard deviation of the median coverage per
intron, which was only 11.52% of the average.
Median coverage has been calculated per intron, while SSI is calculated per 5’ and 3’ end of each
intron separately. SSI can indicate various alternative splicing events, i.e., (partial) intron retention and
exon skipping (data shown for sample N2, Figure 2.6).
Decreases in the SSI5 of intron 2 and in the SSI3 of intron 1 are indicative of the skipping of exon 2
in a subset of transcripts. This is confirmed by the relatively low coverage of exon 2. The coverage of
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Figure 2.5: Classification
of reads from the cap-
ture dataset mapped to
FXR1. For sample iden-
tifiers see Table S1. The
figure displays the percent-
age of reads mapped to
FXR1 classified into pre-
, intermediate- and post-
splicing fractions for pre-
mRNA and total RNA
samples in the captured
dataset.
intron 13 is significantly higher than the average intronic coverage, which can indicate intron retention
in both pre- and mature mRNA. This is also supported by low SSI5 and SSI3 values of intron 13, which
means that the number of reads mapped to the boundary of exon 13 and intron 13 and the boundary
of intron 13 and exon 14 are overrepresented. The retention of intron 13 and skipping of exon 2 were
experimentally confirmed for sample N2 (Figure S5). Thus, low SSI5 and SSI3 on the same intron are
the indication of an intron retention, whereas low SSI3 of an intron in combination with low SSI5 of the
next intron is an indicator of exon skipping.
We also developed a module to rank introns based on their probability to be retained. For retained
introns, both SSI5 and SSI3 values should be low. To estimate that, we calculate the magnitude of
SSIs (how big the difference between SSI5 and SSI3 values is) and the likelihood of each magnitude
(Appendix). The introns with the highest magnitude and a low p-value are the main candidates for
retention (Table S2).
2.4.3 Non-sequential splicing in captured dataset
In the captured dataset, we searched for non-sequentially spliced introns in FXR1. Multiple candidate
pairs of introns with a difference in median coverage below Q3 were found: introns 1 and 2; introns 3
and 4; introns 10 and 11; introns 16 and 17. (Here Q3 stands for the third quartile – the middle value
between the median and the highest value of the data.) To confirm this, we calculated the ratio of
read pairs in support over those not in support of non-sequential splicing. If the splice-ratio is close
to 1, the splicing is most likely sequential, the lower the ratio is, the more non-sequential splicing
occurs. We observed a very strong correlation between both methods, supporting the idea that these
methods are suitable to identify non-sequentiality spliced introns (Pearson R2 ≤ 0.86 and Spearman
R2 ≤ 0.85 (Figure S7).
We used DNA as a negative control, since DNA does not undergo splicing and the coverage of the
introns should not differ significantly. If introns have significantly different coverage on DNA level, this
may be due to sequencability, mappability bias or other technical artifacts (not a biological reason).
Two pairs of introns predicted to undergo non-sequential splicing in RNA samples (introns 3 and 4;
introns 10 and 11) survived this extra control step. They were not classified as non-sequentially spliced
in DNA. Introns 10 and 11 have been selected for further the experimental validation and showed to be
non-sequentially spliced (Figure 2.7).
33
Figure 2.6: Splice Site Index (SSI) and medians of coverage of exons and introns in FXR1. Gray bars in the left panel represent the coverage
of exons (exon 1 on top). Black bars in the middle panel represent SSI5 values the introns and gray bars on the middle plot represent SSI3
values of the introns (intron 1 on top). Black bars in the right plot represent the coverage of introns (intron 1 on top). Data shown for nuclear
RNA sample N2.
2.4.4 Recursive splicing in captured dataset
We searched for the evidence of multi-step splicing in our captured dataset (as described in Section 2.3.6).
Wiggle files containing coverage at positions where the reads were split have been created for four pre-
mRNA samples (reads spanning exon-exon junctions were excluded). We considered positions present
in all samples with the same sign for further analysis, because they were deemed most reliable.
We assessed the distribution of peak coverage and tried to identify the minimal coverage for the peak
to be included in the final list. We first investigated the highest peaks and found out that the coverage
of the regions between the peaks is higher compared to the rest of the introns. These observations let
us hypothesize that such intronic regions with high coverage and split reads mapped to them and to the
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Figure 2.7: Experimental valida-
tion of predicted non-sequential
splicing of introns 10 and 11 in
FXR1. A. The design of the
primers for the validation of non-
sequential splicing of intron 10.
B. The results of quantitative
real-time PCR showing the rela-
tive abundance (on the Y axis)
of splicing intermediates with
primer combinations described in
A (on the X axis). Since three
tested cell lines showed similar
reproducible results, the figure
shows the average. C. Results
of PCR showing the presence
of the fragment of anticipated
size. Lane 1 contains the marker,
lanes 2, 3 and 4 represent three
cell lines, lane 5 shows the nega-
tive PCR control. D. The results
of Sanger sequencing of the band
shown on C. The top panel shows
the output of Sanger sequencing,
black box around “AG” depicts
the acceptor splice site, the boxes
around “GA”, “AC” and “GG”
depict ends of the exons. The
bottom panel shows the design
of the primers for the sequenced
amplicon.
adjacent exons might be novel exons. We were able to experimentally validate one of potential novel
exons (Figure S6). Our findings thus suggest that the method developed for the detection of recursive
splicing events is also suitable for finding novel exons.
After excluding the peaks with the highest coverage we found eight events to be recurrent and
consistent across all RNA samples (Table S3). These events were not present in the DNA sample D1,
which had only 61 split reads (against hundreds of split reads in RNA samples), none of the split
positions was supported by more than one read. The vast majority of split reads in DNA were mapped
with a large number of mismatches (unlike split reads in RNA samples).
The most abundant events of recursive splicing occurred on the 5’ end of the intron (when the donor
splice site is canonical and the acceptor splice site is situated within the downstream intron, Figure S8).
The second biggest class (three cases, or around 40%) were the cases of recursive splicing occurring on
the 3’ end of the intron. We also found a pair of events with shared canonical acceptor splice site (the
intron 10-exon 11 boundary), which suggests the possibility of multi-step recursive splicing in this area
(Figure S9). Furthermore, we were also able to identify one recurrent event of inner recursive splicing
with two non-canonical splice sites (Figure S10).
The strength of the newly identified donor or acceptor splice sites associated with potential recursive
splicing events was assessed with Human Splicing Finder5. All sites were identified as highly probable
putative splice sites.
To obtain further evidence that the recursive splicing events identified by SplicePie are genuine,
we evaluated the sequence motifs flanking the splits. We selected events present in two, three, four or
five out of five samples and extracted the splice sites and two nucleotides upstream of the donor and
5http://www.umd.be/HSF3/HSF.html
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downstream of the acceptor sites. We calculated the percentage of canonical and non-canonical donor
and acceptor splice sites in the events with non-annotated donor or acceptor splice site. In this analysis
we omit potential recursive splicing events with both non-annotated splice sites, as they are more likely
to be novel exons. Such events require further experimental validation, and only experimentally showing
there presence in pre- and possibly mature mRNA will distinguish between recursive splicing and novel
exons.
Our results (Table S4) show strong enrichment for canonical donor (GT) and acceptor (AG) splice
sites for events with one non-annotated splice site present in five samples. The enrichment becomes
weaker for the events detected in only a subset of the samples, especially for the events with a non-
annotated acceptor site. This indicates that the recurrent events with one non-annotated splice site are
the most robust recursive splicing events. Note that the aligner we use does not have any preferences
for splice motifs when splitting reads.
Apart from the in silico validation, we also used RT-PCR followed by Sanger sequencing to validate
potential recursive splicing events. We designed primers flanking two events found in all five samples
and analyzed nuclear and cytoplasmic RNA isolated from two of the muscle cell lines. For the first event,
(chr3:180,689,975-180,692,201, Table S3), detected a product of the expected length and sequence. How-
ever, it was found in both nuclear and cytoplasmic RNA, suggesting that the detected event represents
a novel exon and not an intermediate splicing product. The second set of primers captured another
recursive splicing event that was not present in the RNA-Seq data.
2.4.5 Performance on non-targeted dataset
To demonstrate the performance of SplicePie on regular, non-targeted RNA-Seq data, three samples
from the Gencode project (the ENCODE dataset) containing RNA from different nuclear compartments
(chromatin- associated and nucleolus RNA) were analyzed following the same procedure as the captured
dataset. Around 95% of reads mapping to the FXR1 gene were classified as pre-splicing for chromatin
and nucleolus RNA in contrast with 20 and 60% for the nuclear and total RNA samples, respectively.
This is in line with the presence of pre-mRNA in chromatin and nucleolus, while mature mRNA is
prevailing in the nucleoplasm.
The values of SSI and medians of exonic and intronic coverage for the non-targeted RNA dataset (Fig-
ure S11) coincide with corresponding values calculated for the captured dataset. Low SSI3 for intron 1
and low SSI5 for intron 2 indicate the skipping of exon 2 and high coverage of intron 13 together with
its low SSI5 and SSI3 are indicative of intron 13 retention. However, the pattern of the medians is less
consistent for both exonic and intronic coverage. The C1 sample contains chromatin-associated RNA,
for which splicing is not known to be in action, the difference between the exonic and intronic coverage
is small, therefore the coverage values for chromatin-associated RNA are less informative than those for
nucleoplasmic RNA.
We were able to confirm the previous findings (of intron 10 and intron 11 being non-sequentially
spliced) using the approach based on median intron coverage (see Section 2.3.5 for details). Other
predictions were mostly confirmed in at least two out of three analyzed samples with the coverage-based
approach (data not shown). However, the number of reads needed to calculate the splice-ratio was not
high enough, so the majority of the ratios equalled zero.
The non-targeted RNA dataset was also analyzed in order to find potential recursive splicing events.
Five peaks were present in all three samples. Two of these peaks were found in the list of donor/acceptor
splice sites identified for the captured dataset. The number of splice sites identified per sample was
approximately 100, while the number of peaks for each sample of the captured dataset was over 450.
In order to demonstrate the performance of SplicePie on the whole-transcriptome dataset, we selected
TIA1 for the analysis of non-sequential and recursive splicing.
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Based on the difference in median intronic coverage (which was at least three times higher than the
upper quartile (75%) in all three samples) and high splice-ratio (average of 0.7 in the three samples),
we could predict two introns of TIA1 to be non-sequentially spliced. Neither intron 2, nor intron 3
are overlapping with any genomic elements that might influence the coverage, such as pseudogenes or
non-coding RNAs.
According to both considerable difference in coverage and high splice-ratio, intron 3 is predicted to be
spliced before intron 2 (Figure S12). Even more cases of potential non-sequential splicing were found in
two out of three samples, however, to claim that the order of splicing of these introns is non-sequential,
experimental follow-up is required.
We also investigated multi-step splicing in TIA1 and were able to detect a number of potential
recursive splicing events. Events present in all three samples C1, C2 and U1 with non-annotated donor,
non-annotated acceptor and both non-annotated splice sites were detected (Table S5).
Therefore, non-targeted total RNA-Seq data provides sufficient information to analyze recursive
splicing for some genes and can be used for the detailed investigation of splicing in action.
2.5 Discussion
Exploring pre-mRNA processing is facilitated by new sequencing technologies reaching higher through-
put, hence producing more data. The analysis of both pre- and mature mRNA provides new insights into
splicing mechanisms and alternative splicing events. However, current software is focusing on mature
mRNA and the identification (and quantification) of transcript variants.
The presented pipeline for the pre-mRNA data analysis, SplicePie, offers a number of approaches
and solutions to study splicing in more details. The proposed strategy performs well on different sample
preparations (sequencing the whole pool of RNAs, or capturing a gene with different relative quantities
of pre- and mature mRNA). Our method can detect various genuine alternative splicing events like
intron retention, exon skipping and novel exons. Furthermore, it is capable to resolve the order of
splicing and recursive splicing events.
The methodology of SplicePie significantly differs from existing pipelines, such as Cufflinks, Scrip-
ture [110] or MISO [111]. These tools focus their analysis on the end result of splicing and mainly use
reads mapped to the exons or exon-exon junctions. Reads mapped to the introns are either treated as
putative exons or not addressed at all (in case of annotation-based pipelines). Therefore these pipelines
are not able to analyze mixtures of pre- and mature mRNA (as found in nuclear RNA extracts). This is
crucial to understand the details of the splicing mechanism. Our pipeline SplicePie is specifically geared
towards the analysis of the full splicing process in action. In order to do so, it uses all reads mapped to
exons, introns, exon-exon junctions or exon-introns boundaries.
For the analysis of alternative splicing events, the SSI and the medians of exonic or intronic cov-
erage methods implemented in SplicePie are mutually reinforcing. In case of captured data enriched
with partly spliced nuclear RNA, the difference in exonic and intronic coverage makes the patterns of
coverage informative for assessing alternative splicing events. In case of “pure” nuclear RNA with lower
abundance of spliced fragments, the difference in exonic vs. intronic coverage drops, however, the SSI
values become more informative.
The main novelty of the methodology introduced in this paper is the possibility to analyze splicing
order and the stepwise nature of splicing. While we are able to judge local splicing order, i.e. one intron
is spliced before a neighboring intron, it is not possible to determine the global order of splicing for the
entire transcript. This happens due to the co-transcriptional nature of the splicing process and the fact
that we capture only one snapshot of the nascent transcript. We show that the local order of splicing
for certain introns within FXR1 is reproducible (in biological replicates) and even consistent across
multiple cell lines. Furthermore, this can be confirmed with independent PCR-based technologies.
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Although the fact that splicing can be performed in multiple steps has been known for over a
decade [112], however, it has never been analyzed bioinformatically. We show that analyzing the in-
termediate category of reads is possible for both potential novel exons and recursive splicing events.
However, focusing on a narrow fraction of reads might result in analyzing random events, which is why
we suggest to use as many samples as possible. To improve reliability even further it is advised to select
events occurring in a significant number of samples. This strategy also helps reducing biases introduced
by PCR duplicates, which are not likely to appear at the same position in replicates. The splice motif
analysis of potential recursive splicing events provides evidence that these events are genuine, consid-
ering the canonical splice motifs and the occurrence of the events across multiple cell lines. However,
as RNA-Seq is more sensitive than PCR, not all detected events can be experimentally confirmed at
the moment. Recursive splicing events with both non-canonical splice sites should be treated especially
carefully, as for these events it is hard to distinguish between recursive splicing and novel exons without
the experimental validation in both nuclear and cytoplasmic RNA.
Detecting background noise is a common problem in bioinformatics and statistics, especially when
working with large datasets containing a mix of introns and exons. Our approach was shown to perform
well on both high (captured dataset) and low (non-targeted ENCODE dataset) coverage data. Moreover,
despite the combination of low coverage and noise, alternative splicing events were detected reliably.
This indicates that total RNA sequencing can be used for detecting non-sequential splicing events
relying mainly on coverage information. SplicePie can be run on any dataset and the main concern is
the average coverage of the introns. Even recent total RNA sequencing protocols do not provide enough
intronic coverage to perform the analyses as powerful and reliable as the analyses on captured data. Our
study shows that even total RNA sequencing of specifically nucleus does not generate enough coverage
to detect non-sequential and multi-step splicing as efficiently as captured RNA libraries. Due to low
intronic coverage total RNA can be used to analyze splicing and certain events will be detected, however,
a lot of events will be missed. Therefore, we would still recommend to do the targeted sequencing of
the genes of interest to allow a more in depth analysis.
Using SplicePie on different datasets revealed various not yet annotated splicing events. Our work
enhances the value of pre-mRNA sequencing data and pioneers the investigation of the mechanisms of
(alternative) splicing.
2.6 Acknowledgements
We thank M. van Iterson and S.P. van Leeuwen for their help with statistical analysis, M. Vermaat for
his help with software development, M.P. Villerius for the help with running the analysis of the cluster,
M. van Galen for his extensive help with this manuscript and W. Arindrarto for suggesting the name
of the pipeline. This work was funded by ZonMW (project code NWO VIDI 91710303 to AAR) and by
the European Commission 7th Framework Program, Project N. 261123 (GEUVADIS).
38
2.7 Appendix
Table S1: Characteristics of samples and summary of results for reads mapped to FXR1. For each sample the reads were classified as pre-,
intermediate- or post-splicing based on the distance between paired ends (<650 being normal and >650 being larger than anticipated). Samples
















D1 DNA 306103 286501 148 29 209 6
N1 nuclear RNA1 317827 139084 11834 64750 6879 33688
N2 nuclear RNA2 586827 224231 28520 134229 12336 47954
N3 nuclear RNA3 431321 184823 15845 91217 12456 44680
N4 nuclear RNA4 1394314 707109 51856 222918 39003 141707
T1 total RNA1 242979 41232 11347 81826 9456 41048
T2 total RNA2 181383 28002 9234 62588 7222 31376
T3 total RNA3 261004 42412 10932 67126 13111 68536
T4 total RNA4 317123 60915 12528 81132 13901 72375
C1 chromatin
RNA1
21632 19445 169 489 77 209
C2 chromatin
RNA3
8600 7251 62 189 39 91
U1 nucleolic RNA 20283 16566 173 152 123 158
Table S2: Predicting intron retention events based on the magnitude of the SSIs and the p-value. Column “5′ ex-int” contains number of reads
mapped to the exon-intron boundary on the 5’-end of an intron (used to calculate SSI5). Column “3′ ex-int” contains number of reads mapped
to the exon-intron boundary on the 3’-end of an intron (used to calculate SSI3).
intron 5′ ex-int 3′ ex-int ex-ex magnitude p-value
1 2463 261 3768 0.03 0
2 679 1465 2100 0.14 6.08e-66
3 1202 1452 6821 0.08 1.32e-06
4 712 1571 10189 0.03 7.54e-74
5 769 1406 9705 0.04 6.09e-43
6 2125 940 17086 0.03 4.19e-104
7 324 1667 5493 0.03 3.13e-217
8 574 409 7064 0.03 1.58e-07
9 1034 1894 12403 0.04 1.46e-57
10 2032 3088 20646 0.05 1.54e-49
11 1840 82 12225 0.01 0
12 880 2660 14853 0.03 1.45e-205
13 7783 9550 7525 0.34 4.29e-41
14 1935 3046 18715 0.05 3.44e-56
15 8137 4099 30855 0.06 4.23e-297
16 4602 3264 11903 0.12 1.36e-51
17 786 2272 14427 0.03 1.15e-165
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Table S3: Representation of recursive splicing events (column “coordinates”) in the captured dataset. All detected events are located on
chromosome 3.
Coordinates Splice site N1 N2 N3 N4
180,653,019-180,665,633 acceptor 1 1 4 1
180,674,213-180,675,607 donor 2 2 4 2
180,674,835-180,675,607 donor 5 4 2 1
180,680,878-180,681,592 acceptor 5 1 4 2
180,686,042-180,687,934 acceptor 20 73 42 23
180,688,146-180,688,665 acceptor 8 401 85 29
180,689,975-180,692,201 both 5 9 10 3
180,692,935-180,693,101 donor 13 37 26 18
Table S4: Canonical and non-canonical splice sites in potential recursive splicing events.
Number of samples Non-annotated acceptor Non-annotated donor





Five out of five 4 75% 3 100%
Four out of five 36 86% 28 100%
Three out of five 53 90% 49 100%
Two out of five 78 85% 95 95%
Table S5: Representation of recursive splicing in TIA1 detected in the non-targeted dataset. Column “coordinates” contains the coordinates
of recursive splicing events in on the reference genome. Column “splice site” indicates which splice site is non-annotated. Columns “C1”, “C2”
and “U1” contain the number of reads supporting each recursive splicing event in each RNA sample from the non-targeted dataset.
Coordinates Splice site C1 C2 U1
70,443,631-70,443,885 donor 15 3 61
70,451,761-70,452,460 donor 16 5 7
70,451,761-70,452,597 donor 1 1 1
70,452,525-70,454,867 acceptor 15 3 17
70,454,954-70,455,476 donor 23 15 16
70,455,594-70,456,191 acceptor 20 20 13
70,457,986-70,460,773 donor 4 3 6
70,460,894-70,463,211 acceptor 1 1 2
70,463,307-70,465,921 donor 5 2 2
70,469,796-70,469,830 both 5 3 2
40
Figure S1: Read pairs supporting sequential (“seq”) or non-sequential (“non-seq”) splicing. Thick black lines represent ends that were split
over a junction (and the thin black line connects the pieces from one end of a read pair). Thick gray lines represent ends mapped to the introns.
























Figure S2: Schematic representation of the recursive splicing analysis. A split read (not mapped to an exon-exon junction) is used to calculate
the inverted coverage. The derivative of the inverted coverage is then calculated, producing peaks at the positions where the split starts and
drops at the positions where split ends. The size of peaks and drops equals the amount of reads split at this position.
41
20 kb hg19




Repeating Elements by RepeatMasker
Figure S3: Overview of the coverage across the whole gene being evenly distributed across exons and introns. Coverage of exons and introns in
the DNA sample and its correlation with the probes and Repeat Masker regions. Top panel (“RefSeq Genes”) indicates the NCBI annotation
of the FXR1 gene used for the analysis, thick blocks depicting exons and thin lines with arrows depicting introns. Second panel (“sample
D1”) shows the coverage of the DNA sample from the captured dataset (y-axis reflects the coverage, maximum coverage being over 2000).
Third panel in red (“Probes”) reflects the areas that have been covered by probes (blank areas depict the regions where no probes have been
designed). The bottom panel (“Repeating Elements by Repeat Masker”) indicate the Repeat Masker track provided by UCSC that has been
used to design the probes (black areas depict repetitive elements that were not included in the probes).
1 kb hg19




Repeating Elements by RepeatMasker
Figure S4: Zoomed-in overview of the coverage, showing no difference between the coverage distribution across an exon and an intron.
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Figure S5: The results of PCR amplification experiments proving a skip of exon 2 and a retention of intron 13 in FXR1, as predicted in silico
by the pipeline. A. PCR primers were designed to anneal to exon 1 and exon 5, and this fragment was amplified. The highest peak indicates
a fragment of exon 1-exon 5 without exon 2 (228 bp in length). The abundance of transcripts containing exon 2 is very low and the fragment
containing exon 2 (571 bp) is not visible. B. PCR primers were designed to anneal to exon 12 and exon 15, and the targeted fragments were
amplified. The lower peak indicates a fragment with intron 13 inclusion (367 bp in length). The higher peak indicates a fragment without
intron 13 (282 bp in length).
Calculating magnitude and likelihood for each intron of a gene in order to estimate its probability




min(ex-int1, ex-int2) + ex-ex
(2.3)
p–value = p-valuebinom(ex-int1, ex-int2, 0.5) < 0.05 (2.4)
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Figure S6: Novel exon (in red) predicted by the pipeline and its location in the full-length FXR1 transcript. The exon is located between
exons 16 and 17 (according to the annotation used in this paper). The full-length transcript has been experimentally validated by Sanger
sequencing.
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Figure S7: Linear correlation between the difference in median coverage (introni+1 – introni) and the splice ratio. Correlation shown for the
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Figure S10: Example of recursive splicing with two non-canonical splice sites in intron 16.
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Figure S11: Splice site index (SSI) and medians of coverage of exons and introns in FXR1 for sample C1 from the ENCODE dataset. Gray
bars in the left panel represent the coverage of exons (exon 1 on top). Black bars in the middle panel represent SSI values for the 5’ end of the
introns and gray bars on the middle panel represent SSI values for the 3’ end of the introns (intron 1 on top). Black bars in the right panel





















Figure S12: Graphical representation of two potentially non-sequentially spliced introns of TIA1 – intron 2 is predicted to be spliced after intron
3. Top three panels represent the coverage from samples N1, N2 and U1. Coverage is the value on the y-axis, and the genomic coordinates
are the value on the x-axis. The bottom panel represents the annotation of the gene available in the RefSeq database. Thick blocks represent
exons, thin lines with arrows represent introns. Note that the gene is transcribed from the reverse strand and on the figure intron 2 is situated
downstream (on the right) from intron 3. None of the introns with high coverage are annotated as retained introns, which gives an extra
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3.1 Abstract
The dystrophin protein encoding DMD gene is the longest human gene. The 2.2 Mb long human
dystrophin transcript takes 16 hours to be transcribed and is co-transcriptionally spliced. It contains
long introns (24 over 10kb long, 5 over 100kb long) and the heterogeneity in intron size makes it an
ideal transcript to study different aspects of the human splicing process. Splicing is a complex process
and much is unknown regarding the splicing of long introns in human genes. We used ultra-deep
transcript sequencing to characterize splicing of the dystrophin transcripts in three different human
skeletal muscle cell lines, and explored the order of intron removal and multi-step splicing. Coverage
and read pair analyses showed that around 40% of the introns were not always removed sequentially.
Additionally, for the first time, we report that non-consecutive intron removal resulted in three or more
joined exons which are flanked by unspliced introns and we defined these joined exons as an exon block.
Lastly, computational and experimental data revealed that, for the majority of dystrophin introns,
multistep splicing events are used to splice out a single intron. Our data show for the first time in a
human transcript, that multi-step intron removal is a general feature of mRNA splicing.
3.2 Introduction
Splicing involves hundreds of proteins that coordinate the excision of introns from the pre-mRNA,
joining the exons and resulting in mature mRNA transcripts. Multiple alternatively spliced transcripts
can be produced from a single pre-mRNA molecule through a highly regulated process, and its disruption
contributes to a large number of human genetic disorders that either directly cause disease or increase
disease susceptibility [113]. RNA splicing occurs after assembly of the spliceosome on the pre-mRNA,
which includes splice site recognition and intron removal steps [114]. Splice site recognition relies on the
identification of exon/intron boundaries. This is achieved by five (U1, U2/U12, U4/U6 and U5) small
nuclear ribonucleoprotein particles (snRNPs), together with more than 100 auxiliary proteins and trans-
acting splicing factors (SR proteins and heterogeneous ribonucleoproteins (hnRNPs)) [115, 116, 117].
The correct recognition is supported by cis-acting splicing signals [118], such as the consensus donor
(5’) and acceptor (3’) splice sites (SS), the branch point sequence (BP) and polypyrimidine tracts
(PPT). Additional exonic or intronic splicing enhancers (ESE or ISE) and silencers (ESS or ISS) motifs
can influence the inclusion or exclusion of an exon by recruiting trans-acting splicing factors. Intron
removal (Figure 3.1, A) is the result of two phosphoryl transfer reactions during the spliceosome assembly
formation on the pre-mRNA, and the catalysis can only occur after the intron is transcribed. The precise
excision of the intron results in the release of a lariat RNA [119, 120] and in two ligated exons.
It has recently been reported that the chromatin structure, the transcript elongation rate and the
pausing of RNA Polymerase (Pol) II can contribute to the regulation of splicing [121, 122, 123]. It
has been established that splicing can occur cotranscriptionally, when the nascent transcript is still
attached to the DNA through RNA Polymerase II [87, 121, 124, 125, 126], and/or post-transcriptionally,
when splicing occurs after transcription has completed and the transcript has been transferred to a
different nucleoplasmatic location, the speckles [126]. Additionally, Vargas et al. [126] showed that
constitutive introns are mainly co-transcriptionally spliced, while alternative splicing may occur post-
transcriptionally [87, 127, 128, 129]. The order of intron removal may confer an important regulatory
layer for alternative splicing.
For large introns, the precise excision and the efficiency of splicing may be hampered by the presence
of multiple splice site-like sequences. Furthermore, the physical distance between donor and acceptor
splice sites offers a challenge. It has been suggested that secondary RNA structure leads to juxtaposition
of remote canonical donor and acceptor sites to facilitate identification and joining of splice sites [130],
but additional mechanisms to facilitate splicing of long introns have been reported for invertebrates,
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such as intron removal in multiple steps (Figure 3.1) [112, 131, 132, 133].
Recursive splicing can occur in different ways. In the 5’ recursive splicing (RS) (Figure 3.1, B, left
panel), a canonical donor splice site is spliced to an internal acceptor site, generating a 5’ ratcheting
point (5’RP) from the juxtaposed exon and 5’ splice site sequences. A similar process can also take
place at the 3’ splice site, but now an internal donor splice site is spliced to the canonical acceptor,
to generate a 3’RP (Figure 3.1, B, right panel). This process can be repeated multiple times, creating
5’ or 3’ splice sites (SSs) that can be used as donor or acceptor splice sites in the next splicing step.
Alternatively, 5’ and 3’ RP steps can generate an intermediate intronic cassette (intermezzo), which
is removed in the last step of splicing (Figure 3.1, B, bottom panel). Finally, intrasplicing or nested
splicing has been proposed as a third potential mechanism [98, 133]. Here the intron is first shortened
by one or more internal splicing steps using internal donor and acceptor sites, and then in the final step
what remains of the intron is spliced out using the canonical 5’and 3’ SSs upstream and downstream
exons are joined (Figure 3.1, C).
Detailed studies on recursive splicing have been performed in Drosophila [112, 131, 132, 134], but
only few analyses, for single intron, have been done for human [98, 135], and vertebrates [130].
The dystrophin protein encoding DMD gene is the longest human gene (2.2 Mb). The coding regions
represent only 0.7% of the gene, and the gene has exceptionally long introns (average 28 kb, size range
107 bp - 360 kb). In the1990s, evidence for co-transcriptional splicing for dystrophin transcripts was
provided [136]. This finding was expected, considering that full transcription of the gene takes an
approximately 16 hours at an average elongation rate of 2.4 kb min−1.
The size and complexity of the gene, containing 79 exons, long introns, 7 different promoters, 2 sites
of polyadenylation and numerous alternative transcripts, has always hampered characterization of the
DMD transcriptome and detailed analysis of its processing. Indeed, only recent experimental evidence
of an internal lariat of dystrophin intron 7 suggested that this long intron (110 kb) might undergo to
nested splicing [98].
In the last few years, the development of next generation sequencing technologies has opened a new
horizon for the detailed analysis of transcript processing. The DMD gene is an excellent candidate for
in depth analysis of the relationship between intron length and the order of intron splicing, as well as
the occurrence of splicing of the large introns in multiple steps.
Here we present detailed analysis of dystrophin pre-mRNA intron splicing using targeted paired end
sequencing of transcripts, Capture-pre-mRNA-sequencing. We provide evidence that the order at which
introns are removed is not consecutive, leading to the formation of blocks of exons flanked by unspliced
introns. We further show the occurrence of multi-step splicing in many dystrophin introns, and show
for the first time the characterization and validation of recursive splicing in the dystrophin transcript.
3.3 Materials and Methods
3.3.1 Cell culture
All experiments were conducted using three immortalized control muscle cell lines (7304, Km155, 8220)
generated by Zhu et al. [137] that were propagated and differentiated as described previously [138].
In short, cells were cultured in Skeletal Muscle cell medium ((PromoCell GmbH, Germany) with 20%
Fetal Bovine Serum (FBS), 1 of penicillin/streptomycin (P/S; Gibco-BRL) at 370C in a humidified
atmosphere with 5 CO2. One hundred million cells were seeded and, as they approached a confluence
of 70%, proliferation medium was replaced with differentiation medium (DMEM, 2% horse serum, 1%
P/S) to obtain multinucleated myotubes. Cells were allowed to differentiate for 8 or 14 days.
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Figure 3.1: Single and multi-step splicing model. A. Single step splicing. The intron is fully removed in one step using annotated 5’ and 3’
splice sites (black rectangles), to join neighboring exons (gray boxes, (N and N+1)). B. Recursive splicing. In the case of 5’ recursive splicing
(5’RS) or 3’ recursive splicing (3’RS), the intron is spliced in multiple steps (ratcheting points), each starting from the 5’ or 3’ splice site (SS),
respectively (left and right panel). Each step generates a new 5’ or 3’ recursive splice site (5’RSS or 3’RSS, white rectangles) respectively. A
combination of 5’ and 3’ recursive splicing or intermezzo can also occur (lower panel). In this intermezzo splicing, parts I and II of the intron
are first removed beginning from the 5’ or 3’ splice sites, leaving part of the intron (III) containing new unannotated 5’ and 3’ RSS (white
rectangles), after which the final part of the intron is spliced. C. Nested splicing. The first step(s) of intron splicing consist of removal of (an)
internal part(s) of the intron using internal 5’ and 3’ splice sites (white rectangles). Subsequently, the remaining part of the intron is removed
using the regular 5’ and 3’ splice sites that border the exon-intron boundaries (black rectangles).
3.3.2 Subcellular fractionation and RNA extractions
Nuclear and cytoplasmic fractions were separated as previously described , with minor changes. All
steps were carried out on ice.
At eight and fourteen days after initiating differentiation, cells were harvested via trypsinization and
centrifuged for 10 min at 2000g. After washing twice with cold PBS, the pellet was resuspended in 2 ml
ice-cold sucrose buffer I (0.32 M sucrose, 3 mM CaCl2, 2 mM magnesium acetate, 0.1 mM EDTA, 10
mM Tris-HCl, pH 8.0, 1 mM DTT, 0.5% Triton) and dounced ten times in a cold Dounce homogenizer.
The resulting lysate was transferred to a new tube and mixed with 2 ml of sucrose buffer II (2 M
sucrose, 5 mM magnesium acetate, 0.1 mM EDTA, 10 mM Tris-HCl, pH 8.0, 1 mM DTT). The sample
was carefully layered on 2.2 ml of sucrose buffer II and was balanced using sucrose I buffer on top off
the gradient, then centrifuged at 30,000 g for 45 min at 40C (SW 40.1 rotor). After centrifugation, the
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supernatant (cytoplasmic fraction) was carefully removed and treated with proteinase K for 1h at 370C,
whereas the tight pellet consisting of nuclear fraction was dried at room temperature. Precipitation
of the cytoplasmic fraction was performed using 0.1 volume of 3M sodium acetate, 2µl paint pellet
co-precipitant (Novagen) and 2 volumes of 100% ethanol, followed by 48h at -800C. After centrifugation
at 30,000g for 30 min at 40C, washing steps with several volumes of 70% (v/v) ethanol were carried
out, followed by a second centrifugation with identical conditions. The pellet was stored at -800C for
further RNA isolation. In parallel, the pellet of nuclei was gently rinsed with cold 1mM EDTA in PBS
and resuspended with 200µl of ice-cold glycerol storage buffer (50 mM Tris-HCl, pH 8.3, 40% (v/v)
glycerol, 5mM MgCl2, 0.1mM EDTA), followed by RNA isolation or storage at -80
0C.
RNA from the nuclear and cytoplasmic fractions was isolated using NucleoSpin RNAII (Macherey-
Nagel) and eluted into 50µl of water, following the manufacturer’s protocol. Additional treatment with
DNase-free RNase (Qiagen) was performed for 15 min at 220C, to completely remove DNA, followed by a
precipitation step as previously described. Quality and concentration of isolated RNAs were tested using
RNA lab on chip (Agilent’s Bioanalyzer 2100) and aliquots were reverse-transcribed with SuperScriptTM
III (Invitrogen). QPCR was performed with intronic and exonic primers for selected genes in order to
test DNA contamination in the samples lacking reverse transcriptase.
3.3.3 cDNA synthesis
Four µg of pre-mRNA was used as template for cDNA synthesis. Reverse transcription was performed
with 3µg/µl random hexamers primers (Invitrogen) at 550C for 1 h, using SuperScriptTM III first-
strand Synthesis System (Invitrogen), according to the manufacturer’s protocol. After the first strand
was synthesized, a second-strand synthesis was generated by adding (5X) second strand synthesis buffer
(Invitrogen), 25nM dNTPs, RNase H and DNA polymerase I (Invitrogen) for 2.5 h at 160C. The double
stranded cDNA was then cleaned up with the MinElute PCR purification kit (Qiagen) and eluted in
30µl EB buffer.
3.3.4 Custom library design
A customized probe library was generated using the eArray software (Agilent Technologies), as described
in the user’s guide. The synthetic 120-mer biotinylated oligonucleotide probes (baits) in solution were
tiled along targeted intronic and exonic regions of the DMD and three different human control genes
(FXR1, CKLF and ACTB). The genomic sequences corresponding to the four target genes were based
on UCSC hg19-GRCh371. To ensure capturing of intron containing pre-mRNA transcripts and low
abundant transcripts, each sequence of the gene (except repeat areas) was covered generally by at least
four baits, and the DMD promoter regions were covered on average by eight baits. The maximum
capacity of the synthesized library was up to 55K baits. The following parameters were chosen: sense
strand, 1x capture-probe tiling frequency, layout strategy-centred, 20 bp overlap region between baits
and avoid repeated masked regions.
3.3.5 Pre- and post-hybridization sample preparations and Illumina se-
quencing
We created a library starting from 4 µg of pre-mRNA. Five cDNA capture libraries were generated
from three different cultures cell lines: 7304 cells (three independent biological replicates), KM155 and
8220 cell lines. Our method has been slightly modified from the version provided by SureSelectXT
1chrX:31,137,336-33,357,726; chr3:180,630,234-180,695,106; chr16:66,586,466-66,600,190; chr7:55,70,372-55,66,779 for
DMD, FXR1, CKLF and ACTB, respectively
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Target Enrichment System for Illumina Paired-End Sequencing Library (based on Agilent Technologies’
updated versions). An additional cDNA synthesis step has been integrated to the original procedure
Agilent prepped library protocol, which was designed for genomic DNA. Since our customized capture
library is highly specific for four genes only, no ribosomal RNA depletion was done.
To define the best sample preparation method, we generated two different cDNA libraries using
random primers and pre-mRNA isolated from nuclei of a differentiated healthy muscle cell line. In
brief, cDNA, synthesized as previously described, was sheared using a Covaris instrument (Covaris,
Inc.) at duty cycle 5, intensity level 5 and 200 cycles for burst (180s). The second method has been
tested in parallel, in which pre-mRNA was fragmented before cDNA synthesis by the addition of 5
times fragmentation buffer (Ambion), heating at 700C for 15 minutes and 5 minutes on ice. In both
methods reverse transcription was applied to generate cDNA, using the same protocol as previously
described and followed by purification with MinElute PCR purification kit (Qiagen). The cDNA ends
were first repaired to obtain uniform double-stranded fragments with blunt ends, and then additional
adenine residues were added to the fragment extremities to increase the efficiency of the following step.
Finally, adaptors for Illumina sequencing were ligated in a concentration 2 fold less than provided in the
instruction. Between each of the previous modification steps, a clean-up was performed using AMPure
XP beads (Agencourt Bioscience Corporation) following the ratio beads/sample suggested by user’s
guide. With the exception after the adaptor ligation step, where the used ratio was 1:1 (volume). The
following minor changes were made to the Agilent Technologies’ protocol: the beads/sample thermo-
mixture was incubated for 15 min at 220C in a thermo mixer (1200 rpm), fresh 80% (v/v) ethanol was
used and the elution step was performed at 370C in a thermo-mixer.
A pre-hybridization amplification was performed with a limited number of cycles (5), reaching the re-
quired 500 ng of sample for the library hybridization step without amplification-induced biases. Primers
were removed with 1 volume of AMPure XP beads, following previously described methods. This gen-
erated a cDNA library ranging in size from 160 to 660 bp. During the multiple steps of the sample
preparations, the library quality was evaluated with an Agilent Bioanalyzer 2100 using HS DNA chips.
The sample was concentrated to 3.4 µl and mixed with 2 µl of the customized capture library (Agilent
Technologies, Inc. USA). The hybridization was further performed as described in the SureSelectXT
Target Enrichment System for Illumina Paired-End Sequencing Library manual. Post-hybridization am-
plification (12 cycles) with a different sequence index (barcode) per sample allowed pooling of samples,
creating a multiplex libraries.
Amplified material was purified with AMPure XP beads, as early described previously. This step
was repeated twice to minimize the amount of unused primers and reduce their sequence read bias.
Using SureSelectXT multiplex indexes, several post-capture amplified samples were pooled to a final
concentration of 2 nM and with fragments size of 250-650 bp. The resulting pool of libraries was
sequenced on an Hiseq PE 2x100 Illumina at a concentration of 7 pM. Output files in fastq format of
the five Capture-pre-mRNA-seq containing paired-end reads and QC information were generated using
CASAVA version 1.1.
3.3.6 Analysis workflow
In order to detect non-sequentially spliced introns, exon blocks and to identify recursive splicing events,
we used the pipeline described in [139]. For the classification and motif analysis scripts, we refer the
reader to the materials available online2.
Alignment, post-alignment quality control: The pipeline first maped paired-end RNA-Seq
data to a reference genome sequence (hg19, GRCh37) with GSNAP aligner version 2012-07-12 [107].
Only uniquely mapped reads with a maximum of 5 mismatches in each end of a read are reported. All
2https://git.lumc.nl/i.pulyakhina/pipeline paper/tree/master
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format conversions were done with SAMtools version 0.1.18 [39]. For downstream analysis we extracted
reads mapped to the target genes: DMD, FXR1, CKLF and ACTB. The annotations containing the
coordinates of each exon and intron for each gene have been extracted from the RefSeq database3.
To remove samples with low sequencing yields, we included only samples where the number of reads
mapped to the DMD gene was >500,000. Considering the length of the DMD transcript for Dp427m
(2,092,329 nt) and the length of paired-end reads (2 times 100 nt) this cut-off means that each position
of the DMD gene was covered on average around 50 times. The same cut-off was applied to RNA and
DNA samples.
Coverage – median coverage of exons and introns: The median value of the coverage (Ta-
ble S1) of each position within the corresponding intron or exon was calculated using the median ()
command in R (version 2.5.1.1). We excluded such regions as promoters, UTRs and pseudogenes that
can potentially influence the coverage and bias the median coverage of introns (Table S2). We only in-
cluded areas of introns and exons that were covered by our designed probes (Table S3). This calculation
reflected an accurate coverage for all introns, except intron 40, where a small area was highly covered
even after removal of a known UTR. We considered this intron an outlier. Positions with zero coverage
were also included in calculating the median. To make the coverage comparable in the different cell line
samples, the coverage for each exon and intron was normalized using the average coverage of the DMD
exons in all cell lines, and the median of the normalized coverage was used for further analysis.
Coverage – no GC bias: To estimate the influence of GC content on the median coverage, we
calculated the length of each exon and intron and the fraction of nucleotides that consisted of G and
C and built a linear regression of the coverage and the GC content for both DNA and RNA samples.
Since no significant correlation of GC content with median coverage of introns was found (p-value=0.26
or higher), median coverage values were not normalized for the GC content.
Classification of reads: Reads were classified in three categories, based on the location of the
alignment and the distance between the two mapped ends of a read pair (expected insert size is ap-
proximately 400 nt). According to the reference alignment the reads were aligned in the exon, intron,
exon-intron boundary or exon-exon junction. Following the reads were classified as pre-, intermediate-
and post-splicing. Mainly, reads belong to the intermediate-splicing category were used for downstream
analysis. If the distance between the two mapped ends of a read pair were higher or lower than the
expected insert size, reads were labelled as “large” or “normal”, respectively. Reads fully mapped to an
exon were classified into a separate category.
Splicing order analysis: The median coverage of each intron was used to extrapolate an estimated
the order of intron removal, based on an assumed correlation between the coverage depth and the relative
speed of intron removal: the slower the intron is removed, the longer the target is available and the
higher is the coverage. The average of the median normalized intron coverage from the five (Capture-
pre-mRNA-seq) libraries was used for downstream analysis. We assessed 26 units of 5 introns, shifting
3 introns for each subsequent unit. Next we compared the normalized coverage of each intron in the
unit, defining two recurrent values (90 and 130) as the cut-offs. Introns with an average coverage of
less than 90 (low coverage) were considered to be spliced quickly (fast splicing), while introns with an
average coverage of more than 130 (high coverage) were considered to be spliced slowly (slow splicing).
The remaining introns with a coverage of 90-130 were considered to be spliced at an intermediate rate.
A paired-end split reads-based method was applied for a straightforward analysis to confirm the
results of the coverage-based analysis. We counted paired-end reads having one split read spanning an
exon-exon (ex-ex) junction and the second read mapped to the intron (in) immediately up- or down-
stream (Figure S1, A). The identification of this type of fragments is limited by the size of the captured
3http://www.ncbi.nlm.nih.gov/refseq, GRCh37.p13 RefSeq gene identifiers are NC 000023.10 (Chromosome X, DMD),
NC 000003.11 (Chromosome 3, FXR1), NC 000016.9 (Chromosome 16, CKLF) and NC 000007.13 (Chromosome 7,
ACTB)
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fragments (250-650nt). However, internal DMD exons range in size from 32-275nt, and this allows for
the detection of splicing intermediates that involve two or more consecutive exon-exon junctions. We









In this formula, “exn-exn+1 ... intn+1” or “S” reflects the number of read pairs supporting sequential
splicing, where one read of a paired-end spans an exon-exon junction arising from the splicing of the
intron, while the other maps to the intron immediately downstream (i.e. for intron 33 this would be
the number of read pairs where one read spans the exon 33-34 junction and the other read maps to the
intron 34).
“intn ... exn+1-exn+2” or “NS” reflects the number of read pairs supporting non-sequential splicing,
where one read of a paired-end maps to an intron, while the other covers the exon-exon junction resulting
from the splicing of the intron immediately downstream (i.e. for intron 33, one read pair would map to
intron 33, while the other would map to the exon 34-35 junction).
We calculated the splice-ratio for each intron and defined introns with a splice-ratio between 0.5
and 1 as sequentially spliced, as the result of reads supporting sequential splicing (S) are more than
non-sequential (NS), while introns with a splice ratio of <0.5 were defined as non-sequentially spliced.
Recursive and nested splicing: Potential recursive and nested splicing events were predicted
using split reads belonging to the intermediate-splicing category. The first and second reads of each
read pair were analyzed separately as single end reads. Each uniquely mapped read that contained
a gapped alignment was selected. Two base pairs at the beginning and at the end of the gap, that
were not covered by the reads, were classified as candidate donor and acceptor splice sites. The splice
sites were assigned based on the split point of the read, the alignment of the flanking sequences and
considering the two nucleotides that had the highest similarity to the splice site sequence. Identified
split reads containing two annotated splice sites were discarded. However, when the donor and/or the
acceptor were not present in the reference annotation of the gene, the read was selected for downstream
analysis. We added the number of reads of the three biological replicates from the same cell line and
performed the analysis for the three different cell lines and selected events present in all three datasets.
Predicted recursive splicing events were reported as a matrix containing the upstream and down-
stream genomic nucleotides flanking the position where the read was split. A matrix where the rows
contained positions of the donor and the columns contained positions of the acceptor splice sites was
created, and the intersecting cell represented the number of reads for that specific pair of the donor and
acceptor site. All the splicing events were also listed in a separate text. We analyzed events happening
within one intron. Reads split within the first 50 intronic nucleotides (near the exon-intron boundary)
were not considered, as they were thought to represent variation in normal exon-exon splicing (including
the well established NAGNAG splice site variations). We classified the events based on (Figure S1, A),
as recursive (5’RS, 3’RS) and nested splicing.
Motif analysis: We performed motif analysis on the donor and acceptor splice sites from the
predicted recursive and nested splicing events. We extrapolated the sequence of the annotated and
non-annotated 5’ and 3’ splice sites from each event and additionally the two nucleotides upstream
from each donor splice site and two positions downstream from the acceptor splice site. Four extracted




For exon block validation, experiments were performed on nuclear RNA from two cell lines and triples
were performed independently three times. For recursive splicing validation, experiments were performed
on nuclear and cytoplasmic RNA from two cell lines. PCR primers for all targeted DMD introns and
exons were designed using Genomic refseq ID NG 012232.1 (Table S4). As a template, 1 µg of isolated
pre-mRNA was reverse-transcribed using SuperScript III (Invitrogen), following the manufacturer’s
instructions.
Exon blocks were validated using qPCR. Quantitative RT-PCR was performed in a 8 µl reaction
containing 4 µl SYBR Green master mix (ThermoScientific), 0.2 pM each primer, and 2 µl of diluted
cDNA template. PCR was performed on the LightCycler 480 (Roche Diagnostics Ltd.). Thermal
Cycling conditions were as follows: 500C for 2 min, 950C for 10 min, 45 cycles of 950C for 15 s and
60 0C for 1 min. Analysis of the raw data and PCR efficiency was performed using the LinRegPCR
software [106]. For all combinations of primers a Reverse Transcriptase negative control sample was
included to exclude DNA contamination. A pair of primers covering the unspliced intron and immediate
downstream exon was used to confirm the ability of the intronic primer to generate a PCR fragment.
For primers spanning an exon-exon junction, there was little flexibility for primer design, resulting
sometimes in low primer efficiencies. For each exon block, all qPCRs were performed simultaneously.
HPRT was used as a reference gene.
PCR followed by Sanger sequence (Figure S1, B) was used to confirm the specific splice junctions
in the predicted exon blocks and splicing events. For the exon blocks, we designed primers in the
unspliced intron and in the last exon, where for the splicing events, we used specific primers upstream
and downstream the split reads (Table S5). cDNA was generated from 100 ng of pre-mRNA using 2x
master mix buffer (Ambion) and 1 µl of enzyme in a total volume of 50 µl. PCR reactions were carried
out as per manufacturer’s instructions. Each assay was performed for the two different cell lines. The
PCR was performed using initial denaturation at 980C for 2 min followed by 35 cycles of (980C for
15s, 550C for 30s, 720C for 30s) and a final extension of 720C for 10min. The PCR products were
subsequently analyzed on a 2% agarose gel. After purification with the MinElute PCR purification kit
(Qiagen), the amplicons were analyzed using Sanger sequencing. The results were blasted in the UCSC
genome browser5 to confirm the correct sequence and identify intron-exons and exon-exon junctions for
each exon block.
3.3.8 Data availability
The fastq and bam files used in this study are accessible online6 through European Nucleotide Archive.
3.4 Results
To investigate the splicing of the dystrophin transcript in detail, we performed Illumina HiSeq paired end
sequencing on pre-mRNA isolated from three differentiated human muscle cell lines. To enrich for pre-
mRNA, we isolated RNA from cell nuclei. Since dystrophin is expressed at very low levels, we enriched
for dystrophin pre-mRNA using a customized library that consisted of biotinylated probes covering all
exons, introns, annotated promoters and UTRs of DMD as well as three control genes, excluding repeat
masked areas. The captured cDNA was sequenced using Illumina HiSeq 2000 to generate paired-ends




Whereas many next generation sequencing analysis pipelines are available for analyzing mRNA-Seq
data, a method for analyzing pre-mRNA has not been reported. To facilitate the analysis of our dataset,
we developed a novel pipeline, SplicePie [139].
3.4.1 Sample preparation
We first generated and sequenced a library using DNA as input to confirm the specificity of the probes
and to rule out any biases in the capture efficiency. Analysis of the DNA sample revealed a 900-fold
enrichment with 56% of reads mapped to DMD out of 11.5 million of uniquely mapped reads. As
expected for DNA, equal coverage of exons and introns was observed with the exception of repeat areas
in which no probes were designed.
For the pre-mRNA splicing analysis, PCR analysis confirmed the absence of DNA from the RNA
that was isolated from the intact nuclei of differentiated myotubes. Comparison of the fragmented and
sonicated cDNA libraries from nuclei of a differentiated healthy muscle cell line (7304) revealed that
the number of reads mapping to the DMD gene was 240,601 1 (1.1%) and 2,245,758 (12.7%) for the
fragmented and the sonicated samples, respectively. Furthermore, for the fragmented sample, we did
not observe a uniform coverage profile of the exonic (Figure S2, A) and intronic regions (Figure S2,
B), while the coverage was much more uniform for the sonicated sample. Additionally, we generated a
cDNA library using reverse transcription with poly (dT) primers to enrich for polyA RNA. However,
this resulted in a very low coverage (638,012 (4%) of reads mapped to the DMD gene) and reduced
representation of 5’ ends of the DMD transcripts (data not shown). This was expected, as the length of
the dystrophin transcript precludes the generation of cDNA from start to finish using oligo dT primers.
For the following experiments random primers and sonication post-cDNA synthesis was used as sample
preparation.
When analyzing the pre-mRNA, we observed clearly higher coverage in exonic regions compared
to intronic regions. This could be due to the presence mixtures of pre-mRNA and co- or posttran-
scriptionally spliced mRNA in the nucleus. We therefore classified our paired-end reads into three
categories: reads originating from post-, intermediate- or pre- splicing phases. The post-splicing cat-
egory contained paired end reads spanning two different exons (ex˜ex), one exon and one exon-exon
junction (ex˜(ex-ex)) or two exon-exon junctions (ex-ex)˜(ex-ex), implying completed splicing events.
The intermediate-splicing category included read pairs where one read spanned an exon-intron boundary
(ex-in; in-ex) or maps to an intron, while the other spans an exon-exon junction (ex-ex). Additionally,
paired end reads mapping to the same intron or different introns (in˜in), but with a mapping distance
(between the two reads) exceeding the library insert distance belong to the intermediate group. This
category contained reads reflecting the initial and ongoing splicing events within one or multiple in-
trons. The pre-splicing category contained paired end reads where one or both ends were mapped to
the intronic sequences or exon-intron junctions (i.e. both reads did not cover exon-exon junctions),
thus reflecting unspliced fragments. For the DNA sample, 99.9% of reads mapped to the pre-splicing
group, which was expected because the DNA sample of course does not contain exon-exon junction
reads. For the five pre-mRNA samples an average of 81% of mapped reads belonged to the pre-splicing
group, suggesting pre-mRNA enrichment. Only 1.5-3.8% of read pairs fell in the intermediate category,
probably due to the fact that splicing is a relatively fast process. The distribution of the reads over the
different categories was similar for all samples.
3.4.2 Reproducibility of the method
We generated libraries from captured pre-mRNA isolated from muscle cell line 7304 after 8 days (bi-
ological duplicate) or 14 days of differentiation, and from muscle cell lines KM155 and 8220 after 8
days differentiation using the optimized protocol. Between 749,012 to 6,140,259 reads mapped to the
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human DMD reference sequence (6.9-65.8% of the total number of reads obtained) (Table S1). To allow
comparison between different samples, the coverage was normalized by the number of reads mapping to
DMD exons.
When analyzing the coverage of introns, we removed regions containing annotated promoters, UTRs,
and expressed RNAs from the analysis (Table S2), because they can have high coverage unrelated to
the splicing process. We did not normalize for the GC content, because we did not observe a correlation
between the intron coverage and GC percentage of introns or the GC percentage of the probes. No 5’-3’
bias (i.e., a bias in the coverage closer to the 5’ or 3’ ends) was detected either. This is a first indication
for co-transcriptional splicing. When splicing would occur only after completion of transcription, the
presence of nascent transcripts would lead to a higher representation of introns at the 5’ end of the
transcript. High intronic coverage was observed for sample 4 and 5 that were derived from 2 different
cell lines (Table S1). For sample 1 and 2 (biological replicates of the third cell line) we observed
that the percentage of reads mapping to the DMD gene was lower, while sample 3 (same cell line but
differentiated for 14 instead of 8 days) had a higher coverage of DMD introns. Such biological variation
is expected, since dystrophin expression is initiated upon differentiation and depends on the amount of
myogenic cells in a culture. We ruled out sample preparation bias, since no large deviation was observed
between the percentage of duplicate reads for DMD (Table S1) or the control genes (data not shown)
between biological replicates or between different cell lines. Out of the reads mapping to the dystrophin
transcript for the five capture-pre-mRNA-seq, 13-30% covered exonic sequences while 67-82% covered
intronic sequences.
Figure 3.2: Graphical representation of the intronic coverage. A. Scatter plot showing a high correlation (r=0.96, p-value <0.0001) of the
median normalized intron coverage for two biological replicates (samples 1 and 2) from the same cell line 7304. The dashed diagonal represents
identity between the two samples. B. Bar graph showing the average normalized coverage of each intron for the three cell lines (error bars
reflect the standard error of the mean). C. The same bar graph as shown in 2B, but now introns are sorted by length (ascending, length
represented by the black dotted line and right y-axis (log10-scale).
To assess the reproducibility of DMD capture cDNA seq analysis, we compared the results from
two biological replicates, performing two independent experiments with cell line 7304. This (Figure 3.2,
A) showed a high correlation (r=0.96, p-value < 0.0001), indicating that the experimental procedure
is consistent and reproducible, which was further confirmed by a significant correlation in exonic read
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distributions (data not shown).
We additionally analyzed two other cell lines (KM155 and 8220). The intronic coverage profiles of the
three cell lines along the whole gene showed the same distribution pattern and similar depth (Figure 3.2,
B).
3.4.3 Sequential and non-sequential splicing
We reasoned that the intronic coverage would correlate with relative speed of intron removal, i.e., introns
that are spliced out quickly are expected to show low coverage, while introns that are spliced out slowly
are expected to show higher coverage. We observed a lot of variation between the coverage of the
different dystrophin introns, while for each intron the coverage was consistent between the 3 different
cell lines (Figure 3.2, B). Since there is a large variation in the length of introns in dystrophin transcript,
we first addressed whether the coverage was proportional to the intron length.
Figure 3.3: Representation of sequential and non-sequential splicing of the dystrophin transcript. Thick and dotted lines between two exons
indicate preferential non-sequential splicing (slow and intermediate, respectively), while introns that are mostly sequentially spliced are not
shown. The exon shape reflects the phasing of exons (in-frame vs. out-of-frame).
We defined intronic length as the amount of nucleotides covered by the probes and then subtracted
sequences containing annotated promoters, UTRs, micro-RNAs for each intron and assessed the read
density of the remaining intronic sequences. No significant correlation between intron length and cov-
erage (Figure 3.2, C) indicating that short introns are not spliced before long introns. Rather, these
results suggested that the introns are non-sequentially spliced. Therefore, some introns may be removed
only after downstream introns have been removed and the splicing does not follow a strict 5’-3’ or-
der. Nevertheless, since transcription of the complete dystrophin transcript takes ˜16 hours, it is likely
that a very slowly spliced upstream intron is spliced out before a very quickly spliced intron further
downstream, simply because the downstream intron is produced hours later than the upstream intron.
Therefore, we analyzed the relative order of intron removal in groups of 5 introns, using a sliding window
of 3. For every group of 5 introns, each intron was classified as fast, intermediate or slow. Fast introns
are represented by a low depth of coverage (normalized coverage <90) due to a quick intron removal
compared to the slow ones, while high depth (normalized coverage >130) is an indication of slow splic-
ing. A small group of introns with coverage between 90 and 130 were defined as “intermediate”. The
classification of introns was very similar for each of the three cell lines showing a strong indications that
several downstream introns were removed before upstream introns, and as a consequence of this, blocks
of exons that were flanked by slowly spliced introns were identified.
Figure 3.3 shows a graphical depiction of sequential and non-sequential splicing, (and intermediate
stage of few introns), of the dystrophin transcript. We propose the presence of blocks of exons, where
3 or more exons are joined flanked by slowly removed introns.
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Sequential and non-sequential splicing events were corroborated by the analysis of paired-end reads
from the intermediate-splicing category. To determine the nature of splicing of each intron, we considered
intron (n) as a starting point. If intron (n) is spliced sequentially (S), it would be spliced before intron
(n+1), leading to read pairs where one end would cover the ex-ex junction (exn-exn+1) and the other read
would align to the flanking downstream intron (n+1) (Figure S1, A). Alternatively, a non-sequential
(NS) splicing would result in the splicing of intron (n+1) before intron (n). This would be reflected by
paired-end reads in intron (n) and in the exon-exon junction of the two exons immediately downstream
of intron (n), (exn+1-exn+2), implying the presence of an unspliced intron and excluding that reads are
derived from excised intron lariats, in which case paired-end reads would both map to the intron.
We defined the splice-ratio for any given intron as the number of reads suggestive of sequential
splicing, divided by the sum of the reads suggestive of sequential splicing and those reads suggestive
of non-sequential splicing. Intron were classified as being sequentially spliced when the splice-ratio was
between 0.5 and 1, while introns with a splice-ratio below 0.5 were classified as non-sequential. For five
introns out of 78, splice-ratios were slightly above or below 0.5, and classified as intermediate. Again,
there was a good correlation between the 3 cell lines. We also observed a correlation between the intron
coverage and the splice-ratio values (Figure 3.4), where introns classified as non-sequential based on the
splice-ratio showed higher coverage (indicative of slower splicing) than introns classified as sequential
(r=-0.32, p-value=0.0043). The fact that the intron coverage analysis may also have included excised
lariats, while the paired-end analysis does not, may have prevented the correlation from being better
than it is now.
Figure 3.4: Scatter plot of the average intron coverage (y-axis) vs. the splice-
ratio (x-axis) of each intron. An inverse correlation between the two methods
is observed (r=-0.32, p-value=0.0043): lower coverage (relatively fast splicing)
is associated with a higher splice-ratio, indicative of sequential splicing.
We experimentally validated the presence
of these blocks using qPCR and Sanger se-
quencing analysis to confirm the presence of
dystrophin pre-mRNA transcripts containing
an upstream intron, when downstream exons
had already been joined (Figure 3.5). With
primers pairs (Table S4) that were designed to
cover unspliced introns, exon-exon junctions
and using predicted quickly spliced introns as
a negative control, we confirmed exon block
14-15-16 (Figure 3.5, A). Using qPCR, we con-
firmed that intron 15 was spliced before intron
13. Additional evidence of the non-sequential
removal of intron 13 was obtained using a for-
ward primer in intron 13 and reverse primers
on the exon 14-15 boundary. The relative
abundance of the product with the exon 14-
15 primer was lower than that obtained with
the exon 15-16 primer, suggesting that intron
15 is spliced earlier than intron 14. This find-
ing was supported by the presence of an addi-
tional PCR fragment that included intron 14
using primers in intron 13 and exon 16.
Conventional PCR and Sanger sequencing
using a combination of primers in intron 13
and exon 16 showed the junctions of the three exons (14-15-16), confirming the predicted non-sequential
splicing of intron 13. Likewise, we observed a block of exons 33-34 and exons 35-36-37 (Figure 3.5, B).
In this case our data was supportive of non-sequential splicing of intron 34, as we did not detect introns
33, 35 and 36, while intron 34 was still present, albeit with low abundance. Quick removal of intron 35
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Figure 3.5: Experimental validation of three
of the predicted exon blocks. A. Intron13-
Exons14-15-16. B. Exons 33-34-Intron 34-
Exons 35-36-37. C. Intron 44-Exons 45-
46-47-48-49-Intron 49. The same analysis
has been performed for the three predicted
cases. For each case the left panel (bar plot)
shows (qRT-PCR) results representing rel-
ative abundance ( to the first primer pair)
of the spliced and unspliced introns using
primer pairs in an intron and downstream ex-
ons, or exon-exon junctions (locations shown
in the panel on the right). List of the
primer pairs used in the qRT-PCR can be
found in Table S4. HPRT expression was
used for normalization. The qRT-PCR val-
ues are based on the average levels of two in-
dependent cell lines (individual levels (based
on triplicates) are indicated with asterisks).
The amplicons A1, B2, C1 were used as inter-
nal PCR efficiency controls. The detection of
one amplicon (B3) was hampered by very low
efficiency of the primer, mainly due to the
hairpin and dimer structures. Attempts with
an alternative primer did not improve the
PCR efficiency. Sequential splicing of introns
14 and 15 is supported by amplicons gener-
ated with the pair of primers A2 and A3.
Additionally, amplification with the forward
primer in intron 14 and the reverse primer
in intron 16 (A5), showed partial splicing
of intron 14, supported by the difference in
the relative abundance between A2 and A3.
Sanger sequencing was used to confirm the
three predicted exon blocks and the electro-
pherograms (right panel) show the junction
sequences for each case (intron-exon, exon-
exon or exon-intron boundaries/junctions de-
tected in a single fragment). The schematic
illustration on the low side of the electro-
pherogram shows the predicted exon block
and the location of the primers used for qRT-
PCR and Sanger sequencing PCR.
was validated as well, since we were unable to generate a PCR fragment using a primer pair in intron
35 and exon 37. Sanger sequencing confirmed the presence of a transcript containing introns 34 and 37,
but without introns 33, 35 and 36.
Finally, a similar approach was used to test the third exon block including exons 45-46-47-48-49. As
shown in (Figure 3.5, C), we were able to detect fragments using the forward primer in the intron 44 and
reverse primers in exons 45-46, exons 46-47 and exons 47-48. Using forward primers in introns 45, 46
and 47 combined with reverse primers in exon-exon junction 48-49, no signal was detected, confirming
these introns are indeed removed quickly. Sequential splicing of introns 47 and 48 was also shown using
primers spanning the junction between exons 46-47 and intron 49. Furthermore, Sanger sequencing
confirmed the exon block from exon 45 to 49, between the unspliced introns 44 and 49, validating that
intron 45, 46, 47 and 48 can be spliced before intron 44.
In addition, we validated few more predicted sequential and non-sequential events directly by Sanger
sequencing (Figure S2, B), showing splicing of intron 8 before intron 7, as well introns 50 and 51 spliced
before intron 49.
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3.4.4 Recursive and nested splicing
Since DMD introns are remarkably long, we hypothesized that multi-step intron removal, such as re-
cursive and nested splicing previously identified in Drosophila, could occur during the splicing of DMD
transcripts (Figure S2, B, C).
To identify potential recursive and nested splicing events in an unbiased way, we analyzed split reads
and first filtered out split reads that aligned to exon-exon junctions or mapping within 50 nucleotides
to an exon junction to maintain only split reads representing a splicing event with a non-annotated
splice donor and/or acceptor site. We generated a matrix that included coordinates of the two genomic
positions for each pair of donor and acceptor sites and the detected number of split reads supporting
the combination. As intermediate splicing events are difficult to detect and may be rare, we jointly
analyzed all split reads from the biological replicates. We only included events present in all three
different cell lines to avoid observations that were a consequence of PCR duplicates and to provide
stronger support for the genuine presence of these intermediate splicing events. Using this filter, we
identified 414 splicing events (Table S5), 35% of which could be classified as potential recursive splicing,
including 5’RP (18%), 3’RP (17%). Splicing events were observed at beginning, in the middle or at the
end of the intron, and were independently of intron length. We also found 266 events (65%) indicative
of nested splicing. Notably, for 27 introns we identified more than one type of events. This could
indicate complementary or independent splicing mechanisms affecting the same or different transcripts,
respectively, speculated to be due to RNA secondary structures. Finally, for 31 introns we established
single step splicing (Table S6).
We tested 13 predicted events and performed RT-PCR amplifications across the split reads to detect
the breakpoints using pre-mRNA from two libraries, followed by Sanger sequencing. We could validate
8 out of 13 events as shown in Figure 3.6. This level of success was higher than anticipated, given that
Capture-pre-mRNA-Seq is a much more sensitive method compared to the standard RT-PCR. We chose
5’RP events identified in introns 42, 43 and 53 for the experimental validation. In introns 43 and 53, we
confirmed the predicted 5’RP events, generating a spliced sequence of 3095 and 9536 bp, respectively.
In both cases, sequencing of the expected PCR products (Figure 3.6, A) showed the junction of the
exon 43 or 53 and the 5’ ratcheting point.
A similar approach was used for the validation of 3’RP in intron 4, 25, 45, 53, 45. A predicted
3’ recursive points in intron 4 was confirmed by Sanger sequencing (Figure 3.6, B). For some selected
events, it was not possible to detect the breakpoint sequence. Furthermore, a few of the selected 5’ and
3’RP sites were revealed to be intermezzo recursive splicing events, where the 5’ and 3’ RP sites were
used as donor and acceptor splice sites. Intermezzo splicing occurs when upstream and downstream
parts of an intron are spliced, leaving the internal area joined to the flanking exons. Theoretically, such
an intermezzo intron could also be an alternative exon. Therefore, we amplified cDNA from pre-mRNA
and cytoplasmic mRNA, arguing that intermezzo introns should not be present in cytoplasmic RNA.
We could validate the intermezzo event for introns 7, 33 and 43 (present in nuclear RNA but not in cy-
toplasmic RNA) by PCR and Sanger sequencing (Figure 3.6, C). Interestingly, for intron 43 we detected
two intermezzo events. No split reads spanning both intermezzo events were found, suggesting that only
one intermezzo is used at a time. For the selected nested splicing event in intron 43, we predicted two
genomic positions based on split reads. Sanger sequencing of the PCR product (Figure 3.6, D) showed
the removal of 58,528 nucleotides from the intron. We observed the retention of nine nucleotides on
each side of the predicted breakpoint. However, this retention could be due to misalignment of partial
repeat sequences (TCAA) on both sides and the fact that we could pinpoint the removal of 58 kb by
RT-PCR confirms this nested splicing event.
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Figure 3.6: Examples of the experimental validation results of different types of intermediate splicing. A. Partial splicing of 3095 and 9536
nucleotides (nt) in introns 43 and 53, respectively, using a 5’RP, are reported in the upper panel. For introns 4, partial splicing of intron of 1803
nt used 3’RP. B. Each electropherogram shows the last six nucleotides of the exon joined to internal intron sequence as consequence of partial
intron removal. C. Four preselected intermezzo events have been validated. In intron 7, a sequence of 158 nt (intermezzo, A.) was joined to
the flanking exons 7 and 8, whereas another intermezzo event involving 96 nt was detected in intron 33. An area of 88 bp for intermezzo A and
72 bp for intermezzo B were identified between exons 34 and 35. D. In intron 43, we predicted nested splicing resulting from partial splicing
(>58kb) of the intron. Two predicted genomic positions are indicated by blue continuous lines. Retention of nine nucleotides in each side of
the split read (identified during the validation experiment) is reported between the continuous and the dashed lines. Joined point of the spliced
intron is represented by a dashed line.
3.4.5 Motif analysis
We evaluated the motif of the areas involved in recursive and nested splicing by analyzing sequence
conservation of the newly detected donor and acceptor splice sites and the two nucleotides upstream
and downstream of these sites, respectively. As shown in the Figure 3.7, for the 5’and 3’ recursive
splicing (RS) we observed AG and GT as the most frequent motifs for the intra-intronic (non-annotated)
acceptor and donor, respectively, showing most 5’ RS and 3’RS use canonical splice site motifs (97% of
acceptor sites and 95% of donor sites). In case of the nested splicing events, no clear consensus motif
could be distilled for the non-annotated donor and acceptor splice sites.
3.5 Discussion
The use of target enrichment in combination with deep sequencing of cDNA offers an opportunity to
study rare splicing events [140]. However, the identification of this small portion of intermediately
spliced transcripts relies on the accuracy and sensitivity of the analysis and source material. Although
RNA-Seq is an appealing approach to study dystrophin transcripts, the use of total mRNA is not
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Figure 3.7: Motif analysis: sequence logo of the donor and acceptor splice sites involved in the recursive and nested splicing. On the first and
second left panels, 5’and 3 recursive splicing (RS) are represented by the split read spanning the exon (1 or 2, respectively) and the middle
part of intron 1. On the right panel (nested splicing) the split read spans part of the internal sequence of intron 1. The beginning and the end
of the dotted line show the positions of the donor and acceptor splice sites involved in the splicing step of intron 1. Non-annotated donor and
acceptor splice sites are indicated with a black arrow. Four nucleotides, including two from each splice site and two upstream of the donor and
two downstream of the acceptor have been used to define the sequence logo. The 5’ and 3’RS display a clear preference for the consensus splice
site motifs. For nested splicing, sequences of both non-annotated splice sites display no particular consensus motif.
suitable, as the vast majority of sequence reads would reflect spliced transcripts. While this would be
useful to identify i.e. alternative splicing or polyadenylation events, it would preclude the analysis of
intron removal and transcript processing, because dystrophin is expressed at low levels, and the pre-
mRNA transcripts would be in very low abundance. As such, it is unlikely that these transcripts would
be picked up during mRNA-Seq analysis. Here, we present a similar approach of deep sequencing of a
specific target gene using pre-mRNA isolated from nuclei as input material (Capture-pre-mRNA-seq).
This method provided us an unprecedented way of understanding the details and mechanism of the
splicing of DMD gene. Using subcellular RNA fractions and a solution hybridization library has been
engaged before in RNA-Seq analysis for human genes [6, 87, 141], but for the first time the combination
of these two methods is applied to a single gene with the aim of dissecting the splicing of large introns.
Additionally we have previously developed a computational pipeline, SplicePie, to comprehensively
analyse and detect intermediate splicing products [139].
Considering the complexity of the DMD gene (Table S7), with co-transcriptional activity varying
intron sizes (between 107 bp-360,000 bp), it was hypothesized that the order of intron removal was not
sequential. Based on our findings using two independent data analysis methods using SplicePie and
experimental validation we confirmed that the order of intron removal does not follow a consecutive
5’-3’ direction. Moreover, the relative speed of intron removal is not dependent on intron length, as
initially hypothesized. Others have reported that the intron length does not influence the order of
intron excision [87, 121]. Additionally, studies in other genes have shown that downstream introns
can be spliced before upstream introns [142, 143, 144], and that introns flanking alternative exons are
more prone to be spliced slower [87]. The speed and efficiency of intron removal may be regulated
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by co-transcriptional activity [145, 146, 147]. Since it is now apparent that intron removal does not
always follow “first come, first served” model [148] a “first served, first committed” model has been
proposed that takes the speed of the RNA Pol II activity into account [129], where the rate of RNA
Pol II elongation affects the speed of splicing factor recruitment to different splice sites, facilitating
introns excision independent of the co-transcriptional direction and strength of the splice sites. The
identification of non-sequential intron removal in DMD has been supported by the evidence that exons
can be joined to generate what we defined as “exon blocks” . These joined blocks of exons flanked by
introns are intermediate steps of the final mature RNA. Notably, our findings reflect a propensity of
sequentially or non-sequentially spliced introns.
Mutations in the DMD gene underlie a severe muscular dystrophy, Duchenne muscular dystrophy and
a milder muscular dystrophy, Becker muscular dystrophy, depending on whether mutations disrupt or
maintain the open reading frame, respectively [149]. Antisense oligonucleotide-mediated exon skipping
is a therapeutic approach that aims to restore the reading frame for DMD transcripts for Duchenne
patients to convert a severe phenotype into a milder one [150]. Our findings explain previous findings,
where the use of one or two antisense oligonucleotides (AONs) could result in the skipping of multiple
exons. Indeed as previously reported [151, 152], all tested AONs targeting exon 8 resulted in skipping
of both exon 8 and 9, and here we show experimental validation for this. Another notable example is
the exon 45-51 skipping [153]. The exon 45-55 area is a hotspot for DMD deletions [154, 155, 156], and
skipping these 11 exons would be beneficial for 40% of patients [157]. So far inducing exon 45-55 skipping
has been challenging for human DMD [153], but successful in the murine Dmd gene [158]. Nevertheless,
this required a mix of 10 different antisense oligonucleotides, which is untenable for clinical development
based on translational and regulatory challenges. Our data on exon blocks however, provides insight in
how to induce exon 45-55 skipping with less antisense oligonucleotides, by targeting the blocks rather
than individual exons. Based on our data exon 45-55 skipping could be technically challenging since
intron 44 is spliced non-sequentially, while intron 55 is not. However, by targeting the exon blocks
involving exon 45-49, exon 50-52 and exon 53-57 it might possible to achieve in-frame exon 45-57
skipping.
Additionally for the first time, we found evidence for recursive and nested splicing for different DMD
introns, employing different ways of multi-step splicing and more likely in the long introns (Figure S2).
Previous evidence from another long human gene, UTRN, indicated that intron length did not correlate
with the time required of splicing [121]. Additionally the authors showed that introns in the range of
1.2kb to 240kb were spliced within 5-10 minutes, suggesting that the physical distance between donor
and acceptor splice site is kept small by mechanisms like recursive splicing or alternatively, by the
associated 5’splice site to the C-terminal domain of the RNA polymerase II, increasing the efficiency of
splicing and reducing the time. Currently, Sibley et al. [159] reported recursive splice sites with high
incidence in long introns in all vertebrates and most of the 435 identified in the longest human genes.
Our data showed that the average size of “single step spliced introns” is 6.4 kb (107-38,368 bp), while
introns spliced via multi-step splicing introns are on average 40 kb long (650-248,401 bp), suggesting
that, as anticipated, multi-step splicing involves generally longer introns. The 31 introns, for which
no evidence of multistep intron splicing was found, were on average shorter than introns exhibiting
multistep splicing (6.5 kb vs 40 kb), but multistep splicing was also found in short introns (shortest
introns: 650 bp for recursive splicing and 7.5 kb for nested splicing). Likewise, we observed that single
step introns were primarily spliced sequentially (19/31), while multi-step introns were primarily spliced
non-sequentially (24/47). Notably, 72% of introns in the first half of the gene were spliced in multiple
steps and non-sequentially, while in the central region (exon 45-55) introns were generally spliced in
multiple steps but in a sequential manner, while 65% of introns in the last part of the gene were spliced
sequentially in a single step.
We assumed the 31 introns, for which no evidence of multi-step splicing was observed, were spliced
in a single step, but since the frequency of reported recursive and nested events was sometimes low,
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we cannot exclude the possibility that some of these introns are removed in multiple steps. For the
remaining 47 introns, evidence for multi-step splicing was found for each of the three tested human
skeletal muscle cell lines, including 5’ and 3’ recursive splicing and nested splicing, which could be
validated by RT-PCR analysis. Additionally, during the experimental analysis a few of the predicted 5’
and 3’RS turned out to be “non-annotated” donor and acceptor splice sites of intermezzo events. This
suggested that some of the other predicted recursive events were also intermezzo splicing events.
Recently, two independent groups reported evidence of recursive splicing in few different human
genes [159, 320]. Both works provided experimental validation of intermezzo splicing, where the inclusion
or exclusion of a “recursive exon” could be detected in the mRNA or was part the last step of splicing.
A previous case of nested splicing was also reported in DMD intron 7 [98]. However, this event was not
detected in our dataset, even when taking only single cell lines into account. This discrepancy can be due
to a different method of identification. Suzuki used PCR primer pairs with downstream forward primers
and upstream reversed primers to generate fragments from lariats removed during nested splicing in
RNA isolated from a single cell line. We analyzed multiple cell lines with capture-pre-mRNA-seq. It is
possible that the events reported by Suzuki et al. [98] occurred in our cell lines, but we were unable to
pick them up, or alternatively that they occurred only in the cell line he used.
Although only the results of the DMD gene have been reported here, extensive analysis has shown
non-sequential and recursive splicing in one of our control genes (FXR1 ) in five capture libraries, which
could be validated experimentally [139]. This suggests that recursive splicing may constitute a common
mechanism to remove larger introns or introns from transcripts undergoing complex splicing pattern.
Motif analysis of sequences involved in multi-step splicing events for DMD revealed that recursive
splicing relies primarily on known 5’ and 3’ consensus splicing motifs. By contrast, no real motif could
be identified for nested splicing events. For 63 events we identified conventional GT-AG sequences, this
was not the case for the majority of events. This suggests that a different, as yet unknown mechanism
is employed for nested splicing.
In conclusion, our work provides splicing analysis of the dystrophin transcript at an unprecedented
depth, shows evidence for non-sequential removal of introns, generating exons block, and multi-step
intron removal as a common mechanism for dystrophin intron splicing.
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Human aging has been associated with large-scale changes in cellular composition and gene expression.
However, the influence of aging on RNA processing has not been studied extensively yet.
Here, we utilize a large collection of transcriptomes from healthy individuals to study alternative
splicing during human aging. Whole blood was collected from 626 individuals between 18 and 81 years
of age. The blood samples were subjected to RNA sequencing. Using a range of statistical approaches,
we evaluated various characteristics of alternative splicing, taking into account potential confounder
effects of phenotypic traits and age related changes in the cellular composition of blood.
We discovered that the rates of exon skipping and intron retention significantly increased with age.
Although the identified changes in individual exons were not significant after multiple testing correction,
such changes cumulated into significantly increased transcriptome-wide exon skipping and intron reten-
tion rates. We consider this a general trend, as the affected genes do not cluster in specific biological
pathways and happen throughout the transcriptome. The increased exon skipping and intron retention
rate contributed to the observed increase in GC content of the transcriptome with age. Furthermore,
more non-canonical donor splice sites were used in older individuals.
Our findings indicate that the splicing machinery undergoes age related changes. These changes
lead to increased incidence of alternative splicing events such as intron retention and exon skipping and
promote the usage of splice sites with unconventional nucleotide motifs.
4.2 Introduction
Aging is one of the major risk factors for chronic disease in human population. Human aging is
characterized by the changes occurring in the individual’s appearance as well as at the cellular and
molecular levels. Gene expression was found to undergo drastic changes with age in all examined tis-
sues [160, 161, 162, 163, 164, 321] but the extent of these changes differed per tissue [166]. Substantial
age-dependent decoupling of mRNA and protein expression was observed after the second decade of life,
and the authors speculate that it could be caused by the deregulation of a specific set of RNA binding
proteins and microRNAs [167].
Alternative splicing, a mechanism allowing genes to produce multiple transcripts through the use
of different splice sites within the same pre-mRNA molecule, has not been studied extensively in the
context of aging. Splicing is performed by the spliceosome, a big RNA-protein complex that excises
certain regions of pre-mRNA (mainly annotated as introns) and joins the remaining regions (mainly
annotated as exons). Alternative splicing is a common process which affects around 95% of human multi-
exon genes [12, 84, 168, 169]. The efficiency of splice sites usage and the transcripts produced via splicing
vary depending on tissue- and cellular origin, gender [170, 171] and genetic factors [172, 173]. Alternative
splicing of individual genes has been shown to contribute to fundamental biological processes, such as
synapse formation [174] and cell migration [175]. Alternative splicing was also found to be associated
with age related disorders such as amyotrophic lateral sclerosis [176] and Alzheimer’s disease [177]. Using
microarray technology, Harries et al. were among the first to demonstrate age-associated disruption of
the balance between alternatively expressed isoforms from the same gene in blood and suggested that
modification of mRNA processing may be a feature of human aging [178]. A more recent study [179]
employing RNA sequencing technology indicated that changes in splicing might be occurring over the
entire lifespan in the prefrontal cortex and cerebellum of human brain. However, large scale sequencing-
based studies focusing on the details of splicing changes with age are currently lacking.
In this study, we explored a cohort of over 600 male and female whole blood RNA-Seq samples with
an age distribution between 20 and 80 years. We used another cohort of over 600 samples with the
age distribution between 50 and 70 years to validate our initial findings. We performed the first in
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depth temporal splicing profiling of human blood and addressed changes in alternative slicing events,
canonical and non-canonical splicing. We also assessed whether age related changes in alternative
splicing accumulated preferentially in certain pathways and functional classes.
4.3 Materials and methods
4.3.1 General information
Whole blood from two Dutch biobanks, “LifeLines” [180] (which will be referred to as LL) and “Leiden
Longevity Study” [181] (which will be referred to as LLS ), has been subjected to RNA sequencing.
Non-strand- specific polyA+ RNA sequencing of globin-depleted whole blood was performed on Illumina
HiSeq2000 sequencers. 2x50bp paired-end RNA-Seq reads were aligned to the reference genome hg19
(NCBI genome build 37, release 104) using the STAR 2.3.0e [182] aligner allowing for at most eight
mismatches and a maximum of five alternative mappings. The resulting alignments were stored in bam
files. Sequencing and the primary analysis (aligning and checking quality) of the data was performed
within the Biobank-based Integrative Omics Study (BIOS, part of the Biobanking and Biomolecular
Research Infrastructure Netherlands, BBMRI-NL1).
We will discuss the findings in LL in Section 4.4 and the replication results in LLS in Section 4.5.
We used the Ensembl v.71 annotation (which corresponds to Gencode v.16) to define exon coordi-
nates, and the expression was further calculated for the annotated exons. Overlapping exons (on the
same or opposite strands) were excluded from the alternative splicing analysis. Only exons that have
a single tag in the Ensembl annotation (i.e., “skipped exon” or “retained intron”) were considered for
the analysis of exon skipping and intron retention.
4.3.2 Calculating exon inclusion rate
To evaluate the rate of skipping or retention of a particular exon while accounting for total gene expres-
sion level, we assessed the relative inclusion of this exon, or its inclusion rate. The inclusion rate R` of
exon l is the ratio between the coverage of l (normalized for its length) and the coverage of the gene
















Here, ` is the exon; g(`) is a gene containing exon `; C` is the exon coverage; Cg(`) is the gene
coverage; i is the number of a base within the exon; d(`) is the length of the exon `; Ni is the amount of
reads covering the base with the number i; k ∈ g(`) means an annotated exon situated in the gene g(`).
4.3.3 Measures for changes in splicing
To track age related changes in splicing, we looked at several measurements and their changes be-
tween samples from individuals of different age. Two groups of measurements, annotation based and
annotation free, were used.
Annotation based measurements comprised inclusion rates of individual exons as well as the sum of
inclusion rates over the whole transcriptome (“global” measures of splicing, see Section 4.4.2 for more
1http://www.bbmri.nl/en-gb/activities/rainbow-projects/268
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detail). We assessed the sum of inclusion rates for all exons from expressed genes that were annotated as
“retained introns” or “skipped exons”. Genes were considered expressed when the average gene coverage
in all samples was at least 1 RPKM. This resulted in a list of 6,959 genes.
Annotation free measurements related to the usage of de novo identified splice sites (Section 4.3.4).
We calculated the fraction of non-canonical donors (donors different from “GT”) and non-canonical
acceptors (different from “AG”) in different samples, as well as the fraction of splice site pairs:
1. canonical donors paired with canonical acceptors;
2. non-canonical donors paired with canonical acceptors;
3. canonical donors paired with non-canonical acceptors;
4. non-canonical donors paired with non-canonical acceptors.
Splice sites found in over 1% of the samples were selected to count the number of canonical and
non- canonical ones. The number of U12 introns [183, 184] (introns spliced via the non-canonical U12
splicing [185, 186]) were obtained from U12DB [187] and the linear regression was performed on this
number to see whether the frequency of U12 splicing changed with age (for more detail about the linear
regression, see Section 4.3.5). We also assessed the average number of donors paired with one acceptor
and the average number of acceptors paired with one donor. We explored whether the number of
acceptors per donor (and donors per acceptor) increased or decreased with age. Within the annotation
free measurements, we also addressed the nucleotide content of used splice sites. A more technical and
detailed description of the analysis pipeline, as well as the source code of the scripts, is available online2.
4.3.4 Identifying used splice sites de novo
In order to identify splice sites de novo (in an annotation free manner), the following approach was
developed (Figure S1). A read was called “split” when at least two pieces were mapped to distant
locations (up to 500 kb apart) in the genome. The two positions at which the read was split were
considered putative splice sites. To reduce the influence of small and possibly spurious overhangs, we
considered only splits where five bases of the read adjacent to the split position on each side had an
exact match with the reference sequence. Only when at least one read was split at the same position
in at least 1% of the samples, these putative splice sites were selected. Since the RNA-Seq data in this
study is not strand specific, it is not known which of the two positions – upstream or downstream –
is the donor and which is the acceptor splice site. To predict the strand of the transcript represented
by the read, five positions around each breakpoint (two in the exon and three in the intron) were
extracted. The reference nucleotide motif of these ten nucleotides around the splice site was extracted
from literature [188]. We compared this reference nucleotide motif with the ten nucleotides around
each split and their reverse complement. If the edit distance between the extracted sequence and the
literature profile was smaller than for its reverse complement, the upstream splice site was considered
the donor and the downstream splice site was considered the acceptor, and vice versa. When both the
extracted ten bases and their reverse complement were equally similar to the literature profile, the splice
site (149 sites in the LL biobank) was excluded from further analysis.
Possible spliceosome slippage events [189, 190, 191] were not considered as independent splice sites.
To this end, we clustered tandem donors (and acceptors) when they were situated at a distance of three,
six, or nine nucleotides from each other. In this case, only the splice site associated with the highest
number of split reads was selected, and the numbers of reads of the adjacent splice sites were added up.
2https://git.lumc.nl/vatakhaveev/alternativeprocessingversusage/tree/master/description of the whole pipeline
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4.3.5 Designing statistical models to evaluate age related changes in splic-
ing
To assess age related changes transcriptome wide (global measures of splicing), such as sums of inclusion
rates, fraction of canonical/non-canonical splice sites and the average number of acceptor/donor splice
sites used with one donor/acceptor, we performed the following linear regression:
Ms ∼ α + β · As + γ · lnSDs + ~δ>~fs, s ∈ S. (4.2)
Here S is the set of samples; Ms is a certain measure of splicing in a sample s; α is the intercept;
As is the age of a sample s; lnSDs is the logarithm of the sequencing depth of a sample s; β and γ
are the coefficients; ~δ is the vector of coefficients; ~fs is the vector of covariates, containing measures of
phenotypic traits of the sample s (i.e., concentrations of different blood cells). The β coefficient and its
p-value reflect age dependence of a measurement. lnSD is essential to normalize for, as more events were
measured at higher sequencing depth. We normalized for the natural logarithm of sequencing depth and
not the sequencing depth itself, as its natural logarithm has a higher correlation (ρ is 0.91 against 0.89)3
with our measurements (Figure S2). Note that throughout the manuscript the Spearman’s ρ coefficient
of correlation is shown as well as the β coefficient, as the correlation coefficient is more common and
easier to interpret for the reader.
The full list of phenotypic traits that were accounted for in the linear regression contains the follow-
ing:
1. Gender (numerical, “0” or male, and “1” or female).
2. Height (numerical, in cm).
3. Weight (numerical, in kg).
4. Smoking status (numerical, “yes” or 2, “gave up smoking” or 1, and “no”or 0).
5. Concentration of HDL (numerical, high density lipoprotein) cholesterol (mMol per L).
6. Concentration of LDL (numerical, low density lipoprotein) cholesterol (mMol per L).
7. Concentration of triglycerides (numerical, mMol per L).
8. Concentration of platelets (numerical, 109 cells per L).
9. Concentration of neutrophils (numerical, 109 cells per L).
10. Concentration of lymphocytes (numerical, 109 cells per L).
11. Concentration of monocytes (numerical, 109 cells per L).
12. Concentration of eosinophils (numerical, 109 cells per L).
13. Concentration of basophils (numerical, 109 cells per L).
3Note that throughout the manuscript the rho parameter reflects Spearman’s coefficient of correlation (pure Spearman’s
correlation, and not the result of a statistical model). However, for this particular case, Pearson’s coefficient of correlation
is used.
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To assess age related changes in the relative inclusion of each individual exon ` present in the anno-
tation, we calculated its inclusion rate in every sample and performed multi-variable linear regression
according to the following model:
R`,s ∼ b+ β · As + ~c>~fs, s ∈ S. (4.3)
Here S is the set of samples; R`,s is the relative inclusion of an exon ` in the sample s. Use of the
other symbols is identical to the use in the formula above.
Analyses stratified for gender gave similar results to joint analyses. Therefore, samples of both
genders were analyzed together, and gender was included as one of the covariates. However, data
obtained from chromosomes X and Y were ignored to minimize the influence of gender.
4.4 Results
4.4.1 Age distribution and phenotypic traits
The analysis was performed on the whole blood transcriptomes from the “LifeLines” Dutch biobank
with a wide age distribution (20–80 years, median around 45, Figure 4.1, A). Several phenotypic charac-
teristics and biochemical parameters were measured for each sample in each biobank alongside age (see
Section 4.3.5 for the full list of phenotypic traits). It has previously been shown that blood composition
– counts and concentrations of various blood cell types – changes with age [192]. We also observed
this in our data. The concentration of lymphocytes decreased with age (ρ = −0.15, p = 2.4 × 10−4,
Figure 4.1, B). In all downstream splicing analyses, we included cell type composition, gender, other
measured phenotypic traits and sequencing depth as covariates in the linear models.
4.4.2 Rates of exon skipping and intron retention increase with age
Using the statistical model described in Section 4.3.5, we assessed the change of alternative exon usage
with age. It has recently been shown [166] that the expression profile of certain genes changes with age.
In order to normalize for age related differential gene expression while assessing changes in splicing, we
used inclusion rates (Section 4.3.2) for the exons available in the Ensembl v.71 annotation.
Figure 4.1: A. Density plot reflecting the age distribution within the
LL biobank. B. Scatter plot reflecting age related changes in the
counts of lymphocytes. Line represents the fitted linear regression
lines for LL data. p-value of the linear regression is shown in the right
top corner.
We selected genes expressed in all samples
(6,959 genes) and looked at the changes in the in-
clusion rate of each annotated exon with age. Out
of these 6,959 genes expressed in all samples, 4,660
genes contained at least one exon annotated as
skipped; 2,823 genes contained at least one exon
annotated as retained intron; 2,354 genes contained
both exons and introns annotated as skipped and
retained, respectively. We refer to the coefficient in
the linear regression reflecting age related changes
in the ratio as beta.
The majority (5,435, or 67.4%) of skipped ex-
ons had a negative beta coefficient, which indicated
that their relative inclusion decreased with age (Fig-
ure 4.2, A, black). However, these changes were
mainly non-significant, we observed only 15 signif-
icant negative betas (Figure 4.3, A) and two sig-
nificant positive betas (Figure 4.3, B and C) after adjusting p-values using the False Discovery Rate
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method of Benjamini and Hochberg, with 5% cutoff (see Supplementary Table ?? for the full lists of
genes containing exons with significant betas).
After exploring the changes of individual exons, we investigated the cumulative change in the rate of
exon skipping. We calculated the sum of inclusion rate for all exons annotated as skipped, and refer to
this as the exon skipping rate. We observed that the sum of inclusion rates for skipped exons decreased
with age (Figure 4.2, B) (ρ = −0.15, p = 3.3 × 10−4; β = −3.12, p = 6.7 × 10−4). The decreased
coverage of this group of exons is suggestive of their overall increased skipping in elderly individuals.
Figure 4.2: A. Distribution of betas for exons annotated as skipped exons (black) and retained introns (gray). x-axis contains the beta values,
y-axis contains the numbers of events. B. Scatter plot showing the correlation between age (x-axis) and the sum inclusion rate of skipped
exons (y-axis). C. Scatter plot showing the correlation between age (x-axis) and the sum inclusion rate of retained introns (y-axis). D. Scatter
plot showing the correlation between age (x-axis) and the average GC content (y-axis) calculated based on the sequenced reads. E. Scatter
plot showing the negative correlation between the sum inclusion rate of skipped exons (x-axis) and the average GC content (y-axis) calculated
based on the sequenced reads. F. Scatter plot showing the correlation between the sum inclusion rate of retained introns (x-axis) and the
average GC content (y-axis) calculated based on the sequenced reads. For the figures B-F each dot represents one sample. The line represents
the fitted linear regression line. The data was generated using the statistical model described in Section 4.3.5.
We discovered that the majority (778, or 52.9%) of exons annotated as retained introns (from now
they will be referred to as retained introns) showed increased relative inclusion with age. Similarly to
skipped exons (an example of an exon with significantly increased skipping rate in the BLK gene is
shown on Figure 4.3, A), the majority of changes were not significant, only one intron with a positive
beta had a significant p-value of 9.1 × 10−5 (after adjusting p-values using the False Discovery Rate
method of Benjamini and Hochberg, with 5% cutoff). This alternative splicing event is located in the
DIDO1 gene, death inducer-obliterator 1, and might be a case of alternative acceptor splice site usage
(leading to the extension of an exon) rather than an intron retention event (Figure 4.3, B). An example
of a real intron retention event, however, non-significant after applying the FDR cutoff, can be found
on Figure 4.3, C.
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In accordance with this, sums of inclusion rate of all retained introns (Figure 4.2, C) significantly
increased with age (ρ = 0.12, p = 3.8× 10−3; β = 0.14, p = 4.3× 10−3). This is suggestive of an overall
increased rate of intron retention in elderly individuals.
We performed a pathway analysis of exons undergoing changes (a significance threshold of FDR=10%
was used). We did not find any pathway or group of genes with a similar function to be enriched for the
genes containing exons with age related changes of their relative inclusion, when compared to a control
set of genes expressed in our blood samples but without changes in exon inclusion rates.
4.4.3 Increased skipping and retention rates contribute to higher GC con-
tent
An important characteristic of an RNA-Seq sample is its average GC content – the fraction of G and
C nucleotides out of all the reads4. It should be noted that, unlike GC content of DNA, which can only
change due to mutations, GC content of a transcriptome can change due to the changes in expression
of GC-rich and GC-poor transcripts and exons.
We observed a higher GC content5 in older compared to younger samples (Figure 4.2, D, ρ = 0.1,
β = 0.0085, p = 4.7 × 10−3). We made an effort to exclude potential technical confounders that may
have caused this association. Longer sample storage times were also associated with higher GC content,
but there was no confounding between age and storage times (Figure S3). Other experimental factors
such as sequencing date or blood collection date were not associated with GC content of the samples
(data not shown).
We looked for the biological factors explaining the increase in GC content of the sequencing files
from older and younger individuals. For that, we extracted reads mapped to all skipped exons and
retained introns and calculated the GC content of there reads (Table 4.1, last four columns). We
also calculated the GC content of skipped exons and retained introns based on the reference genome
annotation (Table 4.1, second and third columns). We discovered that, compared to the average GC
content of all annotated exons, the GC content of exons annotated as skipped was lower (Table 4.1).
At the same time retained introns had a higher average GC content compared to all introns.
As it has already been shown (Section 4.4.2), sum inclusion rate of skipped exons decreased with age
and skipped exons had lower GC content (calculated on the sequencing files) than average (calculated
on the reference genome, Table 4.1). We explored whether the sum inclusion rate of skipped exons
correlated with the GC content of a sample. We revealed a significant negative correlation (Figure 4.2,
E) between the sum inclusion rate and the GC content of a sample (ρ = −0.49, p = 8 × 10−38; in the
regression with the GC content as the dependent variable, the sum inclusion rate as a predictor and the
covariates used before, the coefficient of the sum inclusion rate equalled -0.0018 with the p = 8.1×10−47).
Similarly, a significant positive correlation (Figure 4.2, F) was found between the sum inclusion rate
of retained introns – intron retention rate – and the GC content of a sample (ρ = 0.62, p = 1×10−65; in
the analogous regression the coefficient of the sum inclusion rate equalled 0.041 with p = 1.3× 10−74).
Table 4.1: GC content of exons and introns in the LL biobank.
biobank all exons all introns skipped exons retained introns
pos. β neg. β pos. β neg. β
LL 51.76% 48.13% 49.67% 49.28% 53.97% 53.40%
4Note that this measure is calculated on the sequencing files and not on the reference genome.
5calculated on the sequencing files.
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Figure 4.3: Example exons which showed changes in inclusion rate with age. A. Exon annotated as skipped (significant changes). B. Exon
annotated as retained intron, however, as can be appreciated from the figure, this event should be classified as alternative 3’ UTR rather than
a retained intron (significant changes). C. Example for an intron retention event, which was non-significant after the correction for multiple
testing (as no significant changes in the betas of exons annotated as retained introns – apart from the example show in the B panel of this
figure – has been found). Coverage data was merged from four randomly selected samples of the age of 45. Wider boxes represent coding
exons, narrower boxes represent non-coding exons or UTRs, lines represent introns.
4.4.4 Frequency of canonical splicing decreases with age
We explored the nucleotide composition of splice sites used. These splice sites were identified de novo
as described in Section 4.3.4. Comparing our identification to known sites, we found 371,740 from
1,001,983 annotated sites in our data, which might have happened due to the fact that only a fraction
of genes present in the annotation is expressed in blood. For these sites, we predicted the strand and
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function (donor or acceptor) correctly for the 99.775% of them. We also discovered 614,564 novel splice
site pairs. The donor splice site was defined as the two most 5’ nucleotides in the intron downstream
from the exon and the acceptor splice site as the two most 3’ nucleotides in the intron upstream from
the next exon. The two splice sites originating from the same read were considered as a pair of splice
sites used within the same splicing event.
The pairs of donor “GT” and acceptor “AG” sites were considered canonical, and deviations from
this nucleotide pattern were counted as a pair with a non-canonical donor and canonical acceptor,
canonical donor and non-canonical acceptor, non-canonical donor or non-canonical acceptor. Over 98%
of the identified splice sites were canonical.
Further analysis of the de novo identified splice sites revealed a significant decrease (p = 0.013) in the
number of used canonical splice site pairs (see Table 4.2). Furthermore, using the linear model described
in 4.3.5, we discovered an age associated increase of non-canonical donor splice sites and the pairs of non-
canonical donor and canonical acceptor (p = 0.019). The number of non-canonical acceptors on their
own, or paired with any type of donor did not change with age (Table 4.26). We calculated the number
of excised U12 introns (introns spliced via the non-canonical U12 splicing mechanism, see Section 4.3.3
for more detail) and whether their splicing rate (identified as described in 4.3.5) changed with age to
evaluate the potential contribution of non-canonical splicing performed by the minor spliceosome (also
known as U12 splicing [193]). We did not observe any significant changes in the amount of U12 splicing
(p = 0.501).
Table 4.2: Usage of canonical and non-canonical donor and acceptor splice sites and usage of multiple donor splice sites with one acceptor
splice site and vice versa.
Type of splice site Usage Beta (p-value)
ND 1.95% 0.00060 (0.017)*
NA 0.58% 0.00028 (0.070)
CD...CA 97.8% -0.00064 (0.016)*
ND...CA 1.56% 0.00036 (0.024)*
CD...NA 0.19% 0.00004 (0.429)
ND...NA 0.39% 0.00024 (0.076)
(U12 db) 0.18% 0.00008 (0.571)
D MA 1.179% 0.000005 (0.860)
MD A 1.180% 0.000022 (0.420)
D/A 1.001% -0.000014 (0.032)*
We explored the nucleotide content of non-canonical splice sites (the two intronic positions, different
from “GT” or “AG” and adjacent to the split). To do this, all splice sites from all samples were used
to generate sequence logos. We analyzed non-canonical donors paired with canonical or non-canonical
acceptors separately from non-canonical acceptors paired with canonical or non-canonical donors. We
observed that the “GC” motif is the dominating motif for non-canonical sites paired with canonical
6Abbreviations use in the table:
“A” – acceptor splice site; “D” – donor splice site;
“CD” – canonical donor splice site; “CA” – canonical acceptor splice site;
“ND” – non-canonical donor splice site; “NA” – non-canonical acceptor splice site;
“U12 DB” – pairs of splice sites used by U12 spliceosome known from literature;
“MD A” – average number of donors used together with one acceptor (multiple donors);
“D MA” – average number of acceptors used together with one donor (multiple acceptors);
“D/A” – ratio between the numbers of donors and acceptors.
The third column contains age coefficients and their p-values derived from the linear regression of corresponding measures.
Asterisks represent significant age-related changes
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acceptors (Figure 4.4, A). Splice sites used in the youngest 25% of the samples were also used to
create sequence logos. Sequence logos for the splice sites used in the oldest 25% did not show any
visual differences. For non-canonical acceptors paired with canonical donors the dominating motif was
“AT” (Figure 4.4, B). This suggests the second common splice site motif – “GC-AG” – being used more
often with age. Non-canonical splice sites paired with each other had a nucleotide distribution close to
random (Figure 4.4, C and D), which suggests that a large proportion of these sites are false positives,
for example due to mapping artefacts.
To investigate the amount of novel non-canonical donor splice sites used in older individuals, we
overlapped the list of all non-canonical donors used in younger samples (youngest 25% of the samples)
and the list of all non-canonical donors used in older samples (oldest 25% of the samples). A splice
site was considered used when at least one read was split at this position in at least 1% of the samples.
Only splice sites from genes expressed in all samples were considered. We identified 382 non-canonical
donor splice sites absent in younger individuals and present in the older ones. They did not cluster in
any specific genes and were situated both within known genes (in the exons and in the introns) and in
the intergenic regions.
4.4.5 Multiple splice sites paired with one splice site
B.A.
D.C.
Figure 4.4: Sequence logos with the frequency of nucleotides at and around
the splice sites. A and C show the last three exonic positions (blurred), the
first two intronic positions (bright, donor splice site) and the following four
intronic positions (blurred). B and D show the four intronic positions before
the splice site (blurred), the last two intronic positions (bright, acceptor splice
site) and the first two exonic positions (blurred). A – non-canonical donor
paired with canonical acceptor splice sites. B – non-canonical acceptor paired
with canonical donor splice sites. C – non-canonical donors paired with non-
canonical acceptors. D – non-canonical acceptors paired with non-canonical
donors.
We investigated whether the number of alter-
native donors or acceptors changed with age.
To do this, we calculated the number of donors
used with multiple acceptors and the num-
ber of acceptors paired with multiple donors.
We then assessed whether the average number
of donors or acceptors paired with one accep-
tor or donor changed with age. Both donors
and acceptors were on average used with more
than one other splice site (1.1803 acceptors
per donor and 1.1793 donors per acceptor).
We did not see age related changes in the av-
erage number of sites used with a donor or an
acceptor (Supplementary Table 4.2).
We applied the linear regression model de-
scribed in Section 4.3.5 individually to each
splice site and investigated whether the num-
ber of its partner sites (donors for an accep-
tor and acceptors for a donor) changes with
age. We found 27,757 and 26,412 donors with
negative (less acceptors paired with the same
donor in older individuals) and positive (more
acceptors paired with the same donor) betas,
25,956 and 24,497 acceptors with negative and
positive betas respectively (Figure 4.5, A). Only three significant changes were found, and two of them
will be highlighted in this section7.
One of the genes in which the number of alternative donors for a specific acceptor decreased with
age significantly from four in younger to two in older individuals (p-value of 2.8×10−06 before and 0.097
7Note that for the third example – gene TSPAN encoding tetraspanin protein – novel splice sites identified in older
samples were situated upstream of the gene’s 5’UTR on the opposite strand. It is not related to any known transcript,
therefore we do not discuss it here and focus on two other examples situated in the known genes.
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after multiple testing correction) is the LTK gene which encodes leukocyte receptor tyrosine kinase
protein (Figure 4.5, B). Two events of alternative splicing uncharacterized before – exon skipping and
usage of a novel non-annotated exon – occurred only in younger samples.
An example of a gene where the number of alternative donor splice sites increased with age (p-value
of 8.1 × 10−7 and 0.039 after multiple testing correction) is the GZMH gene encoding the granzyme
H protein (Figure 4.5, C). Where only three alternative donor splice sites were used with a specific
acceptor in younger individuals, six donors were used in older samples, all of them representing non-
annotated alternative splicing events. Unfortunately, we could not check whether a potential protein
can be produced with with any of the new splice sites, as transcript assembly (necessary for that) is
not available and our analysis considers only pairs of splice sites. Predicting whether an open reading
frame is maintained or an alternative open reading frame is created also becomes complicated, since the
second border of the exon is not always known (almost 30% of the splice sites were identified outside
the annotated genes).
Figure 4.5: A. Distribution of betas for donor splice sites paired with multiple acceptors (solid line, label in black) and acceptor splice sites
paired with multiple donors (dotted line, label in gray). Linear regression described in 4.3.5 was used for each splice site to assess whether
the number of sites it is used with changes with age (positive beta reflects an increasing number, negative beta reflects a decreasing number
of splice sites). Absolute values of beta lower than 10−10 were discarded, therefore the total percentage of betas signed on the plot does not
add up to 100. x-axis contains betas. y-axis contains absolute numbers. B. An example of a gene – LTK – demonstrating an age dependent
decrease in the number of donor splice sites paired with the same acceptor splice site. Top red panel represents the transcripts reported for
LTK in the Ensembl v.75 database (the gene is situated on the reverse strand, so the leftmost part of the graph is the 3’ end of the region).
Wider boxes represent coding exons, narrower boxes represent non-coding exons or UTRs, lines represent introns. Middle black panel shows
reads mapped to one acceptor and two donor alternative splice sites that were found in older individuals. Bottom gray panel shows reads
mapped to one acceptor and four alternative donor splice sites that were found in younger individuals (no reads split at the two of these donor
splice sites were found in older individuals). Only representative two reads are shown for each splice site on B-C. C. An example of a gene –
GZMH – demonstrating an age dependent increase in the number of donor splice sites paired with the same acceptor splice site.
4.5 Discussion
In this study we performed a transcriptome wide analysis of age related changes in RNA processing.
The study was conducted on a large cohort of samples with the widest age distribution collected so far.
We statistically evaluated a number of aspects of alternative splicing while accounting for differences
in the composition of the major cell types measured for our data – platelets, monocytes, eosinophiles,
basophils, lymphocytes and neutrophils – as covariates. Blood contains many more cell types, which
may still bias the expression and splicing data. However, given that these cell types are typically rare,
we do not expect that they can explain the effects that we observed. We focused on different aspects
80
of splicing. Even though some studies have suggested that age related changes may follow a non-linear
behavior and, for example, occur from mid-life only [166, 194], we assumed a linear association with
age. In line with this, most of the associations detected were only significant when including samples
in the full age range of 20–80 years.
A limitation of current age related expression studies, including ours, is their cross-sectional nature
and the large inter-individual variation [166, 179]. Longitudinal studies will have more power to detect
molecular changes like the ones described in this paper.
Using the LL biobank as our main data source, we assessed the changes in the relative expres-
sion of individual exons and introns across samples with different age. Namely, exons annotated as
“skipped exons” or “retained introns” were analyzed, and, as mentioned earlier, we found a restricted
list of 15 skipped exons with decreased relative expression in older samples, two skipped exons with
increased relative expression and one retained intron with increased relative expression in LL. The list
of genes containing these exons was too limited to perform pathway analysis and draw statistically valid
conclusions on. Genes involved in various cellular processes were identified (i.e., ABLIM1 encoding a
cytoskeletal LIM protein that binds to actin filaments via a domain that is homologous to erythrocyte
dematin; KDM5A binding to retinoblastoma protein and regulating cell proliferation). Genes associated
with various diseases were also identified (i.e., the deficiency of AK2 in humans causes hematopoietic
defects associated with sensorineural deafness [195, 196]; ATP2A2 is an ATPase associated with Darier’s
disease; MBNL1, shown to regulate its own splicing, is implicated in Myotonic dystrophy [197]). Unfor-
tunately we could not replicate any of these findings in the LLS dataset; only non-significant changes
for the listed exons were found.
The main dataset available for replication was the “Leiden Longevity Study” biobank, also sequenced
in the BIOS study. The age range of LLS samples was much more limited (between 50 and 70 years,
Figure S4). To study age dependent changes in the Rotterdam Study is even more challenging, because
samples from younger individuals were collected earlier than samples from older individuals, and the
confounding effects of age and storage time may complicate the interpretation. The number of indi-
viduals from the CODAM cohorts was limited and did not provide enough power to detect age related
changes. Unfortunately no other large-scale dataset with a similar age range as LL is available at the
moment. E.g., the dataset of a similar size covers less than 40 years [172].
The increased rates of exon skipping and intron retention discovered in LL were not found in LLS,
likely due to its more restricted age range. Although we observed a similar distribution of betas for
skipped exons in LLS (Figure S5, A, black line) and retained introns (Figure S5, A, gray line) with
more loci annotated as skipped exons having negative age coefficients (betas), the majority of changes
were not significant. Only one exon had a significant negative beta with a p-value of 0.015 and was
not significant in LL. We did not observe significant changes in the sum inclusion rate of skipped exons
(Figure S5, B, p = 0.83) or retained introns (Figure S5, B, p = 0.95). We argue that the restricted age
range of the LLS biobank does not allow to detect subtle changes in the relative expression of skipped
exons and retained introns.
Exploring the increase of exon skipping and intron retention with age, we discovered that the GC
content of the transcriptome increased with age (based on the sequenced reads), and that these changes
may be partly attributable to alternative splicing events (based on the GC content of skipped exons and
retained introns, which was calculated on the reference sequence). Even though we could see a positive
correlation between the sum inclusion rate of retained introns and GC content in LLS (Figure S5, F,
ρ = 0.21, p = 2.9 × 10−7; β = 0.014, p = 5.4 × 10−7), GC content of the samples from LLS did not
increase significantly with age (Supplementary Table S2, Figure S5, D, ρ = 0.07, p = 0.082; β = 0.0020,
p = 0.68). This might once again suggest that the age range in the LLS biobank is too narrow to
capture minor changes in splicing.
Assessing used splice sites de novo, we showed that the fraction of non-canonical donor splice sites
increases with age, which is reflected in the decreasing rate of canonical-canonical splice site pairs in both
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biobanks (LLS: Table S3, p = 0.045). More frequent usage of non-canonical splice sites, in particular
donors, might point at new types of splicing which use different donor and a canonical acceptor splice
site.
The number of alternative splice sites (both donors and acceptors) did not significantly change with
age. However, we found several genes with increased or decreased numbers of alternative splice sites in
the elderly. For one of the genes, the LTK gene encoding leukocyte receptor tyrosine kinase protein,
additionally to the splice sites throughout the gene used in all samples, for one particular acceptor
(genomic coordinates chr14:25,075,953-25,075,954) the number of alternative donor splice sites in older
samples decreased from four to two. Both splice sites used only in young individuals lead to the shift of
the open reading frame (the distance between the two donors and the acceptor is 778 and 154 nucleotides,
respectively). Another gene – GZMH, encoding a protein that is expressed by cytotoxic immune effector
cells, showed an opposite change in the number of splice sites used in younger vs. older individuals. In
contrast to LTK, in GZMH the number of alternative donor splice sites used with age increased from
three to six. Two alternative donor splice sites lead to the shift of the open reading frame for this gene,
one of which is used only in older individuals, while the other is used in both older and younger samples.
Possible outcomes of the usage of a new alternative splice sites and their effect on protein structure and
function should, however, be studied only when the whole transcript structure is available. Discovering
the number of alternative splice sites both increasing and decreasing with age might once again point
at non-specific, non-targeted and a rather random nature of changes happening in splicing with age.
Overall age related changes found in alternative splicing performance are mainly non-significant
at an individual event level. In other words, usage of single exons or splice sites on their own do
not undergo drastic changes and the contribution of age to the overall variation in inclusion rates is
rather limited. However, on a transcriptome wide scale multiple non-significant changes cumulate into
significant trends. Unfortunately such subtle changes could not be captured with a narrow age range,
and more datasets with wider age distribution (preferably between 20 and 80 years) are needed for the
appropriate validation of our findings. We might also underestimate the frequency of some events, i.e.
mis-spliced transcripts and transcripts with retained introns, as they may undergo faster degradation.
To study the details of splicing in more depth, a targeted approach of extremely deep sequencing might
be the best, as it would be more sensitive to very low concentrations of certain transcripts. Reads long
enough to make transcriptome assembly possible would also help the age related splicing research, as
this would allow to predict potential proteins and open reading frames disrupted or introduced with
new splicing events.
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Table S1: GC content of exons and introns in the LLS biobank.
biobank biobank all exons all introns
LLS ENSG00000004455, AK2 Exon skipping −1.2× 10−3
LLS ENSG00000143420, ENSA Exon skipping −6.9× 10−4
LLS ENSG00000081237, PTPRC Exon skipping −1.4× 10−3
LLS ENSG00000099204, ABLIM1 Exon skipping −2.9× 10−3
LLS ENSG00000198561, CTNND1 Exon skipping −3× 10−3
LLS ENSG00000073614, KDM5A Exon skipping −4× 10−3
LLS ENSG00000174437, ATP2A2 Exon skipping −7× 10−3
LLS ENSG00000075399, VPS9D1 Exon skipping −1.2× 10−3
LLS ENSG00000003400, CASP10 Exon skipping −2.9× 10−3
LLS ENSG00000069849, ATP1B3 Exon skipping −4.3× 10−4
LLS ENSG00000152601, MBNL1 Exon skipping −3.9× 10−3
LLS ENSG00000168685, IL7R Exon skipping −8× 10−4
LLS ENSG00000077809, GTF2I Exon skipping −1.5× 10−3
LLS ENSG00000136573, BLK Exon skipping −5.4× 10−3
LLS ENSG00000107099, DOCK8 Exon skipping −1.5× 10−4
LLS ENSG00000168010, ATG16L2 Exon skipping 3× 10−3
LLS ENSG00000006114, SYNRG Exon skipping 8.6× 10−3
LLS ENSG00000101191, DIDO1 Intron retention 6.1× 10−3
LL ENSG00000106554, CHCHD3 Exon skipping −3.5× 10−2
Table S2: GC content of exons and introns in the LLS biobank.
biobank all exons all introns skipped exons retained introns
pos. β neg. β pos. β neg. β
LLS 51.76% 48.13% 49.11% 49.69% 53.18% 54.14%
Table S3: Information about splice site usage and its changes with age in LLS biobank.
Type of splice site Usage Beta (p-value)
ND 2.04% 1.2× 10−3 (0.045)*
NA 0.63% 6.1× 10−4 (0.109)
CD...CA 97.77% −1.3× 10−3 (0.051)
ND...CA 1.60% 6.6× 10−4 (0.077)
CD...NA 0.19% 0.5× 10−5 (0.602)
ND...NA 0.44% 5.6× 10−4 (0.093)
(U12 db) 0.19% −1.9× 10−5 (0.578)
83
Figure S1: Method to identify putative splice sites and their strand from non-strand-specific data. Split reads are used to detect potential
donor and acceptor splice sites. The nucleotides around the splice sites are extracted and compared to the canonical splice site profile known
from literature. The reverse complement of the extracted nucleotides is also compared to the canonical profile. Depending on whether the
surrounding of a splice site or its reverse complement is closer (based on the Similarity, or edit distance) to the canonical profile, the read is
considered to be mapped on the forward or the reverse strand, respectively.
Figure S2: Correlation between the number of canonical splice sites (y-axis) and the sequencing depth (x-axis, A) or the natural logarithm
(x-axis, B) of a sample.
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Figure S3: A. Scatter plot showing the correlation between the RNA storage time (number of days, x-axis) and the GC content of a sample
(y-axis) in LL biobank. RNA storage time was calculated as the number of days from the day of RNA isolation to the day of sequencing.
B. Scatter plot showing no correlation between the age (x-axis) and the RNA storage time (y-axis) in LL biobank. C. Scatter plot showing a
subtle correlation between the RNA storage time (number of days, x-axis) and the GC content of a sample (y-axis) in LLS biobank. D. Scatter
plot showing no correlation between the age (x-axis) and the RNA storage time (y-axis) in LLS biobank.
Figure S4: A. Density plot reflecting the age distribution within the LLS biobanks. B. Scatter plot reflecting age related changes in the counts
of lymphocytes. Line represents the fitted linear regression lines for LL data. p-value of the linear regression is shown in the right top corner.
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Figure S5: GC content, exon skipping and intron retention in LLS data. For more details on what is represented on the plots see the legend
to Figure 4.2 from the main text.
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Differential allelic expression (DAE) refers to differences in expression levels between the two alleles
of a gene in a cell. DAE can be caused by genetic variation and is known to affect a considerable
fraction of genes in the human genome. DAE has been suggested to play an important role in human
phenotypic variability, including complex traits and diseases. We hypothesize that DAE contributes to
the pathogenesis of breast cancer and that changes in the DAE patterns in control versus breast tumor
tissue can be associated with the disease. Deleting or decreasing the expression of the highest expressed
allele of a tumor suppressor gene may have larger consequences than deletion of the lower expressed
allele.
We analyzed whole transcriptome sequencing data of paired normal-tumor samples from breast
cancer patients provided by the TCGA consortium. The allelic expression was examined by analyzing the
coverage of the alleles of each variant. We focused on the heterozygous SNPs showing consistent changes
in allelic expression in at least 5% of the patient cohort to identify common regulatory mechanisms in
breast tumorigenesis.
We introduced a classification of different types of allelic expression changes, and observed that the
majority of SNPs showed differential allelic expression only in tumor but not in normal tissue. We
found nine SNPs with significant and consistent changes in allelic expression in normal versus tumor
RNA. Evaluation of the allelic ratio in tumor DNA demonstrated that the majority of changes in allelic
expression was caused by allele-specific aneuploidy. We also found one SNP situated in the NBPF9
gene that had imbalanced allelic expression already in normal RNA, and this imbalance increased even
further in tumor RNA.
The non-random SNP-behavior in the breast cancer patient cohort suggests that DAE is contributing
to the mechanism of breast cancer development. DAE and its quantitative effects on gene expression
might become the next milestone in understanding breast cancer pathogenesis after the discovery of
LOH (loss of heterozygosity) due to aneuploidy at DNA level.
5.2 Introduction
Breast cancer is one of the most important causes of cancer-related deaths, the most common malignancy
worldwide in women and the second leading cause of cancer death after lung cancer [198].
Breast tumors are characterized by genomic instability and gross chromosomal aberrations on a
genome wide scale, including loss or duplication of whole chromosome arms [199]. Aneuploidy, a pro-
cess when (parts of) chromosomes can be lost or duplicated, possibly more than once [200, 201], is often
observed in breast cancer [202], as well as other types of cancer [203, 204, 205]. The most common con-
sequence of genomic instability and a hallmark of cancer cells is the presence of an abnormal number of
chromosomes, or aneuploidy [205]. Aneuploidy has been extensively studied and characterized to better
understand the cell’s evolutionary pathways towards carcinogenesis. Errors in replication, segregation
and telomere function are generally assumed to occur in the absence of properly functioning cell cycle
checkpoints [206, 207]. During tumorigenesis, DNA regions that include oncogenes are frequently ampli-
fied causing their overexpression and endowing the cell a growth advantage; tumor suppressor genes are
often lost during the evolution of cancer allowing cells to escape mitotic arrest and/or cell death. Loss
of tumor suppressor genes is often a prerequisite for tumorigenesis [208]. Aneuploidy does not affect
every chromosome equally; some chromosomes (e.g., chromosome 17 in breast and colon cancer) are
more prone to aberrations [209], giving rise to distinct patterns of aneuploidy in certain tumors [210].
An unresolved issue is why there seems to be chromosomal specificity in the pattern of allelic losses and
gains in different types of cancer and also in different subtypes of breast cancer [211].
DNA rearrangements can also occur subchromosomally. These rearrangements may result in dis-
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torted number of alleles for individual (or sets of neighboring) genes [212]. A frequent phenomenon in
breast cancer is loss of heterozygosity (LOH), signifying chromosome regions in the tumor DNA where
either the paternal or maternal copy is missing [213, 214, 215]. Simple copy-number loss – monosomy –
will therefore show as LOH, but LOH can also be copy-number neutral, when the final number of alleles
equals the initial number of alleles [216]. Copy-number neutral LOH happens when one allele is lost
and the other allele is gained at the same time [217]. Deviations from the expected 1:1 ratio (different
from 1:0 or 0:1) of parental chromosome copies are called allelic imbalance.
Two examples of genes undergoing LOH in sporadic breast tumors are BRCA1 and BRCA2. Regions
of the chromosomes where BRCA1 and BRCA2 are located (i.e., 17q21 and 13q12, respectively) undergo
allelic imbalance or loss of heterozygosity (LOH) in 30-50% of the cases. It was expected that these
events would unmask somatic (i.e., acquired) mutations in these genes, but such mutations have rarely
been observed [218, 219, 220, 221, 222]. A number of studies have shown that in many individuals
the two parental alleles of a gene are not expressed at equal levels [223, 224]. Both cis- and trans-
regulatory mechanisms are at the basis of this phenomenon, which may affect several thousand genes.
Genetically, BRCA1 and BRCA2 behave like classical tumor suppressor genes, meaning that almost
all breast tumors of gene mutation carriers show loss of the wild-type allele [225, 226, 227]. BRCA1
and BRCA2 have been implicated in tumorigenesis of sporadic breast cancer as haploinsufficient tumor
suppressor genes through the loss of their expression [228, 229]. Mechanistically, this expression loss has
been explained either by promoter hypermethylation or LOH, or a combination of both [230]. However,
the proportion of tumors with decreased mRNA expression is much higher than the proportion with
promotor hypermethylation, while LOH, although found in 30-50% of breast tumors at the BRCA1 and
BRCA2 loci, reflects a number of different chromosomal mechanisms, not all of which are predicted
to lead to expression loss. LOH could affect the expression level of a gene if one allele was physically
lost (copy-number loss). If both alleles were expressed at equal levels, this would be predicted to lead
to a 50% decrease in expression, but the effect would be stronger if the two alleles of the gene are not
expressed at equal levels and the allele with the highest expression is lost. In the latter situation, even
copy-number neutral LOH would affect final expression levels.
The examples of BRCA1 and BRCA2 discussed above are not allele specific, meaning that either
allele can be gained or lost, and such loss leads to reduced and gain to increased gene and protein
expression. However, another type of aneuploidy – allele specific aneuploidy, or allelic disparity – has
also been described [231, 232]. The wild-type allele of the APC gene (located on 5q31, associated with
hereditary colorectal cancer) was shown to be lost in 22 out of 23 analyzed colon tumors. However, the
mutant allele was shown not to contain any typical, inactivating APC mutations, but to be expressed
at much lower levels than the wild-type allele, leading to lower APC protein expression levels and
predisposition to the disease [233]. Unequal expression of the two alleles of a gene, termed Differential
Allelic Expression (DAE), has also been shown to be associated with breast cancer [234, 235, 236]. Genes
as BRCA1/2, CCND3, EMSY, GPX1, GPX4, MLH3, MTHFR, NBS1, TP53 and TRXR2 showed
distinctive DAE patterns similar among samples of EBV-transformed lymphoblastoid cells [234]. Array-
based analysis of eight breast cancer patient-derived normal mammary epithelial lines revealed genes
showing DAE to cluster in one major breast cancer-relevant interaction network, which includes two
known cancer causative genes, ZNF331 and USP6, and a breast cancer causative gene, DMBT1 [236].
Thus, aneuploidy plays an essential role in tumorigenesis and breast cancer. Investigating DNA
copy number alterations across a tumor’s entire genome was a challenging task until the comparative
genomic hybridization (CGH) technology was introduced [237]. Subsequently SNP arrays have been
used by numerous researchers to explore chromosomal aberrations in tumor DNA, i.e., by comparing a
set of healthy control tissues to a set of tumors [238, 239, 240]. With the arrival of Next Generation
Sequencing (NGS) and, more specifically, RNA sequencing (RNA-Seq), it became possible to study
DAE genome-wide and in genes that were not primary candidates. RNA-Seq is quantitatively more
accurate than SNP arrays in determining mRNA levels, so it should be more sensitive to minor changes
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in expression. In addition, it facilitates the research on a whole genome level and is not limited to the
probe design, as a SNP array is [241]. By comparing genome-wide sequence data (i.e., from normal and
tumor RNA of the same patient, or from RNA of healthy subjects and patients with breast tumors),
DAE can be investigated for all genes expressed at mRNA level [231, 232, 242, 243, 244].
Some studies have exploited DAE to search for genes in which an allele had been inactivated by
protein- truncating mutation, leading to nonsense-mediated mRNA decay. CHEK2, a G2 checkpoint
kinase 2, showed allelic expression imbalance in 10% of lymphoblastoid cell lines (LCLs) from high-risk
breast cancer from whom no mutation in BRCA1 or BRCA2 had been identified. All samples with
such DAE were carriers of the truncating mutation NM 007194.3:c.1100del [235]. Likewise, in families
with pituitary adenoma, a genome-wide scan for genes with DAE in predicted gene carriers led to the
discovery of AIP1 as the culprit underlying gene for this familial cancer syndrome [245]. Individual
examples, showing an impact of a certain allelic imbalance event at a patient level, have also been
characterized [246]. However, none of the studies so far has attempted to compare DAE of genes with
allele-specific patterns of LOH or allelic imbalance in breast tumors, certainly not in a large patient
cohort.
In this study, we assessed the phenomenon of allelic imbalance at the DNA level and differential
allelic expression at the RNA level. We analyzed a dataset of over 80 breast cancer patients, having data
from normal DNA, normal RNA, tumor DNA and tumor RNA from the same patient. The data used
in this study was generated within The Cancer Genome Atlas project. We identified coding SNPs in
normal DNA to be able to distinguish between the two alleles. We used a combination of statistical tests
and developed a statistical framework to assess those SNPs in normal RNA, tumor DNA and tumor
RNA from the same patient. We provide a classification of different cases of allele-specific expression
using the changes in DAE between normal and tumor RNA. We also address the mechanism causing
such DAE patterns using normal and tumor DNA in each patient.
5.3 Materials and methods
5.3.1 TCGA dataset
The analysis was performed on the sequencing data from 89 breast cancer patients having triple-negative
breast invasive carcinoma (Figure 5.1, A) available within The Cancer Genome Atlas (TCGA) project.
Each patient contributed four samples: normal and tumor DNA samples, and normal and tumor RNA
samples. The sample underwent whole exome sequencing. Normal samples were collected from the
unaffected part of the patient’s breast, while the tumor samples were collected from the breast tumors.
DNA/RNA from formalin-fixed, paraffin-embedded tissues were sequenced on the Illumina HiSeq 2000
platform and mapped to the hg19/GRCh37 genome using the BWA aligner [107] for aligning DNA and
MapSplice [96] for aligning RNA. The alignment was performed by the TCGA consortium1. Level two
access data (bam files containing aligned reads) were requested from the NCI’s Cancer Genomics Hub2.
5.3.2 Calling and analyzing variants
The workflow of the analysis is represented in Figure 5.1 (panels B and C). Calling variants in patient
DNA derived from normal breast tissue has been performed with SAMtools [39] using default parame-
ters. Only heterozygous variants were considered3. For that, we selected allelic ratios in normal DNA
1http://tcga-data.nci.nih.gov/tcga/
2https://cghub.ucsc.edu/
3Note that when calling variants in RNA or tumor DNA, heterozygous variants with the unequal coverage of the two
alleles are also considered.
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Figure 5.1: A. Design of the dataset, in which normal DNA and RNA and tumor DNA and RNA was collected from 89 breast cancer patients.
B. Filtering steps used during the analysis to select reliable variants. See Section 5.4.2 for more details. C. Set-up of the statistical test used
to select variants with a change in allelic ratio between normal vs tumor RNA. SNPs showing changes in allelic ratio in normal vs tumor RNA
were selected. Note that only recurrent events were selected for the statistical framework to get statistically valid results.
which did not differ significantly from 0.5 (Figure 5.1, B). This was done to exclude variants situated in
regions of potential copy number variants (which would result in an allelic ratio different from 0.5), as
any change in allelic ratio of these variants in tumors versus normal tissue would be harder to interpret.
Each of the alleles also had to be covered at least twice to be selected for further analysis. Calling
variants on RNA derived from normal breast tissue has been performed using VarScan [248], reporting
homozygous reference, heterozygous and homozygous alternative positions. Only positions where the
sum of the coverage of both alleles was above 20 and which had high mapping quality were considered.
They were selected using the “NC” flag, variants with “NC=1” (meaning that the position had the
mapping quality high enough to be called) were further analyzed. Calling variants on tumor RNA was
also performed using VarScan reporting only heterozygous and homozygous alternative variants. The
same filtering criteria were used to select high quality variants.
Note that we address variants and SNPs as two separate types of events. We call “a SNP” a
nucleotide change on DNA or RNA that has been seen in at least 5% of the cohort, and any other
nucleotide change on DNA or RNA is referred to as “a variant”.
5.3.3 Statistical framework
We developed a statistical model to identify changes in allelic expression (the ratio between the number
of reads mapped to one allele and all reads mapped to this position), which is consistent across multiple
samples (Figure 5.1, C). Paired observations – e.g., allelic counts from a normal and a tumor RNA
sample – are required. One SNP at a time is tested. The reference allele is referred to as “allele A”,
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and the alternative allele is referred to as “allele B”.
A generalized linear mixed model is fitted for each SNP considering a negative binomial distribution
of the allelic counts c. In the model, the fixed effect X is the status of the tissue (normal/tumor) and
individuals are modeled as random effects Z :
A generalized linear mixed model is fitted for each SNP considering a negative binomial distribution
of the allelic counts c. In the model, the fixed effect X is the status of the tissue (normal/tumor) and
the random effect Z is the read counts (different per individual):
c = logN + E, (5.1)
where c is the coverage of an allele, N is the linear predictor for the response variable and E contains
random errors;
N = XB + ZU, (5.2)
where X is the matrix containing two indicators – showing the tissue state (normal/tumor) and the
type of allele (reference/alternative), both can be 0 or 1; Z are the random effects; B and U are the
coefficients.
Since the input data is counts, a negative binomial distribution is used as it allows the variance
to differ from the mean via introducing an extra parameter of over-dispersion. In the current model,
several parameters are estimated, namely the coverage allele A in normal RNA (intercept), the difference
in coverage of allele A between tumor and normal RNA, difference between the coverage of allele A
and allele B, the interaction between the tissue status (normal/tumor) and the difference between the
coverage of allele A and allele B (A 2-way anova model). Four degrees of freedom are needed to estimate
these parameters. Two degrees of freedom for the fixed effects, one degree of freedom for the random
effect, and one degree of freedom is needed to estimate the standard error. Variants present in at least
five patients (20 complete observations: five for each allele in tumor and normal) were selected. The
statistical model was implemented in R and is freely available online4.
To select changes in the expression ratios for non-recurrent events (see Section 5.4.1 for more detail),
Fisher’s exact test was used (an FDR of 5% was used as a cutoff).
5.4 Results
We assessed variants showing DAE and/or a change in allelic expression in normal versus tumor RNA. At
first, we categorized variants (Figure 5.2, A) based on DAE pattern and after that we identified variants
present in multiple breast cancer patients and showing a consistent change in RNA allelic expression
between normal and tumor tissue. Lastly, we tried to explain the patterns of allelic expression in tumor
RNA using tumor DNA information from the same patients.
5.4.1 Variant categories based on DAE
Analyzing 89 breast cancer patients, we identified 78,539 variants heterozygous in at least one patient
in normal DNA and present in normal RNA, tumor DNA and tumor RNA (either heterozygous or
homozygous). We ran the exact Fisher’s test on normal and tumor RNA on each of the variants in
each patient individually (which means that the same variant in multiple patients was counted multiple
times) and used the FDR cut-off of 5%. This left 5,446 variants present in at least one patient and
4https://git.lumc.nl/i.pulyakhina/ase in brc/blob/master/TCGA analysis/
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Figure 5.2: Differential
DAE in normal or tumor
RNA. A. Categories of
variants based on DAE
present in either normal
RNA, or tumor RNA, or
both. B. The percent-
age of variants present
in each category for the
variants showing a signif-
icant change in the allelic
ratio between control and
tumor RNA. Note that
the fifth category – when
both normal and tumor
RNA shows DAE to the
same extent – is dis-
carded (see Figure 5.1, C)
from the analysis and is
hence not shown here.
Dark grey parts of the
bars represent the per-
centage of variants that
showed allelic ratio dif-
ferent from 0.5 in tumor
DNA.
showing a change in allelic expression ratio between normal and tumor RNA. We subdivided the variants
into the following categories (Figure 5.2, A):
1. DAE only in normal RNA and not in tumor RNA (category 1);
2. DAE only in tumor RNA and not in normal RNA (cat. 2);
3. DAE in both normal and tumor RNA; the imbalance is stronger in normal RNA (cat. 3);
4. DAE in both normal and tumor RNA; the imbalance is stronger in tumor RNA (cat. 4).
Figure 5.2, B depicts the percentage of variants present in each category.
5.4.2 Changes in allelic ratio
Looking at the distribution of the variants across the categories (Figure 5.2), we can appreciate that
the vast majority of variants – 89.5% – shows DAE in tumor, i.e., only in tumor – 62% (category 2)
– or both in tumor and in normal RNA – 27.5% (category 4). A much smaller percentage of variants
shows DAE only in normal RNA (category 1, 4.8% of variants). We can also appreciate that, even when
the expression of both alleles is not equal in normal RNA, the imbalance often increases in tumor RNA
(category 4) or remains the same (data not shown, as it is not further analyzed, see Figure 5.1, C for
details) and rarely decreases (category 3, 5.7% of variants).
We expected aneuploidy to be the major driver of differential allelic expression in tumor RNA, and
assessed tumor DNA allelic ratios using two-sided Binomial test against 0.5. When an allelic ratio was
significantly different from 0.5 in tumor DNA, we considered that an allele might have been lost or
gained. For category 2, 95.7% of the DAE events seen in tumor RNA could be explained by putative
aneuploidy in tumor DNA; 97.6% of the variants from category 3 and 97.1% of the variants from
category 4. We used category 1 as a control group and expected less allelic imbalance in tumor DNA
for the variants from this category, as they did not show any significant imbalance in tumor RNA. As
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Figure 5.3: Allelic ratio (y axis) and its changes across variant categories introduced in Figure 5.2 in normal vs tumor RNA (x axis). A.
Variants showing DAE only in normal RNA and not in tumor RNA (category 1 from Figure 5.2). B. Variants showing DAE only in tumor
RNA and not in normal RNA (category 2 from Figure 5.2). C. Variants showing more extreme DAE in normal RNA than in tumor RNA
(category 3 from Figure 5.2). D. Variants showing more extreme DAE in tumor RNA than in normal RNA (category 4 from Figure 5.2).
Each dot represents a variant in one sample, same variant from tumor and normal RNA is connected with a line. Only twelve representative
variants are shown per group. Note that we did not distinguish between recurrent and non-recurrent events here. RsIDs are not shown, as not
all variants have rsIDs.
expected, only a small amount of variants from category 1 (14.6 %) showed allelic imbalance in tumor
DNA (Figure 5.2, B).
We further inspected individual variants present in each category. In Figure 5.3, expression of
different alleles (allelic expression ratios) for both normal and tumor RNA are depicted for the different
previously introduced classes (Figure 5.2). For Figure 5.3, A, variants show DAE only in normal RNA,
which means that the allelic expression ratio can be either <0.5 or >0.5. To make the figure easier
to interpret, only variants showing DAE >0.5 in normal RNA are depicted on Figure 5.3. Note that
variants showing DAE <0.5 behave similarly to the variants represented in Figure 5.3. For the category
of variants where tumor RNA was more imbalanced than normal RNA (category 3 from Figure 5.2;
1,502 variants), the allele ratio was below 0.5 for 627 variants. This indicates that B allele was lost or A
allele was gained in tumor compared to normal RNA. For 875 variants the allelic expression ratio was
above 0.5 in tumor RNA, which indicates the opposite behavior – the B allele was gained or A allele
was lost in tumor compared to normal RNA.
94
5.4.3 SNPs showing recurrent DAE
After categorizing variants based on DAE, we selected heterozygous SNPs present in multiple patients
and consistently showing loss or gain of one of the alleles. We call such SNPs recurrent. These SNPs are
primary candidates to play a role in the mechanisms of breast tumorigenesis, unlike individual variants
which rather explain the cause of the disease in an individual patient [247].
To focus on recurrent SNPs and see how consistent they are across the dataset of 89 breast cancer
patients, we selected heterozygous SNPs found in normal DNA of at least five patients (5% of the
patient cohort). The statistical framework (described in Section 5.3.3) assigned low p-values to the
SNPs that showed significant changes in the allelic expression ratio between tumor and normal RNA,
and the change had to be consistent across all patients in which the SNP was expressed. Note that this
statistical framework was designed to distinguish between the reference and the alternative allele and to
find only cases of allelic disparity. We also performed the analysis to find non-allele-specific aneuploidy
events, however, we did not get any significant results different from what is discussed here. From the
list of 975 SNPs present in at least 5% of the patient cohort, we detected nine SNPs (Table S1) which
showed a recurrent change in allelic expression ratio in tumor versus normal RNA. Figure 5.4 (panel A)
contains allelic expression ratios in all patients containing the SNP, and the majority of allelic expression
ratios is concentrated around 0.5 in normal RNA and elsewhere in tumor RNA. More information about
these nine SNPs can be found in Table S1.
5.4.4 Mechanism behind DAE in tumor RNA
Figure 5.4: A. Scatter plot showing the distribution of allelic ratios for the
nine SNPs showing significant changes of allelic ratio in normal vs tumor
RNA. x axis shows the allelic ratio in normal DNA. y axis show the allelic
ratio in normal RNA. B. Correlation between the allelic ratio in tumor DNA
(x axis) and tumor RNA (y axis). Allelic ratio on plots A and B is calculated
as the expression of the alternative allele divided by the total coverage of
the allele. Each dot represents one sample, meaning that the same SNP
coming from different patients is present multiple times. See Figure 5.5 for
the examples of individual SNPs.
After we identified differences in allelic expres-
sion between normal and tumor RNA, we as-
sessed tumor DNA to find an explanation for
different allelic expression patterns.
We discovered high correlation between
tumor DNA and tumor RNA for six out of
nine SNPs (average Pearson’s correlation co-
efficient >0.8). For the same six SNPs, allelic
ratio in tumor DNA was significantly different
from 0.5 (between 0.67 and 0.98). Both obser-
vations indicate the presence of aneuploidy in
tumor DNA which is likely to explain the al-
lelic expression observed in tumor RNA. Since
allelic expression ratio is calculated as the ra-
tio between the B allele (alternative allele)
and the total expression of the variant (Fig-
ure 5.4, B), allelic expression ratio equal or
higher than 0.5 means that the alternative B
allele was gained (or the reference A allele was
lost) in all patients. The events displayed in
Figure 5.5 are examples of allele-specific aneuploidy, previously introduced as allelic disparity – when
one specific allele is consistently gained or lost in all the patients. We observed that the same allele that
was lower expressed in normal RNA was gained in tumor DNA and became higher expressed in tumor
RNA (Figure 5.5, A, three panels show the data for an example SNP, rs946837, TMTC4 ). We also
observed one SNP which showed the opposite pattern – the allele that was higher expressed in normal
RNA was lost in tumor DNA and became lowew expressed allele in tumor RNA (data not shown, as it
resembles Figure 5.5, A, but with a decreasing slope).
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We observed a different behavior of allelic expression for the other three SNPs that showed different
allelic expression in tumor RNA versus normal RNA (Figure 5.5, B, three panels show the data for an
example SNP, rs2798893, NBPF9 ). All three SNPs had coverage above nine in all samples, and for the
vast majority of patients the coverage in each sample was above 20. However, at the RNA level we
could see that the allele that was lower expressed in normal RNA lost even more expression in tumor
RNA (and the allelic expression ratio went down) (for rs7185949, USP10 and rs2798893, NBPF9 ). A
slight (but consistent) increase of the lower expressed allele was observed for rs617073 situated in the
U2AF2 gene.
Figure 5.5: A. Example SNP representing SNPs with potential allelic disparity. B. Example SNP representing the rest of identified SNPs.
Left panel – correlation between the allelic ratio in normal RNA (x axis) and tumor DNA (y axis). Middle panel – correlation between the
allelic ratio in tumor DNA (x axis) and tumor RNA (y axis). C. Changes in the B allele frequency in each pair of samples in normal vs tumor
RNA. Each dot represents a variant in one sample, same variant from tumor and normal RNA is connected with a line.
5.4.5 Allelic imbalance in normal RNA and its behavior in tumor RNA
The previous paragraph highlighted SNPs (present in at least five individuals) that showed consistent
changes in allelic ratio of RNA in tumor versus normal tissue state. The majority of variants that we
identified showed no DAE in normal RNA, meaning that both alleles were equally expressed. Here,
we focused on the variants present in at least 5% of the samples, that already have DAE in normal
96
RNA and show a change in the allelic expression ratio in tumor RNA. We found almost 50% of variants
(12,011 of 29,140 variants) imbalanced in normal RNA to be detected only in one sample (Figure 5.5, A
and B). Only 15% of the variants (4,348 variants) were found in at least 5 samples with DAE in normal
RNA. We assessed whether any recurrent change in the allelic ratio between normal and tumor RNA
within these 4,348 variants were found.
Figure 5.6: Distribution of variants showing DAE in normal RNA across the 89
samples of breast cancer patients. A. Number of samples (x axis, i.e., “1” on the x
axis means that the variant has to been seen only once and not more) containing a
certain number of variants (y axis). B. Zoomed-in version of A, y axis is restricted
by 100 variants.
Out of these 4,349 SNPs, we dis-
covered only one SNP – already men-
tioned above, rs2798893 in the NBPF9
gene – imbalanced in normal RNA to
be present in at least 5% of breast can-
cer patients, which showed a signifi-
cant change in DAE in tumor vs normal
RNA. This SNP was also identified pre-
viously without pre-selecting SNPs with
DAE in normal RNA before running the
statistical framework. Analyzing tumor
DNA and RNA profiles, we did not see
any correlation between the allelic im-
balance in tumor DNA and allelic ex-
pression ratio in tumor RNA (ρ = 0.45).
We observed allelic expression patterns
depicted on Figure 5.5 (panel B) – fre-
quencies of the lower expressed allele in tumor DNA were mainly concentrated in the window of [0.4, 0.6].
The majority of nine samples heterozygous at this SNP showed a consistent decrease of the expression
of the allele that was lower expressed in normal RNA.
5.5 Discussion
Aneuploidy, LOH and their role in breast cancer have extensively been studied over the past decades.
Resulting in the unequal expression of the two alleles, aneuploidy was shown to lead to reduced gene
expression [230]. Genome-wide research of aneuploidy in breast cancer was conducted mainly using
CGH arrays and exome- sequencing with Next Generation Sequencing (NGS) technology and resulted
in numerous regions showing genomic instability in multiple or individual breast cancer patients. Earlier
considered not to be allele-specific, meaning that either of the two alleles can be gained (or lost) with
the same probability, aneuploidy was recently shown to occur in allele-specific manner [220, 242, 243].
One would expect that loss or gain of an allele in tumor DNA would have a direct influence on the gene
expression in tumor RNA, which indeed has been shown [220]. However, unequal RNA expression of
alleles, or Differential Allelic Expression (DAE), present already in normal RNA – and its changes in
breast cancer tumor RNA – has not been extensively studied yet.
In this study we performed a thorough examination of a breast cancer patient cohort provided by
The Cancer Genome Atlas project. Leaving the somatic mutations behind, we explored SNPs present
in normal DNA and RNA of each patient individually and examined the behavior of these SNPs in
the tumor DNA and RNA of the same patient. We observed that the majority (over 50%, data not
shown) of variants occurred in normal and tumor DNA and RNA of only one patient and showed equal
expression of both alleles in normal RNA and DAE in tumor RNA. We also found variants (33.2%)
that showed DAE in both normal and tumor RNA, 27.5% of detected variants showed a stronger allelic
imbalance (further away from 0.5) in tumor RNA and only 5.7% of detected variants showed a stronger
imbalance in normal RNA.
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We assumed that the majority of the SNPs which showed DAE in tumor RNA can partly be explained
by aneuploidy, which we tested using tumor DNA of the same patients. We could indeed see that over
95% of variants which showed DAE in tumor RNA also showed allelic instability (allelic ratio different
from 0.5) in tumor DNA.
Despite a lot of variation between the patients and the presence of patient-specific variants, we were
able to identify 975 heterozygous SNPs present in more than 5% of the patients. We discovered that nine
of these SNPs showed a significant and consistent change in allelic expression between normal and tumor
RNA. For six out of these nine SNPs, showing allelic expression ratio significantly different from 0.5 in
the majority of patients and high correlation between tumor DNA and tumor RNA (average Pearson’s
correlation coefficient >0.8), suggested that aneuploidy could be one of the potential contributors to
DAE in tumor RNA. Moreover, from the values of allelic ratios in tumor DNA and allelic expression in
tumor RNA of these SNPs, we derive that one specific allele was gained or lost, which suggests that these
SNPs are probable cases of allele-specific aneuploidy (or allelic disparity). Such behavior – the presence
of DAE and the absence of aneuploidy – might for instance be explained by allele-specific binding of
transcription factor proteins (that would explain DAE in normal RNA), for which the expression is
altered in breast tumors (that would explain changes in DAE in tumor versus normal RNA). Further
investigation is necessary in order to explain the mechanism driving allelic disparity.
Discovering a very limited number of recurrent events is an expected outcome, as is has already been
shown for a number of different cancer types including breast cancer that, i.e., for somatic mutations
only a few altered genes are recurrent in at least 10% of the patients, while the vast majority of changes
happens in less than 5% of the samples [249, 250]. Another study which focused on the analysis of DAE
in a limited set of just eight breast cancer patients was only able to find three genes – ZNF331, USP6
and DMBT1 to show a change in DAE in tumor vs normal cDNA. Our analysis assessed individual SNPs
(which we used as the markers for different alleles), as we hypothesized that specific gene alterations
recurrent in the patient cohort might have a contribution to breast cancer pathogenesis. As the number
of identified recurrent SNPs is limited, we suggest that we should rather look to the patterns observed
for larger chromosomal regions, as certain parts of chromosomes are expected to show similar aneuploidy
pattern. However, a recent study [251] suggests that, as recurrent events are rare due to the nature of
cancer, a more meaningful analysis should be conducted on a level higher than gene or locus, which can
be done via phasing the genotypes. A pathway or network analysis can help us to effectively uncover
biological systems perturbed in tumor cells which is unfortunately still a very challenging analysis and
has to be developed and studied more extensively.
Our understanding of aneuploidy and its contribution to breast cancer pathogenesis, as well as LOH
and DAE, is still not full despite the decades of analyses on various levels. However, the increasing power
of bioinformatic analysis transcriptome- and genome-wide and a potential of extensive research on large
patient cohorts make a great promise for understanding and explaining breast cancer development and
pathogenesis.
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5.7 Appendix
Table S1: Description of nine identified SNPs described in the main text.
Chrom. Position rsID Gene
name
ρ Gene description
chr1 144,931,392 rs2798893 NBPF9 0.45 neuroblastoma breakpoint family mem-
ber 9, higher expressed in breast, ovar-
ian and pancreatic cancer
chr1 201,112,981 rs8158 TMEM9 0.84 a positive regulator of neurite out-
growth and its overexpression was sug-
gested to play primary role in prostate
carcinogenesis
chr9 96,238,578 rs10821135 FAM120A 0.98 a constitutive coactivator of PPAR-
gamma-like protein 1, which has a
higher expression in numerous cancers
(including breast cancer)
chr12 9,232,268 rs669 A2M 0.72 alpha-2-macroglobulin which was sug-
gested to play a role in inhibiting brain
tumors
chr13 101,287,340 rs946837 TMTC4 0.67 transmembrane and tetratricopeptide
repeat containing 4 known to be ex-
pressed in breast (mammary gland) tu-
mor
chr16 68,857,441 rs1801552 CDH1 0.95 cadherin-1 protein, for which the in-
creased risk of having breast cancer has
been shown in case of genetic variations
chr16 711,905 rs2301426 WDR90 0.69 WD repeat-containing protein 90,
higher expressed in about 45% of
known cancer types (excluding breast
cancer)
chr16 84,779,248 rs7185949 USP10 0.21 tumor-associated marker in gastric car-
cinoma
chr19 56,180,968 rs617073 U2AF2 0.96 U2 small nuclear RNA auxiliary fac-
tor 2, has not been associated with any




General discussion and future
developments
As can be appreciated from this thesis, RNA sequencing is used for a variety of applications [252, 253,
254]. Bioinformatic analysis of mRNA sequencing data can reveal the effect of different treatments via
the analysis of differential gene or transcript expression (see Chapter 3 for the examples of mRNA
analyses in the context of aging). It can be used to explore alternative splicing, perform functional
studies via pathway analyses, detect allele specific expression (see Chapter 5 for the examples of ASE
in context of breast cancer) [255, 256, 257, 258]. Nuclear RNA data analysis makes it possible to
study intermediate splicing events and explore intermediate products and their impact on the splicing
mechanism (see Chapter 2 and Chapter 3 for more details).
However, regardless of the progress in data analyses, one should not forget that the analysis is
performed on biological systems. The analysis will produce artificial results when the sequencing ex-
periment does not adequately capture the required data and the technical procedure to obtain the data
introduces biases [259, 260, 261]. One solution is to improve the analyses, however, a more solid solution
is to address and eliminate the steps introducing the biases. Note that technical artifacts will always
be present in any dataset, however, it is important to recognize the biases and correct for them, which
becomes easier with less biases from other sources.
6.1 Direct RNA sequencing
For RNA sequencing, the main source of biases comes from the cDNA synthesis step. The majority of
RNA-Seq techniques does not sequence RNA directly. A possible solution to avoid technical artifacts
which are incorporated during the cDNA synthesis step is to skip this step [266] – such techniques are
called direct RNA sequencing, or DRS. Researchers started developing DRS after failing to elucidate
numerous biases that cDNA synthesis introduces (see the Introduction for more detail).
6.1.1 Possibilities of direct RNA sequencing
The first DRS technique that became available was Helicos True Single Molecule Sequencing, or tSMS.
Helicos tSMS [263, 264] works via the direct hybridization of RNA to the surface of an ultra clean
glass slide containing poly(dT) oligonucleotides covalently attached at their 5’ ends [265]. During
sequencing, the terminating nucleotides with a fluorescent label are incorporated one per cycle. The
terminator prevents incorporating multiple nucleotides in one cycle and the fluorescent label (specific
per nucleotide) is used to identify the incorporated base [266]. Helicos tSMS single-end short reads
are 30-35 nucleotides long with a relatively high sequencing error rate (the frequency of substitutions is
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0.2%, insertions – 1.5%, deletions – 3.0%), which makes it hard to analyze such reads. Another common
technical issue that biases the data and complicates the bioinformatic analysis is the “dark” nucleotides.
A fraction of nucleotides remains unlabelled and therefore is not detected upon the incorporation. Such
dark nucleotides will appear as deletions in the sequenced reads. The problem of unlabeled nucleotides
is common for other sequencing techniques, but we only detect them with single molecule sequencers.
Bioinformatic analysis of the Helicos data revealed that, even though DRS has great potential and
opens a wide range of opportunities, a new technique comes with new challenges. Helicos tSMS was
the first NGS technique to sequence single molecules without the necessary PCR step, which was the
main advantage of the technique. Another advantage was that very short sequences could be used as
the input material, which would be beneficial when dealing with fragmented DNA, i.e., ancient DNA
which is often partly degraded. The main difficulty for the analysis in Helicos tSMS technology is raised
by the presence of dark nucleotides. Bioinformatic pipelines that were designed, tested and adjusted
on the Illumina data cannot be directly applied on Helicos data, and new tools for the analysis of DRS
need to be developed.
6.1.2 Future of direct RNA sequencing
Along with Helicos tSMS, more techniques are currently being developed and are expected to be available
soon. One of them – DRS by Oxford Nanopore – will be discussed.
Figure 6.1: Main principles of the Oxford Nanopore sequencing. An
exonuclease attached to the protein nanopore situated in a hydropho-
bic lipid layer (membrane) cleaves nucleotides on one of the DNA
strands (left panel of the figure). The second, untouched DNA strand
passes through the nanopore. Every time a new nucleotide going
through causes a disruption of membrane potential (right panel of
the figure). Based on the intensity and the duration of the potential
the number and sequence of passing nucleotides are identified.
Oxford Nanopore1 sequencing is a new technol-
ogy for nucleic acid sequencing [267]. The technique
uses a protein nanopore incorporated into a poly-
mer membrane (Figure 6.1). The membrane has
a very high electronic resistance and a potential is
applied across it. A DNA molecule is sequenced as
it passes through the nanopore. Every nucleotide
passing through the nanopore gives a disruption of
the membrane potential, which can be measured
and associated with a base [268]. In addition to
DNA sequencing, Oxford Nanopore is currently de-
veloping direct RNA sequencing and adapting the
nanopore to distinguish RNA nucleotides. Protein
sequencing using nanopores is also potentially pos-
sible, as proteins have been shown to move through
nanopores [269, 270, 271]. The major challenge
of unfolding a protein – denaturating the tertiary
protein structure and making the amino acids pass
through the nanopore – has recently been success-
fully addressed [272], which promises a wide poten-
tial of protein sequencing using nanopores.
As mentioned before, together with the oppor-
tunities and expanded applications of direct RNA
sequencing come new technical and bioinformatic
challenges. One of the technical challenges can be
RNA secondary structures. When researchers are
interested in full length RNA sequencing, regions of
RNA forming semi-stable structures might be more
1https://nanoporetech.com/
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challenging to sequence and will potentially have lower coverage. Another challenge comes from RNA
modifications (see Section 6.2 for more detail), as we do not know how chemically modified nucleotides
will contribute to the process of direct RNA sequencing. For example, using the Oxford Nanopore
system, incorporating modified nucleotides will result in a different membrane potential. However, it
might also come as an extra complication, as not all types of RNA editing are known at the moment,
and not all changes in the membrane potential can be discriminated. This can result in misclassified
nucleotides due to unknown changes in the membrane potential. Therefore, current pipelines and tools
can rarely be applied directly on the sequencing data generated with novel sequencing techniques.
6.2 Contribution of RNA editing
When RNA-Seq data is generated with as few technical biases as possible, the analyses results can still
contain misinterpreted observations due to biological mechanisms that are not well studied or known
at all. One of such mechanisms that has a direct influence on the interpretation of certain RNA-
Seq analyses and which has been underestimated for a long time is the phenomenon of RNA editing.
RNA editing is a chemical modification of mature RNA (not necessarily messenger RNA). A number
of chemical modifications [273] has been discovered, although the function of the majority of these
modifications remains unknown. Some types of RNA editing are introduced enzymatically, while others
may occur due to chemical instability, damage or free radical mediated adduct formation [81]. RNA
editing events, or REEs happen with different frequencies, the most frequent and well studied being
editing by deamination and methylation.
6.2.1 Types and potential function of editing
One of the most frequent RNA editing events – adenosine deamination – is performed by ADAR,
Adenosine Deaminases Acting on RNA. As the result of this hydrolytic deamination, inosine is created
in place of adenine. Inosine is recognized as guanine by the cellular machinery and will be represented
as G in the output of Illumina sequencing (as the DNA polymerases used in the PCR reactions prior to
sequencing will introduce a C at all positions complementary to I) [82]. A-to-I editing is known to affect
a large amount2 of adenines [3] and effects mainly (but not only) double-stranded RNA. Since structural
RNAs tend to form double-stranded structures, they are extensively undergoing A-to-I editing. This
type of editing can be specific or promiscuous; in some cases a particular position is edited in multiple
molecules and in other cases different positions within a certain region are edited in different RNA
molecules [274]. Studies on RNA editing in cancer [275, 276, 277, 278] point towards the instability of
RNA editing (meaning that the same position will not always be edited in all the transcripts) and go
hand in hand with the potential importance of RNA editing.
The second most frequent type of RNA editing event, detected in up to 0.5% of isolated RNA
molecules, is RNA methylation [279, 280] performed by the methyltransferase enzyme. Methyltrans-
ferases bind to RNA regions with a certain sequence and methylate adenosines [281, 282, 283]. RNA
methylation is enriched near stop codons, in 3’ UTRs and long internal exons, and methylation was
discovered to happen during or after splicing [284].
RNA editing and its functions have not been studied extensively yet. Position-specific RNA editing
can be used by cells as a mechanism to recode genomic information and increase functional protein
diversity, as editing can take place in exons and alter the coding sequence [285, 286]. Promiscuous RNA
editing is considered to play a regulatory function, i.e., occur in miRNA targets or protein binding sites,
as it is also known to often take place outside the coding region [287]. Editing happening immediately
2Note that the frequency of A-to-I editing can be low, even too low to be distinguished from sequencing errors,
therefore estimating the amount of edited positions is challenging.
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after transcription prior to splicing might have an effect on splicing progress, as edited positions can be
located around splice sites in the regions that the spliceosomal proteins bind to.
6.2.2 Bioinformatic analysis of RNA editing
RNA editing is a fundamental biological process which deserves thorough exploration on its own. How-
ever, as can be appreciated from Chapter 5, it is also crucial to detect REEs because they can interfere
with RNA-Seq bioinformatic analyses. For instance, A-to-I REEs can be misinterpreted as A-to-G ge-
nomic variants in samples with unknown genotypes. Since editing does not happen in 100% of the
transcripts, it might cause false-positives in the detection of allele-specific expression. There is cur-
rently a scarceness of bioinformatics methods to reliably detect REEs [288, 289]. At the moment, all
RNA positions different from the reference genome and not present in the list of genomic variants are
often considered REEs or sequencing errors and are discarded from the downstream analysis [290]. It is
a considerable challenge to differentiate between REEs and sequencing errors. As mentioned before, it
is performed by the editing enzymes that introduce the chemical modification at a single RNA molecule
level, therefore the frequency of RNA editing varies widely and is mainly very low [278, 291]. There
is a strong need in new bioinformatic pipelines to reliably distinguish between genomic variants and
REEs [292].
6.3 RNA and proteins
Bioinformatic analysis of mRNA sequencing data is challenged by both technical and biological issues,
but when the analyses results are clean and reliable, the next step is to study the consequences of these
results at a protein level. Various events that are detected in the RNA-Seq data may have an effect
on the sequence and thereby the structure, stability, expression level and even function of proteins.
Note that this has limited effect in the experiments, when two samples with similar protein profiles are
compared, and has a greater effect on the experiments when no controls or references are used (i.e., one
sample or sample group).
6.3.1 RNA and protein expression
Integrative -omics analysis is a class of methods that link RNA and protein expression [293]. RNA-Seq
and mass spectrometry data is combined to identify expressed genes and proteins/peptides and to get
a reliable list of expressed proteins (Figure 6.2). This is a powerful approach, since not everything
that happens with RNA will be translated and will lead to a functioning protein [294, 295, 296], in
other words, RNA 6= protein. Not all RNAs will be translated, nor when present, with the same
efficiency. It has been shown that the correlation between protein and gene expression is not high,
which indicates either biases in the process of sequencing and mass spectrometry [297, 298], or the
bioinformatic analysis [299, 300], or the combination of both. One of the main pitfalls in the integrative
-omics is that the protein expression is correlated with the gene expression, while the real RNA molecule
that leads to a protein and should be correlated with protein expression is a transcript [294]. Since more
than one transcript is produced from the majority of human genes, and proteins have different stability,
correlating gene and protein expression becomes artificial [301, 302].
A logical step to correct for the biases would be to use transcript expression instead of gene ex-
pression. Gene expression is measured as the cumulative expression of all transcripts produced from it
and expressed in the cell. However, different proteins can be translated from different transcripts of the
same gene. Unfortunately, the latter is more difficult to analyze, as to measure transcript expression
actual transcripts need to be identified. With currently used Illumina sequencing as one of the main
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sources of the RNA-Seq data and its relatively short reads of hundreds of bases, reliable detection of
full-length transcripts is challenging and often impossible [303]. This task becomes harder when the
difference between the transcripts is minor, i.e., in such cases as allele specific gene expression [304].
The structures derived from the two chromosomes may differ due to allele-specific alternative splicing
which can be tagged only with one heterozygous SNP [305]. Due to ASE, a certain allele coding a
deleterious or a toxic protein (unlike the other allele) might be higher expressed, which might lead to
the overexpression of a deleterious protein [306]. However, it is very complex to study its effect on
protein level. When two transcripts differ in only one nucleotide, current limitations of Illumina read
length (hundreds of nucleotides) will fail to distinguish between the two transcripts on a whole tran-
script scale. Using sequencing techniques producing longer reads, such as Pacific Biosciences or Oxford
Nanopore, might become a pivotal point in the integrative -omics analysis. However, even transcript
and protein expression does not always show a good correlation. E.g., as mentioned above, some RNAs
can be translated more efficiently than the others. A current study [167] shows a decoupling between
transcript and protein expression occurring with age.
6.3.2 RNA and protein structure
Whereas tools for linking RNA and protein expression are developing quite fast, the link between RNA
and protein structure remains understudied. Genetic variants and REEs can cause non-synonymous
mutations resulting in altered protein sequence, structure and function. A mutation in the human
dystrophin gene in the locus Xp21 of the X chromosome can lead to the development of a muscular
disorder called Duchenne Muscular Dystrophy. The dystrophin protein (encoded by the dystrophin gene)
is responsible for connecting the cytoskeleton of the muscle fiber to the extracellular matrix. Known out-
of-frame mutations result in a transcript from which it is not possible to produce dystrophin. This leads
to the loss of the dystrophin’s function and the development of a muscular dystrophy [307, 308, 309].
A mutation in LMNA gene – a gene encoding lamin A, a protein providing structural support to the
nucleus – creates a 5’ cryptic splice site within exon 11 resulting in an abnormally short mature mRNA
transcript [310]. This transcript yields an abnormal isoform of prelamin A – precursor of lamin A
– which is not able to provide the necessary support to the nuclear lamina, which leads to reduced
cell division and premature aging (also known as progeria, or Hutchinson-Gilford disease). Another
example of a mutation which causes the creation of non-functional protein and leads to a disease is a
mutation in human CFTR gene (C ystic F ibrosis TRansmembrane conductance Regulator) located in
the q31.2 locus of chromosome 7. The proteins encoded by CFTR functions as a channel for chloride
ions, which can move in and out of cells. The most common mutation, which is a three nucleotide
deletion, leads to the loss of an amino acid and a non-functional protein [311, 312].
Apart from single nucleotide changes, alternative splicing events might lead to a whole protein do-
main removal or incorporation. Studies of protein structures and structural alterations are challenging,
as structural biology and exploring protein structure and molecular dynamics involves computationally
heavy, intensive tasks. These tasks include protein modelling, molecular dynamics and quantum me-
chanics calculations (to be precise, short cuts based on knowledge derived from quantum mechanics),
i.e., to study the changes in the binding between the substrate and the amino acids in the enzymatic
active site, which can be caused by a genomic variant [313]. Apart from the need in extended compu-
tational power and resources, the task of linking transcriptomics and structural biology is challenged
by the limited amount of available 3D protein structures. This makes the task even more complex,
especially when considering linking transcriptomics and structural biology genome wide. Unfortunately
a possibility of local modelling of certain protein domains does not give a lot of insight, as even very
conserved and closed domains often behave differently in different circumstances [314, 315]. These cir-
cumstances can be the surrounding amino acids, the electrostatic potential around them, or the level of
the domain’s exposure to the surface.
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Figure 6.2: The Figure shows that multiple mRNAs can be transcribed from
one gene (left panel of the figure). Some of the mRNAs lead to a stable
functional protein, while some result in non-functional protein and some are
not used as a protein template at all.
A developing field of structural genomics
might be the bridge connecting transcrip-
tomics and protein structures and func-
tions [316]. The principle of structural ge-
nomics is to identify as many protein struc-
tures as possible using all currently available
resources and techniques. These techniques
include de novo structure determination using
X-ray crystallography and Nuclear Magnetic
Resonance, modelling based methods such as
ab initio modeling, sequence based homology
modelling and domain modeling based on the
fold similarities rather than the sequence iden-
tity [317, 318].
The intermediate goal of the field is to pro-
vide as many protein structures as possible,
and the end goal is to identify and describe all
proteins within the genome of interest. Struc-
tural genomics has already successfully been applied on bacteria [319] and extending the initiative to
higher organisms, such as humans, is hopefully a matter of time.
The initiative of structural genomics has a great potential, as it will expand our understanding
of protein folding, structure conservation among and within species, provide a better and broader





Bioinformatics, first introduced in 1970 by Paulien Hogeweg and Ben Hesper, has changed and evolved
drastically. Bioinformatics was formed as a field to get information about various processes in biological
systems (hence the term bio-informatics). Initially, bioinformatics focused on analyzing a handful of
gene and protein sequences, protein structures and organism evolution based on protein sequences and
structural domains. However, with years it shifted to the exploration of whole genomes and transcrip-
tomes and the study of biological processes at a genome- (and transcriptome-) wide scale in model
systems, living cells and organisms. After the introduction of one of the greatest scientific and techno-
logical breakthroughs of the past two decades – massively parallel Next Generation Sequencing (NGS)
– sequencing of genomes and transcriptomes of whole organisms became possible. Bioinformatics faced
a new challenge of analyzing high throughput genomic and transcriptomic data. The main challenge
introduced by complex NGS data is in its nature – DNA has to be shredded before sequencing, therefore
NGS produces millions of very short sequenced DNA fragments (reads). Despite the recent increase in
read length, finding the origin of reads on the genome is still a challenge, as the length still does not
exceed hundreds of nucleotides. Pacific Biosciences’ SMRT technology and Oxford Nanopore, recently
introduced high-throughtput sequencing technologies, are the only technoloies available on the market
capable of sequencing thousands of bases.
An additional challenge in analyzing NGS data emerges when working with transcriptomic material
– reads originating from RNA. Multiple RNA transcripts from one gene often share a specific region, and
each transcript can be present multiple times. Therefore, the origin of reads – the transcript they are
coming from – is hard to find. This introduces numerous biases and limits our understanding of RNA
biology and molecular processes happening at the RNA level. As this thesis was written, the analysis
of an RNA sequencing sample was limited due to the limited amount of programs for the bioinformatic
analysis of RNA. Available RNA analysis tools only focussed on finding differences in the expression
of certain genes between different samples (i.e., healthy individuals versus diseased patients), discover
alternative splicing events, identify alternative polyadenylation events.
The focus of this thesis was to explore the possibilities of current bioinformatic analysis of tran-
sciptomic data and complement such tools by newly developed programs. The latter was particularly
important for atypical RNA analyses revealing yet unexplored molecular mechanisms in RNA biogene-
sis. This is covered in Chapter 2, where we analyzed nuclear RNA – not commonly used for RNA-seq.
The majority of established RNA-seq data sets are derived from total cellular or cytoplasmic RNA. In
the analysis of total RNA, the focus is on the result of transcription and RNA processing. Studying
nuclear RNA facilitates a more thorough exploration of ongoing mRNA processing events like splicing.
Splicing is a process during which the regions of a gene called introns are removed and the remaining
regions – exons – are joined. As simple as splicing might sound at first, it consists of numerous steps, and
each of those steps deserves a thorough exploration. Analyzing reads from nuclear RNA in Chapters 2
and 3 of this thesis, we discovered that introns in human genes are not always excised sequentially, from
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the beginning towards the end of the gene. Also, some introns are not removed at once, they are rather
excised in multiple steps, piece by piece. In fact, using the example of the gene coding for dystrophin
(DMD), the longest gene within the human genome, we show that more than half of DMD introns are
removed in multiple steps.
In Chapter 4, we complemented publicly available programs with in-house developed scripts and
performed a study of age related changes in RNA processing, namely splicing, in over 600 healthy Dutch
individuals. The analyses were conducted on adult individuals with ages spanning more than 60 years.
We found alternative splicing events such as exon skipping – when during the process of splicing not
only introns but also an exon is excised – occurring more often in older individuals. We noticed the
same trend for another type of alternative splicing event, intron retention, an event when an intron is
not excised and is included in the nascent transcript. Both of these events were occurring more often in
older individuals transcriptome-wide, without any preference for a specific pathway or functional group
of genes. These findings suggested that such age related changes might have a fundamental nature and
can potentially help to understand how and why we age.
Next to the bioinformatic analyses of RNA sequencing samples from healthy individuals, in Chapter
5 we analyzed samples from patients with breast cancer. In this study we were particularly interested in
allele-specific expression, a biological event potentially important for the pathophysiology of cancer. A
healthy human genome is diploid, which means that every chromosome occurs in pairs and that there are
two copies of each gene in a cell (the two copies are the two alleles). For each position of a gene sequence
two different nucleotides can be present (unless we are facing an insertion or a deletion, which results in
a missing nucleotide). Chromosomal aberrations – duplication or deletion of (parts of) a chromosome
(allele) – are frequent in tumors. Such events may result in an unequal expression of the two alleles. This
unequal allelic expression may also be present in healthy individuals and can be directed via biological
mechanisms different from DNA chromosomal aberrations (e.g. parental imprinting). In this study we
compared the differences between imbalanced allelic expression between healthy and tumor tissue and
explored the potential role of allelic imbalance in the pathogenesis of breast cancer. We provided a
detailed classification of allele-specific expression cases, compared them in control versus tumor tissues
of the same patients and explained each pattern on RNA expression (e.g., a downregulation of an allele’s
expression) by the underlying DNA alterations.
In summary, this thesis focuses on the uncovering of previously unexplored information in RNA
sequencing data. We show that use of unconventional types of RNA for sequencing and new tools for
the analysis RNA-seq can reveal novel insights in the transcriptional and post-transcriptional regulation
of gene expression, relevant for the understanding of normal physiological processes such as aging and
pathophysiological processes such as Duchenne muscular dystrophy and cancer.
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Chapter 8
Samenvatting (summary in Dutch)
Bioinformatica werd in 1970 gëıntroduceerd door Paulien Hogeweg en Ben Hesper. Sindsdien is deze
wetenschap ingrijpend veranderd. De essentie van de bioinformatica ligt in het verkrijgen van infor-
matie over biologische systemen. Vandaar de naam. Aanvankelijk richtte de bioinformatica zich op
de analyse van een beperkt aantal eiwit sequenties, eiwit structuren en evolutie studies op basis van
eiwit sequenties en structurele domeinen. Met de jaren heeft het zich ontwikkeld tot een wetenschap die
hele genomen, transcriptomen en biologische processen op een genoom-wijde schaal bestudeert in model
systemen, levende cellen en organismen. Na de introductie van een van de grootste wetenschappelijke
en technologische doorbraken van de laatste twee decennia — grootschalige, parallelle next generation
sequencing (NGS) – werd het mogelijk om genomen en transcriptomen van hele organismen te bepalen.
De bioinformatica werd geconfronteerd met nieuwe uitdagingen bij de analyse van deze genomen en
transcriptomen. De grootste uitdaging in de analyse van complexe NGS data ligt verborgen in de ben-
odigde fragmentatie van het DNA voorafgaande aan de sequencing. Hierdoor ontstaan miljoenen korte
sequentie fragmenten (‘reads’ ). Ondanks de recente toename in de lengte van deze reads, is de gemid-
delde read lengte nog steeds beperkt tot ongeveer 100 nuleotiden. Dit maakt het lastig om de oorsprong
van de reads te bepalen. Alleen met reads van het Pacific Biosciences platform, die vele duizenden
nucleotiden lang zijn, wordt dit probleem verholpen. Het aantal reads per run in dit platform is echter
nog beperkt in vergelijking met de platformen met korte read lengtes.
Transcriptoom data (RNA-seq) vormen een extra uitdaging bij de analyse. Verschillende RNA
transcripten afkomstig van hetzelfde gen delen vaak een groot gedeelte van hun sequentie. Daarom is
het moeilijk om te bepalen van welk transcript de read afkomstig is. Dit resulteert in onevenredige
representatie van transcripten (‘bias’ ) en belemmert de studie van de biologische processen die bij de
vorming en afbraak van RNA een rol spelen. In de tijd dat het onderzoek zoals beschreven in dit
proefschrift werd verricht, waren nog niet veel geavanceerde programma’s beschikbaar die specifiek voor
RNA analyses waren gemaakt. Met de beschikbare software konden slechts verschillen in de expressie
van genen worden bepaald (bijvoorbeeld tussen zieke en gezonde personen), en alternatieve splicing en
alternatieve poly-adenylerings posities worden gedetecteerd.
De focus van dit proefschrift ligt op het onderzoeken van de mogelijkheden van bestaande bioinfor-
matische analyse programma’s voor transcriptoom data en het ontwikkelen van algortimes voor analyses
die niet uitgevoerd konden worden met bestaande software. Dit laatste was met name belangrijk voor
atypische RNA analyses om nog niet ontdekte mechanismen in RNA biogenese op te helderen. Dit is
het geval in hoofdstuk 2, waar we RNA uit de celkern hebben geanalyseerd — iets wat niet standaard
wordt gedaan omdat men zich over het algemeen richt op de analyse van het totale RNA in de cel of
het cytoplasmatische RNA. Waar bij de analyse van totaal RNA de nadruk veelal ligt op het resultaat
van transcriptie en RNA processering, opent de analyse van RNA uit de nucleus de mogelijkheid om
processen die een rol spelen bij de maturatie van mRNA, zoals splicing, te bestuderen.
Splicing is een proces waarbij bepaalde regionen in een gen, de zogenaamde intronen, worden ver-
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wijderd en de overgebleven exonen met elkaar worden verbonden. Hoewel dit simpel klinkt, is splicing
een meerstapsproces, waarbij iedere stap nadere bestudering behoeft. Door de analyse van RNA uit de
celkern in hoofdstukken 2 en 3, ontdekten we dat intronen in humane genen niet altijd in volgorde,
vanaf het begin tot het einde van het gen, worden verwijderd. Verder vonden we dat sommige intronen
in meerdere stappen worden gespliced. In het DMD gen, het langste gen in het humane genome, gold
dit laatste voor meer dan de helft van de intronen.
In hoofdstuk 4 gebruikten we publiek beschikbare software en zelf ontwikkelde scripts en onder-
zochten leeftijd-gerelateerde verandering in RNA splicing in meer dan 600 gezonde, nederlandse indi-
viduen, variërend in leeftijd van 18 tot 80 jaar. We vonden dat een bepaalde vorm van alternatieve
splicing, exon skipping, het verwijderen van exonen samen met intronen, meer voorkomt bij oudere dan
bij jongere individuen. Eenzelfde trend werd gevonden voor intron retentie, een vorm van alternatieve
splicing waarbij een intron terecht komt in het uiteindelijke transcript. Beide vormen van alternatieve
splicing kwamen meer voor bij ouderen, maar werden niet aangetroffen in specifieke genen maar kwa-
men in het gehele transcriptoom voor. Deze bevindingen suggereerden dat deze leeftijds-gerelateerde
veranderingen fundamenteel van aard zijn en mogelijk bijdragen tot het verouderingsproces.
Naast de bioinformatische analyse van RNA sequencing monsters van gezonde individuen, onder-
zochten we in hoofdstuk 5 ook monsters van patiënten met borst kanker. In deze studie waren we in
het bijzonder gëınteresseerd in allel-specifieke expressie, een biologisch fenomeen dat mogelijk een rol
speelt in de pathofysiologie van kanker. Een normaal humaan genoom is diplöıde. Dit betekent dat er
van elk gen twee copieën aanwezig zijn in een cel op twee verschillende chromosomen. Chromosomale
afwijkingen — deleties of duplicaties van (gedeeltes van) chromosomen — komen in veel tumoren voor.
Dit kan leiden tot een ongebalanceerde expressie van de twee allelen. Echter, ongelijke expressie van
de twee allelen kan ook voorkomen in gezond weefsel, door andere biologische mechanismen. In deze
studie vergeleken we de ongebalanceerde expressie tussen gezond en tumor weefsel van dezelfde patiënt
en probeerden de expressie patronen in de tumor te verklaren uit de DNA veranderingen.
Kortom, dit proefschrift beschrijft verschillende nieuwe manieren om de informatie die verborgen
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